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I. Introduction
One of the more significant scientific developments in the last thirty years has
been the continued research towards an understanding of DNA replication. This
process of reproducing one's own genetic code is essential to all living organisms, and
malfunctioning of this event can result in gross cellular aberrations or cell death. Every
organism evokes a distinctive mode of replication; from the simple strand displacements
of characteristic prokaryotic viruses to the complicated schemes by which humans and
other higher eukaryotes duplicate their DNA, each replication method reflects a different
evolutionary path.
The synthesis of DNA requires a balanced supply of four precursor compounds
called deoxynucleoside triphosphates (dNTP's). The supply of each dNTP neededat
the replication fork for a given cell type depends not only on the metabolic state of the
cell, but also on the specific deoxynucleotide base composition of the organism's DNA.
The store of deoxynucleotides in a cell can be derived from either salvageprocesses, or
from de novo biosynthesis. The salvage pathways function by utilizing material
obtained from the degradation of RNA and DNA. Salvage enzymes, including kinases
and phosphohydrolases, help regulate the flux of intracellular levels of nucleotides and
deoxynucleotides through a process known as 'substrate cycling' (for a review, see
Reichard, 1988). The de novo biosynthetic pathway produces deoxynucleotides by
synthesis of nucleotides from small molecules and then subsequently by reduction of
the nucleotides. This biosynthetic path is regulated by feedback inhibition and by theallostery of two enzymes in the pathway, dCMP deaminase and ribonucleotide
reductase. The combination of these two pathways must not only provide a balanced
pool of each deoxynucleotide, but must regulate the overall levels of
deoxyribonucleotide precursors to meet varying needs of the cell cycle-dependent
replication process. In non-dividing eukaryotic cells, the basal levels of
deoxynucleotides are extremely low (0.1-0.3 mM), well below the optimal level
necessary for DNA replication. However, just prior to DNA synthesis, the dNTP
pools increase markedly. These pool expansions are an essential requirement for DNA
synthesis during the S-phase of the cell cycle (Reichard, 1988). Most organisms
coordinately regulate deoxynucleotide production and initiation of DNA replication.
However, the means by which this feat is accomplished is not yet fully understood.
Imbalances in deoxynucleotide pools can have drastic effectson cellular
processes (reviewed by Weinberg et al., 1981). Pool biases can be caused by
malfunctioning or mutation of enzymes involved in maintaining balanced poolsor may
be caused by severe metabolic changes within a cell. These imbalancesnot only lower
the fidelity of DNA synthesis, but also impair the important role of DNA repair in
preventing DNA strand breakage and base rnispairing (Meuth, 1989; Kunz and
Kohalmi, 1991).
The rate-limiting enzyme involved in de novo biosynthesis of deoxynucleotides
is ribonucleotide reductase (Thelander and Reichard, 1979). Figure I.1 detailsthe
central role of ribonucleotide reductase in the deoxynucleotide metabolism of E. coli
and higher eukaryotes. Reduction by ribonucleotide reductase is the first committed
step in deoxynucleoside triphosphate synthesis. This complex enzyme catalyzes the
reduction of the 2' hydroxyl group on the ribose moiety ofprecursor nucleoside
diphosphates (or triphosphates) to form the corresponding 2'-deoxynucleoside5'-
diphosphate (or triphosphate) products. Theenzyme irreversibly reduces the fourADP GDP C DP
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common nucleotides: adenosine diphosphate, guanosine diphosphate, uridine
diphosphate and cytidine diphosphate. Because of the critical role of thisenzyme
reaction, this enzyme and its regulation has been the center of much importantand
onging research. The complex regulation of this metabolicstep has been well studied
in terms of both the amounts of enzyme activity during the cell life cycle(reviewed by
Wright, 1989) and the allosteric effectors for theenzyme catalyzing the reaction
(reviewed by Eriksson and Sjoberg, 1987). Furthermore, the central role of
ribonucleotide reductase has made it an attractive target for the design ofantineoplastic
and antiviral agents (Moore and Hurlbert., 1985; Spectoret al., 1987). Selection of
mutant forms of ribonucleotide reductase has led to a better understanding of
deoxynucleotide pool imbalances and how these imbalances affect DNAsynthesis.
Studies examining the structural organization of ribonucleotide reductase andother
enzymes involved in precursor synthesis and replication have led to a better
understanding of how these two events function inconcert (recently reviewed by
Mathews, 1993).
This dissertation is an attempt to further characterize the ribonucleotide
reductase enzyme from a large eukaryotic DNA virus. Vaccinia virus encodesmany of
the enzymes necessary for replication (including ribonucleotide reductase)and
synthesizes its own DNA entirely within the host's cytoplasm.In addition, the virus
utilizes de novo DNA synthesis for virion particle formationas host cell DNA synthesis
is inhibited during infection (Jungwirth and Launer, 1968), andhost cell nuclear DNA
is made unavailable to the virus (Parkhurst et al., 1973). For thesereasons, and
because the virus is well defined genetically and is easily manipulated,vaccinia is an
ideal system with which to study the reductaseenzyme and viral replication.
Since the virus infects mammalian hosts and viralenzymes share much
sequence homolgy with their mammalian enzyme counterparts, it seemed plausible that5
the vaccinia ribonucleotide reductase would share many biochemical characteristics with
its host. Work described in this dissertation along with initial studies of the viral
enzyme confirm this hypothesis. The earliest studies with the vaccinia virus
ribonucleotide reductase characterized the requirements necessary for enzyme activity in
virus-infected cells extracts and demonstrated that the viral enzyme is allosterically
regulated in a manner similar to the mammalian and E. coli enzyme (Slabaugh et al.,
1984). In further studies, the locations of the two genes which encode the viral
reductase were identified, and the genes were sequenced (Slabaugh et al., 1988;
Schmitt and Stunnenberg, 1988; Tengelson et al., 1988). Northern blot analysis
revealed that both genes are actively transcribed during a viral infection (Roseman and
Slabaugh, 1990; Tengelson et al., 1988). Concurrent with the work described herein,
Slabaugh has pursued the purification and characterization of the recombinant large
subunit protein of ribonucleotide reductasel.
One incentive of this work is to provide a level of understanding and
information about the viral enzyme which will readily lend itselfto further structural
and functional studies. To this end, this dissertation describes cloning of the small
subunit gene of vaccinia virus ribonucleotide reductase into a bacterial expression
system and characterization of the recombinant gene product. Because both subunits of
vaccinia virus ribonucleotide reductase are now available in large quantities and in
purified form, many interesting kinetic and physical association studiesare now
possible. Potential experiments for further study of this, and other work,are discussed
in the conclusion chapter of this work. Another major goal of this dissertation isto
compare the supply of deoxynucleotide precursors made available through the activity
of the viral ribonucleotide reductase with the biosynthesis and accumulation of viral
DNA. To accomplish this, the kinetics of ribonucleotide reductase expressionare
I M. Slabaugh, manuscript in preparation.6
examined and the amounts of viral enzyme and viral genomic DNA accumulationare
quantitatively determined. The third motivation for this work is to aid in the study of
the mechanism of action of the ribonucleotide reductase inhibitor, hydroxyurea. To this
end, we use purified vaccinia virus small subunit to spectrophotometrically examine
enzyme inhibition by hydroxyurea. We also describe conditions (additions to the tissue
culture medium) that allow for circumvention of hydroxyurea inhibition in the viral
system. In vivo experiments demonstrate that deoxynucleotide pool imbalances are
induced by hydroxyurea treatment and a proposal is put forth for the biochemical
mechanism of hydroxyurea circumvention under these conditions.
The first section of this dissertation summarizes initial studies andrecent work
with the enzyme ribonucleotide reductase from various organisms. Special attentionis
given to current hypotheses on enzyme activation and formation of the tyrosyl radicalin
the small subunit protein. The literature review also describes the vaccinia virussystem
in terms of the viral lifecycle, expression of viral genes, and early workto characterize
viral replication. The experimental results are described in three manuscripts.The first
manuscript characterizes the recombinant small subunit protein of ribonucleotide
reductase. A second manuscript compares regulation of ribonucleotide reductase with
viral DNA synthesis. The third manuscript details circumvention of hydroxyurea
inhibition during viral infection. Because of this author'smore limited involvement in
publication of the third work, the manuscript describing the hydroxyurea studies is
presented in the appendix. Finally, the relevance of these studies is discussed, and
specific conclusions are put forth.7
II. Review of Literature
The intention of this literature review is to acquaint the reader with thecurrent
emphases in the study of ribonucleotide reductase. The elaborate and thorough
investigations of this enzyme and its metabolic roleconvey its importance in
biochemistry. Special attention is given to studies which characterize the small subunit
polypeptide of the enzyme, because these specifically pertain to the work in this
dissertation. Many exciting discoveries have recently been made in thearea of cell
cycle coordination. Ribonucleotide reductase isone of several eukaryotic enzymes that
is regulated by these cellular events. The second section of this literature reviewis a
survey of recent work describing ribonucleotide reductase gene and gene product
expression and ribonucleotide reductase protein synthesis. Finally, this review
describes the organism of study, vaccinia virus. The lifecycle of the virus is described
and viral gene expression and replication are summarized. This review also outlines
preliminary characterizations of ribonucleotide reductase in this viral organism.
II.1 Ribonucleotide Reductase
II.1.1 Different Classes of the Enzyme
Work in the ribonucleotide reductase field has recently acceleratedto a vigorous
rate. In the last ten years, two new forms of the enzyme have been described. This
brings the total of distinct classes of ribonucleotide reductaseto four. Because of the
variability in the specific requirements for deoxynucleotide synthesisamong different
organisms, it is not suprising that several different types ofenzyme have evolved to
catalyze this critical reaction. All classes of reductase catalyzea reaction which involves8
an unpaired electron or free radical species. The various classes of the enzyme can be
distinguished by how the source of radical species is generated (Table II.1). The
radical species is absolutely required for catalysis and playsa crucial role in the first
step of the reaction mechanism.
Much of the early work characterized the first class ofenzyme from organisms
as diverse as E. coli, T4 bacteriophage, herpes simplex virus, vaccinia virus,yeast,
clam, and mammalian and higher plant species. This first class of ribonucleotide
reductase employs a conserved tyrosyl residue and a binuclear ferriccenter to generate a
stable free radical species. The stability of the radical allows for its detectionby
electron paramagnetic resonance (EPR) spectroscopy and UV/visiblespectroscopy. In
this class of ribonucleotide reductase, the holoenzyme is composed oftwo nonidentical
homodimer polypeptides. The smaller of these subunits contains thetyrosyl residue
and the iron center. The larger subunit contains binding sites for thenucleoside
diphosphate substrates and for allosteric effectors.
A second class of ribonucleotide reductase, characterized by severalGram
positive bacteria, substitutes manganese for iron in forminga binuclear manganese
center (Willing et al., 1988a). This group of enzymes also generatea stable radical
species at the conserved tyrosyl residue in the smaller subunit, butare insensitive to the
negative allosteric effector of the class I reductases (Willinget al., 1988b). In addition,
these reductases are able to convert both nucleoside diphosphate andnucleoside
triphosphate substrates to the corresponding deoxynucleotide product(Willing et al.,
1988a).
The ribonucleotide reductase from L. leichmannii is theprototype for the class
of enzyme that uses adenosylcobalamin (AdoCbl)as a dissociable cofactor. This
enzyme class includes both prokaryote and eukaryote species and the holoenzyme
consists of only a single polypeptide. The reaction catalyzed by thisenzyme isTable 11.1 Different Classes of Ribonucleotide Reductase
Class of Ribonucleotide Reductase Source of Radical Species Substrate
I.Esherichia coli
mammal
higher plant
virus
H. gram positive bacterium:
Brevibacterium ammoniagenes
Micrococcus luteus
arthrobacter
HI. L. leichmannii
Corynebacterium nephridii
Thermus aquaticus
Rhizobium leguminosarum
Euglena gracilis
Fe3+, R2subunit
Mn2+, R2 subunit
Ado-Cbl,
radical chain initiator
NDP's
NDP's, NTP's
NTP's
IV. Methanobacterium thermoautotrophicum S-AdoMet, NTP's
anaerobically grown Esherichia coli ?? radical chain initiator ??
C10
restricted to the conversion of ribonucleoside triphosphates to deoxyribonucleoside
triphosphates. In a reaction mechanism common to other AdoCbl-requiringenzymes, a
homolytic cleavage of the carbon-cobalt bond results in formation ofa 5'-
deoxyadenosyl radical (Stubbe et al., 1983). The radical species then performs the
function of chain initiator to start catalysis (Ashley et al., 1986).
The most recently characterized class of reductase includes the anaerobic
methanogen, Methanobacterium thermoautotrophicum, andan E. coli form of the
enzyme that is oxygen-sensitive and active only during anaerobic growth (Fontecaveet
al., 1989; Hogenkamp et al., 1987). Thisgroup of enzymes is thought to utilize S-
adenosylmethionine (AdoMet) and a metal to generatea radical chain initiator (Eliasson
et al., 1990). The specific mechanism that generates this radical species isnot yet
understood. These enzymes are also restricted to the catalysis of thereduction of
ribonucleoside triphosphates (Eliasson et al., 1990).
11.1.2 Class I Ribonucleotide Reductase Holoenzyme
The best-characterized ribonucleotide reductase is theenzyme from E. coli. In
1990, the three-dimensional structure of the E. coli small subunitprotein was published
in detail to 2.2 A (Nordlund et al., 1990). Preliminary X-ray diffractionstudies have
resolved the large subunit dimer to 18-A resolution (Ribiet al. 1987). This
crystallographic work, as well as binding and kinetic studies and mutationanalysis,
have led to the proposed model of the E. coli holoenzyme shown inFigure II.1. This
section describes that model and makes comparisons between the E.coli enzyme and
other class I ribonucleotide reductases.Activity Site
Specificity Site
SH SH
HS HS
HSSH HSSH
11
*---- SubstrateBinding
Site
z-
Fe"+'Fe"
.4%1V 1+
Figure II.1Model of the Ribonucleotide Reductase
Holoenzyme from E. coli12
11.1.2.1 Large Subunits
As the model indicates, the larger subunit dimer contains threetypes of binding
sites: activity sites, specificity sites, and substrate bindingor 'active' sites. The
physical model of the large subunit differs for mammalian reductase in that onlyone
activity and specificity site was detected from Scatchard analysis of equilibriumdialysis
studies for each large subunit dimer (Thelander et al., 1980). The activityand
specificity sites both confer allosteric regulationon the enzyme by binding positive and
negative effectors. This control helps maintaina supply of precursor products
commensurate to the needs for DNA synthesis. The complexities of the enzymes'
allostery were uncovered and clarified by two Swedish laboratories underthe direction
of Reichard and Thelander. Initial studies by Reichard determinedthat in the absence
of effector, the enzyme exhibits a very low turnover number (Larssonand Reichard,
1966a). Further studies demonstrated that the activity sites bind ATPand dATP and
regulate the overall activity of the enzyme (Larsson and Reichard, 1966b).In the
presence of dATP the enzyme is inactive. Only when ATP is bound at the activity site
is the enzyme capable of substrate catalysis. Moreover, itwas determined that binding
and reduction of substrate requires the presence of additional effectorsat the specificity
sites (Larsson and Reichard, 1966a). The specificity sites bind ATP,dATP, dGTP,
and dTTP. It was demonstrated that binding ofa specific effector to these sites results
in a conformational change at the active site which leadsto preferential binding of a
particular substrate (Brown and Reichard, 1969). Itwas subsequently established that
the conformational shift results in a decrease of the KM andan increase of the kcal at the
active site for the corresponding substrate (von Dobeln and Reichard,1976).
Equilibrium dialysis studies by von Dobeln and Reichard (1976) alsorevealed
that dATP binds to both specificity and activity sites but with differentaffinities. dATP
binds with high affinity (Kd = 0.03 p.M) to the specificity siteto enhance the binding of13
the substrates CDP and UDP. However, at higher concentrations of dATP, the low-
affinity dATP activity sites, (Kd = 0.1-0.54M), become filled and this inhibits overall
activity.
Determining the mechanism for dATP inhibition of enzyme activitywas also the
basis for a another series of studies which examined peptide interactions of theenzyme
subunits (Brown and Reichard, 1969a; Thelander, 1980). Sucrose gradient
sedimentation of the E. coli enzyme demonstrated that the holoenzyme changed intoa
heavier complex when inhibiting concentrations of dATP (above the dissociation
constant for activity site binding) were added to the enzyme preparation (Brown and
Reichard, 1969a). Isolation and analysis of these heavy complexes established thatan
inactive tetrameric form of the enzyme (two small subunit dimers andtwo large subunit
dimers) was formed after dATP addition. Analytical ultracentrifugation of calf thymus
reductase also demonstrated that the enzyme complexes into multimeric forms after
addition of inhibiting concentrations of dATP ( Thelander et al., 1980). However, in
this case, only the large subunit formed a tetrameric species. As competingamounts of
ATP (positive effector) were added to the solution, the ratio of dimericto tetrameric
species changed accordingly. Taken together, these results suggest that dATP
inactivates the enzyme by inducing conformational changes in the subunits that allow
for these increased peptide interactions.
The conformational states of the E. coli ribonucleotide reductase in thepresence
of dATP and other effectors are outlined in Table 11.2. The enzyme reduces both
purine and pyrimidine substrates at the same rate in the presence of appropriate
effectors. Substrate saturation curves show that the enzyme reaction displays
hyperbolic kinetics in the presence or absence of effectors (Larsson and Reichard,
1966a). This demonstrates that there is no cooperativity for substrate binding. The
system of allostery and feedback inhibition was first studied in 1966 by Larsson andTable 11.2Allostery of Class I Ribonucleotide Reductases
Nucleotide Bound in
Activity Site Specificity Site Activates Reduction of Inhibits Reduction of
ATP ATP,dATP CDP,UDP
ATP dTTP GDP CDP,UDP
ATP dGTP ADP CDP,UDP
dATP any effector ADP,GDP
CDP,UDP
4=,15
Reichard for the E. coli enzyme (Larsson and Reichard 1966a; Larsson and Reichard
1966b). Kinetic and photoaffinity studies with mammalian enzyme have shownan
allosteric regulation pattern similar to the E. coli model (Eriksson et al., 1979;
Thelander et al., 1980; Eriksson et al., 1982; Caras et al., 1982). Inan intriguing
discovery, the enzyme encoded by herpes simplex virus, which is alsoa class I-type
enzyme, was found to contain neither type of effector binding site (Averett et al.,
1983). The activity of the herpes virus enzyme is constitutive.
The third type of binding site on the large subunit is at the site of catalysis. The
four nucleoside diphosphate substrates compete for two substrate binding siteslocated
on the large subunit (von Dobe In and Reichard, 1972; Thelander et al., 1980). In
addition to substrate binding, the active site also contains two sets of redox-active
sulfhydryl groups, at or near the active sites. One set of thiolgroups is directly
involved in catalysis and stoichiometrically reduces substrate (Thelander, 1974). The
second set of thiols, which is located near the active site, transfers the reducing
equivalents to the active site from an electron transfersystem on the outside of the
enzyme. Evidence for the dual role of the thiol groups and the location of both thiol
groups came from site-directed mutagenesis studies in which successive conserved
cysteinyl residues were mutated (Lin et al., 1987; Aberg et al., 1989). These studies
established that Cys-462 and Cys-225 were the thiols that participateat the active site
and that two carboxyl cysteines, Cys-754 and Cys-759are involved in transfer of
reducing equivalents from the hydrogen donor systems.
11.1.2.2 Electron Transfer Systems
Concomitant with each reduction of NDP to dNDP is the net oxidation ofone
pair of redox active thiols. Reduction of the cystine disulfidesto regenerate cysteine
thiol groups is accomplished by either one of two electron transfersystems outlined in16
CDP
SH SH
Ribonitclentide
Reductase
dCDP
S S
Thioredox in
SH SH
Thioredox in
SS
Thioredoxin
FADH2Reductase
FAD
NADPH NADP
Glutaredoxin Glutaredoxin
SH SH SI 1
Glutathione
SH SH
_IL---
Glutathionc
Glutathione FADH 2 FAD
Reductase
NADPH NADP
Figure 112Biological Reduction of Large Subunit Disulfides17
Figure 11.2. In the first system, reviewed by Holmgren (1985), a reduced form of the
small protein thioredoxin, which itself contains a set of redox active thiols, serves as an
efficient hydrogen donor for the disulfide groups on the outside of the enzyme.
Thioredoxin is eventually reduced in the cell by NAD(P)H through the action of the
flavoprotein, thioredoxin reductase. Thioredoxin operates by a ping-pong mechanism
for both thioredoxin reductase and ribonucleotide reductase (Thelander, 1974).
Thioredoxin was first characterized as the physiological electron donor for
ribonucleotide reductase from E. coli (Laurent et al., 1964). Analysis of thioredoxin
mutants, however, led to the discovery of a second bacterial reducing system from the
protein, glutaredoxin (Holmgren, 1976). The reduced form of glutaredoxin, another
small protein which contains redox active thiols, is likewise able to reduce the
ribonucleotide reductase disulfide. Glutathione, which is supplied via glutathione
reductase and NADPH, then reduces the oxidized glutaredoxin. Glutaredoxin and
thioredoxin have both been identified in mammalian cell extracts (Luthman and
Holmgren, 1982). The principal hydrogen donor for the type-1 herpes simplex virus-
encoded ribonucleotide reductase has been identified as the cellular thioredoxin
(Darling, 1988). It has been demonstrated that bacteriophage T4 encodes and
expresses its own thioredoxin (Berglund and Sjoberg, 1970), and that vaccinia virus
contains an open reading frame with homology (40%) to the eukaryotic glutaredoxin
(Goebel et al., 1990). In fact, after overexpression of the putative vaccinia virus
glutaredoxin, a 30-kDa protein was purified and it has been demonstrated that this viral
protein contains the reducing activities of a bona fide glutaredoxin2.
The overlapping functions of thioredoxin and glutaredoxin have made it very
difficult to determine which system is primarily used in vivo for reduction of
ribonucleotide reductase in E. coli and mammalian cells (Luthman et al., 1979). In
2 W. Thresher, manuscript in preparation.18
vitro studies with E. coli extracts have demonstrated that glutaredoxin has a ten-fold
higher turnover number for ribonucleotide reductase than thioredoxin (Holmgren,
1979). However, thioredoxin is typically 50-100 times more abundant in
logarithmically dividing bacterial cells than glutaredoxin (Holmgren, 1979). Deletion
analysis of components from either reducing system was unable to establish the
primary hydrogen donor (Kren et al., 1988; Russell and Holmgren, 1988).
Interestingly, after deletion of components from both systems at the same time,
deoxynucleotide synthesis was still active (Russell and Holmgren, 1988). This new
evidence suggests there may be a third unknown hydrogen donor for ribonucleotide
reductase. The genes for the bacterial thioredoxin and glutaredoxin have been cloned
and the recombinant proteins have been characterized (Holmgren, 1985; Wallace and
Kushner, 1984). Further deletion analysis and kinetic studies will, one hopes,
distinguish the roles of these proteins towards ribonucleotide reductase.
For in vitro studies of ribonucleotide reductase, the glutaredoxin and
thioredoxin reducing systems are often replaced by the chemical reductants,
dithiothreitol or B-mercaptoethanol. The purified reductase enzyme, however, requires
a dithiol reductant.
11.1.2.3 Small subunits
The small subunit dimers of class I ribonucleotide reductases contain two
covalently bound binuclear centers which act as cofactors. Biophysical methods were
used to elucidate the nature and location of these iron centers. X-ray diffraction studies
on a radical-free diferric form of R2 established that the iron centers are buried 10 A
from the surface of the polypeptide and 5.3 A away from the tyrosyl radical residue
(Nordlund et al., 1990). As shown in Figure 11.3, the iron centers are composed of
two high spin iron atoms in the 3+ oxidation state that are antiferromagnetically coupledTyr 122 0---Glu 238
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through a p.-oxo bridge. The iron cluster is covalently stabilized by histidine,
glutamine, and aspartic acid residues of the R2 protein in addition to H2O molecules.
Early Mossbauer and magnetic susceptibility measurements on the E. coli protein
revealed that there was a great deal of similarity between the iron center from
ribonucleotide reductase, and the iron center from the well-characterized oxygen-
transporting protein, hemerythrin (Atkins et al., 1973; Peterson et al., 1980). These
techniques also established the oxidation and spin states of the iron atoms and the
degree of antiferromagnetic coupling in the iron centers. The structure of the p.-oxo
bridge was identified by resonance Raman spectroscopy (Sjoberg et al., 1982). In
addition, Raman studies were used to compare the Fe-O-Fe symmetric stretching
vibrations of the small subunit protein with a model compound which also contained a
.t -oxo bridge (Backes et al., 1989). After addition ofH2180 to the reductase
preparation, a characteristic shift in the Raman spectrum (due to exchange of180) was
seen that was consistent with the assignment of the bridge structure. Finally,X-ray
absorption field spectroscopy (EXAFS), resonance Raman, and X-ray diffraction
studies revealed the length and angle of the Fe-O-Fe bridge and identified ligands
surrounding the iron center (Scarrow et al., 1986; Backes et al., 1989; Bunker et al.,
1987).
Involvement of a free radical species in the enzyme reaction was confirmed in
1972 by detection of an electronic signal using EPR spectroscopy (Ehrenberg and
Reichard, 1972). The radical was unequivocally localized to the conserved Tyr-122
residue of the E. coli small subunit protein by analyzing a site-directed mutant in which
the tyrosine residue was converted to a phenylalanine (Larsson and Sjoberg, 1986).
The mutant Phe-122 enzyme lacked both tyrosyl radical and enzyme activity. Electron
nuclear double resonance (ENDOR) and resonance Raman studies established that the
tyrosyl residue forms a phenoxy radical and that the radical species is not protonated as21
was earlier believed (Bender et al., 1989; Backes et al., 1989). Amino acid sequence
homology of various small subunit proteins revealed that the location of the tyrosyl
residue that forms the radical is strictly conserved in class I reductases.
Figure 11.4 shows the EPR spectra of small subunit proteins from E. coli,
mouse and herpes simplex virus. The radical EPR signal is a doublet that is centered at
g = 2.0047. As the figure details, the hyperfine splitting of the radicals differ among
the protein preparations. Differences also exist among these various radical proteins in
the power dependence for microwave saturation of the radicals. These differences
reflect variations in orientation of the B-CH2 group with respect to the tyrosine ring
(Graslund et al., 1982) and the degree of magnetic interaction between the tyrosyl
radical and the binuclear iron center (Sahlin et al., 1987). The radical from the mouse
enzyme appears, from these results, to be in closer association with the iron center than
the radical from E. coli. The stoichiometry of the iron/radical cluster and the
mechanism for its activation will be discussed in a subsequent section.
11.1.3 Proposed Enzyme Mechanism
Through the use of chemical modeling studies, a hypothetical mechanism has
been proposed for the 2' reduction of nucleotides by ribonucleotide reductase (reviewed
by Stubbe, 1990). The proposed mechanism is shown in Figure 11.5. The first step in
the reaction is a protein-mediated hydrogen abstraction from the 3' carbon of the ribose
moiety, which produces a 3' nucleotide radical (Panels A and B). Next, a H2O
molecule is lost through the facilitating action of a general acid catalysis (Panel C). The
acid catalysis in this step is postulated to involve one of the redox active thiol groups on
the large subunit. Cleavage of the H2O molecule, therefore, results in the formation of
a thiolate and a thiol within the active site. H2O loss also results in the formation of a
formyl methyl radical intermediate (Panel D) which displays an equilibrium between22
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Figure 11.5Proposed Reaction Mechanism of Ribonucleotide Reductase24
radical formation at the 2' and 3' ribose carbons. In the next step of the reaction (Panel
E), reduction of the formyl methyl radical through an electron transfer from the thiolate
produces a 3' ketone deoxynucleotide and a disulfide radical anion.This latter species
mediates a one electron reduction of the 3' ketone to produce a 3-deoxynucleotide
radical (Panel F). This intermediate then removes a hydrogen atom from the protein
residue to regenerate the protein radical (Panel G).
Through the efforts of several laboratories utilizing isotopically-labeled
substrates, substrate analogs, and site-directed mutants, support for Stubbe's model
and the direct involvement of radical intermediates has been made. Studies using [3'-
3H
or -2H1 nucleoside diphosphate substrates established that the hydrogen abstracted
from the 3' carbon of the ribose moiety is returned to the same position during the final
step of product formation (Stubbe et a/., 1983). Using the mechanism-based inhibitor,
2'-chloro-2'-deoxyuridine 5'-diphosphate (Cl-UDP), researchers demonstrated the
formation of a 3'-keto-dUDP intermediate (Harris et al., 1984; Ator and Stubbe, 1985;
Salowe et a, 1987). (The intermediate was subsequently shown to producea highly
reactive furanone which led to enzyme inactivation.) Another substrate analog, 2'-
azido-2' deoxyuridine 5'-diphosphate (N3UDP), was used in further studies and
revealed the ability of the enzyme to mediate a radical-dependent reaction (Saloweet al.,
1987; Sjoberg et al., 1983). In this reaction, one equivalent of N3UDP inactivated the
enzyme, producing one equivalent each of N2, PPi, and sugar. More than 90% of the
tyrosyl radical was destroyed, and a new nitrogen-centered radicalwas formed from the
N3 moiety of N3UDP.
Although the tyrosyl radical is absolutely required for activity, there had been
much debate about whether the radical acted directly during catalysisor through some
form of electron transfer. The crystallographic studies established that the ironcenter
and radical are buried in the small subunit, and therefore excluded mechanisms25
involving direct transfer of electrons (Nordlund et al., 1990). The current theory about
how electrons are transfered from the radical to the catalytic site is through an electron
tunneling mechanism. Electron tunneling is the phenomenon of long distance (>5 A)
electron transfer through a protein, by interacting networks of chemical bonds that form
a physical tunnel for electrons (Beratan et al., 1991). In order to identify target
residues for electron transfer (the end of the tunnel), site-directed mutagenesis studies
have been undertaken (Mao et al., 1989; Aberg et al., 1989).
11.1.4 Iron Center/ Radical Activation
Another intriguing aspect of this complicated enzyme is the mechanism of
assembly of the iron center and generation of the radical species. Although several
other binuclear iron cluster proteins have been described (Que et al., 1990; Sanders-
Loehr, 1988; Fox et al., 1988), only ribonucleotide reductase uses the iron center fora
one-electron oxidation that generates a stabilized free radical. This section describes the
stoichiometry of this reaction and the components that are necessary in vivo and in vitro
to generate the iron/radical cluster. Models for the oxidative states of the cluster and the
mechanism of activation are also discussed.
Recent evidence from plasma emission spectroscopy and X-ray diffraction has
demonstrated that one binuclear iron center is generated per protomer and that one
tyrosyl radical could potentially be formed per R2 peptide (Lynch et al., 1989;
Nordlund et al., 1990). Once the tyrosyl radical is formed, however, the concentration
of radical can fluctuate in the cell in response to the cell's growth cycle (Barlow et al.,
1983). This finding first suggested that cellular mechanisms are available in vivo to
reduce and regenerate the radical. By fractionating E. coli extract with column
chromatography, it was established that three protein components, Fe2+, and 02
participate in vivo to generate the tyrosyl radical (Fontecave et al., 1987a). Theenzyme26
NAD(P)H:flavin oxidoreductase was identified as one of the protein components, and
was shown to reduce both ferric ions to ferrous. These ferrous ions then self-
assembled into the active center in the presence of 02 and reductant. In addition,
superoxide dismutase was found to be a required component during radical
regeneration, and was shown to prevent the formation of superoxide anion (02) from
reduced flavin oxidation (Fontecave et al., 1987b). The third peptidecomponent of the
E. coli extract that was necessary for generation of the active center hasnot yet been
identified (Eliasson et al., 1986).
For in vitro systems, addition of Fe2+, in thepresence of 02, to the reduced
form of the enzyme (without the metal) led spontaneouslyto the reassembly of the
active binuclear iron/radical cluster (Atkin et al., 1974). The stoichiometryof this
reaction was recently resolved for both the bacterial and mammalianenzymes (Elgren et
al., 1991; Ochiai et al., 1990). Elgren and co-workers determined thebalanced
equation for 02 activation of the bacterial R2 protein by simultaneously usingan
oxygraph to quantify oxygen consumption, EPR spectroscopyto measure tyrosyl
radical content, and Mossbauer spectroscopy to determine theextent of Fe oxidation
(Elgren et al., 1991). Figure II.6 shows the chemical equation thatwas derived from
these experiments. Analogous experiments on the mouse R2 protein revealeda similar
stoichiometry (Ochiai et al., 1990). In the equation, four reducing equivalentsare
necessary to form active protein; two of these electrons are provided by reduction of the
diferrous center to a diferric center, and a third electron is donated by theTyr-122. The
source of the fourth electron in vivo has been intensely debated. One possiblesource,
derived from the R2 protein itself, is discussed below.
Other than the inactive R2, which lacks both metal and radical, and thefully
activated R2, two additional oxidative states for the R2 protein have beenidentified.
Characterization of these states has led to a proposal for how the iron/radicalcenter isR2-Tyr + 2Fe2-f + 02 + e-+2H+ --->
R2-Tyr-+
,02,-
Fe3+ Fe-++ H20
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generated (Figure 11.7). The first of the depicted subunit states, the inactive apo- form,
lacks an iron center and contains a nonradical tyrosyl residue. Addition of two
equimolar equivalents of ferrous ion under anaerobic conditions converts the apo- form
of the enzyme into the R2red state. The R2fed subunit contains a unique binuclear
ferrous species, but no tyrosyl radical. In mammalian cells, admission of air
spontaneously converts R2,,,d into the active R20,; R20, contains both the binuclear
ferric center and the tyrosyl radical. For in vitro bacterial extracts, 02, and dithiothreitol
are able to convert R2,,d to R2ox only if the pH is maintained between 8.0-9.5
(Fontecave et al., 1989). Presumably, at the increased pH, the iron center binds less
tightly to the E. coli protein, and is more easily replaced witha reduced iron center.
Because iron binding for the mammalian enzyme is weaker than for the E. colienzyme,
the higher pH is not needed to release iron. The final state of the subunit is formed by
one-electron reduction of R2ox. The product, R2Toet, contains the intact ferric center,
but is without tyrosyl radical. Hydroxyurea, a radical scavenger andpotent inhibitor of
ribonucleotide reductase, is capable of the one-electron reduction of R20 that leadsto
its conversion to R2me, (Sahlin et al., 1989). R2,et can be converted back to active
R2ox by two different means. In an indirect route, the ferric center of R2me,can be
reduced back to the R2,1 ferrous center, and then oxidation by 02 reforms the ferric
species and simultaneously forms the tyrosyl radical. In an alternate route,treatment of
R2roei with hydrogen peroxide directly generates the free radical (Sahlinet al., 1990).
There is evidence that conversion of R2,e, to R2ox proceeds througha ferryl(Fe02+)
intermediate (Sahlin et al., 1990; Yamazaki and Piette, 1990).
Detection of transitory intermediates during the iron-mediated oxidation reaction
has added additional insights to the understanding of this mechanism of radical
generation. Two reactive intermediates were detected by Bollinger et a/. (1991a),
through stopped-flow absorption spectroscopy and rapid freeze-quench EPR{ Fe(III), Tyr }
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spectroscopy. They proposed that one intermediate is a t- peroxodiferric complex and
the other, an iron-coupled radical (Bollinger et al., 1991a). Kinetic data showed that
both new species were able to oxidize Tyr-122 to the stable tyrosyl radical. The
proposal by these authors, for the oxidation reaction of R2v, to form R2., is shown in
Figure 11.8. In the model, R21 with 02 and two equivalents of ferrous ion to
form the .t- peroxodiferric intermediate. In the presence ofexcess reductant (Fe2+), the
p.- peroxodiferric species is rapidly converted to the radical intermediate. This
intermediate then undergoes one-electron reduction by Tyr-122to generate the final
products. One unique feature of this model is that it does not predict high-valenceiron-
oxo intermediates; the apparent intrinsic reactivity towards the one-electron reduction
comes from the putativeg-peroxodiferric intermediate. Although the structure of the
new radical intermediate has not been determined, Mossbauer spectroscopy indicates
that the species contains two spin-coupled ferric ions (Bollingeret al., 1991b).
An additional mixed valence form of the iron cluster Fe(II)Fe(III)was recently
identified and characterized by two independent laboratories (Hendrichet al., 1991;
Gerez et al., 1991). In a novel approach to EPR spectroscopy, Que'sgroup submersed
R2 subunit in liquid nitrogen, and then it was slowly heated in thepresence of ionizing
radiation from an X-ray source. The X-irradiation and slow heating stabilizedthe mixed
valence intermediate, and allowed for its detection. Latour identifiedthe same partially
reduced iron species by treating R2 with a diimide (at high pH), and monitoringthe
disappearance of the characteristic EPR radical signal and theappearance of an
intermediate signal. The intermediate signal was shifted toa lower microwave
frequency and was identified as the mixed valence Fe(II)Fe(III) species. Theexistence
of a mixed valence state does have precedence in other binuclear ironproteins (Fox et
al., 1988). Although the presence of the mixed valencestate in ribonucleotide
reductase seems to contradict the activation model proposed by Stubbe, Quedescribes a31
unique role for the species. Que proposes that the fourth electron required to generate
active protein comes from intra- or intermolecular electron transfers from neighboring
iron clusters. Oxidation of one of the neighboring ferrous ions in a diferrous cluster,
would then form the mixed valence species. The newly formed mixed valencecenter
would then be incapable of oxidizing its own Tyr-122 to the radical state. This model
not only provides a role for the mixed valent intermediate, but proposes a protein
source for the elusive fourth electron.32
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Although the maximum theoretical yield of radical is one per protomer, this
amount of radical has never been detected; the largest number of radicals reported
experimentally was 1.6 per R2 dimer for the mouse enzyme (Mann et al., 1991). A
theory presented to explain the discrepancy between the values for theoretical and
experimental radical concentration involves the concept of "half-site reactivity" (Sjoberg
et al., 1987; Larsson et al., 1988). In this model, only one of the Tyr-122 residues is
activated and utilized for catalysis; it is suggested that the other Tyr-122 residue could
assist in iron/radical center generation (Sjoberg et al., 1987; Larsson et al., 1988). The
recent work by Que, describing the mixed valent intermediate, has given added
credence to this model. Formation of the mixed valent species in an iron cluster,
predicts less than complete occupancy of radical at that particular Tyr-122 (Elgren et al.,
1991).
11.1.5 Hydroxyurea Inhibition Studies
Hydroxyurea (HU) is a hydroxamic acid that is frequently used as an inhibitor
of DNA synthesis, an agent for synchronizing cells, and as an antineoplastic
chemotherapy drug (reviewed by Moore and Hurlbert, 1985). The structure of HU and
other hydroxamic acids that inhibit ribonucleotide reductase are shown in Figure 11.9.
Treatment of cultured cells with HU leads to deoxynucleotide pool imbalances,
reversible inhibition of DNA synthesis, reversible arrest of the cell cycle in early S
phase, double-stranded breaks in DNA, chromosomal aberrations, and ultimatelycan
cause cell death (reviewed by Timson, 1975). The primary target of HU was identified
in 1964 as ribonucleotide reductase (Frenkel et al., 1964). This section describes the
mechanism of ribonucleotide reductase inhibition by HU, and examines how the
structural and regulatory state of the enzyme affects HU inhibition. Molecular
mechanisms for resistance to HU are also discussed.34
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11.1.5.1 Mechanism of Inhibition
Early mechanistic studies with hydroxyurea, hydroxamic acids, and related
analogs established that the activity of the inhibitors towards ribonucleotide reductase
could be correlated with the ability of these compounds toreact with the model free-
radical salt, potassium nitrodisulfonate (Kjol ler-Larsen et al., 1982). Since ithad
previously been established that the R2 protein of ribonucleotide reductasealso
contained a free radical species (Ehrenberg and Reichard, 1972), itwas not long before
experiments determined that the R2 radical was the direct site of inactivationby HU
(Atkin et al., 1973). Studies with the unusual ribonucleotide reductases(those that
used AdoCbl and AdoMet as cofactors), revealed that theseenzymes were insensitive to
the effects of hydroxyurea (Lammers and Follman, 1983; Hogenkampet al., 1987).
These results were expected, as theseenzymes do not contain stabilized free radical
species.
Subsequent experiments with the T4 and E. colienzymes demonstrated that the
tyrosyl radical exhibited a ten-fold higher susceptibility towardsinactivation by HU
during catalysis (Sahlin et al., 1982; Kjoller-Larsenet al., 1982). The rate of E. coli
holoenzyme inactivation was recently examined in thepresence of positive and negative
effectors and substrate and product .3 Formation of the Rl/R2 holoenzymewas found
to change the susceptibility of the radical towards HU in amanner than reflected the
regulatory state of the enzyme. For example, addition of the positiveeffector ATP
increased the sensitivity of the holoenzyme radical towards HU by 30%.Addition of
inhibitory concentrations of dATP decreased radical susceptibility,two-fold, and
addition of either CDP or dCDP increased the sensitivity of the radical.These results
suggest that a conformational change in R2 is induced by binding of effectors and
3 M. Karlsson, M. Sahlin, B.-M.Sjoberg, submittedto J. Biol. Chem.36
substrate. In addition, this conformational change appears to directly alter the ability of
HU to reduce the radical species.
Comparative studies of ribonucleotide reductase from different organisms
showed that the sensitivity to HU and structural impediments towards inactivation
differed for the various enzymes. Enzyme activity from mammalian cells (Sahlinet al.,
1982), T4 bacteriophage (Yeh and Tessman, 1978), herpes simplex virus(Langelier
and Buttin, 1981) and pseudorabies virus (Lankinen et al., 1982)were all found to be
much more sensitive to HU than the E. colienzyme (Yeh and Tessman, 1978). The
mammalian and viral enzymes were also effectively inhibited bya wide size range of
HU analogs. The E. coli enzyme, on the other hand,was insensitive to analogs with
bulky side groups larger than 4 x 6 A (Kjoller-Larsenet al., 1982). Access of HU
towards the E. coli radical is also shielded from negatively charged molecules(Sahlin et
al., 1989). These studies suggested that the mammalian and viral ironcenters are more
accessible to HU than is the E. coli center.
Other studies with the HU-inactivated mammalianenzyme demonstrated that
HU inhibition of ribonucleotide reductasewas reversible. After removal of HU, the
mammalian enzyme was able to regenerate spontaneously undernormal assay
conditions (dithiol, 02, Fe2+), (Graslund et al., 1982). On the other hand,studies with
purified E. coli ribonucleotide reductase showed that the HU-inactivatedenzyme could
be regenerated only by removing and replacing the iron-oxo bridge,or enzymatically,
through the addition of Fe2+, 02, NAD(P)H:flavin oxidoreductase andsuperoxide
dismutase (Petersson et al., 1980; Eliasson et al., 1986) As discussedin the previous
section, the iron redox studies demonstrated that HU acted througha one electron
reduction to convert R20x to R2,, (Sahlin et al., 1989). It has sincebeen suggested
that treatment of mammalian enzyme with HUcauses the loss of iron from the protein,
while the E. coli iron center remains intact. In fact,a recent paper describes37
destabilization of the mammalian iron center after HU treatment (McClarty et al., 1990).
Current mechanistic studies are aimed at confirming this prediction by kinetically
measuring the dissociation of iron from both the E. coli and mammalianenzyme.
11.1.5.2 Deoxynucleotide Pool Effects
The functional role of ribonucleotide reductase is to supply balanced levels of
deoxynucleotide precursors for DNA synthesis and repair. Inhibition of theenzyme
would, therefore, be expected to decrease the flux of deoxynucleotides from the de
novo source. Without the regulatory control from the allosteric enzyme, distortion of
the relative concentrations of the individual pools might also be anticipated.
Researchers have examined the effect of the inhibitor, HU, on deoxynucleotide pools
and metabolism (Reviewed by Fox, 1985). The effect of inhibiting concentrations of
HU on deoxynucleotide pool levels in various cultured cell lines is reviewed in Table
11.3. Rather than the predicted reduction in synthesis and pool size of all
deoxynucleotides, these studies consistently showed that HU addition appearedto
differentially deplete just the purine pools. In most cases, the dATP poolwas most
drastically depleted, while the dGTP pool was also significantly diminished. The
pyrimidine pools actually showed increases in dTTP and dCTP levels after HU
treatment. Through the elegant work of Reichard and co-workers, the mechanism
behind the pool size variations in the presence of this inhibitor was revealed (Bianchiet
al., 1986a: Bianchi et al., 1986b). These researchers showed thatan additional
mechanism for regulating pyrimidine deoxyribonucleotides existed. This regulation
occurred through 'substrate cycling' by directing the flow of pyrimidine
deoxynucleotide across the cell membrane. In the presence of HU, the intracellular
pyrimidine pools are fed by a net influx and phosphorylation of deoxyuridine from theTable 11.3Effect of 1-1U on Deoxynucleotide Pool Levels
Cell Type Reference Hydroxyurea
Concentration
Fold change from Control, (where control = 1)
dATPdGTPdCTPdTTP
Mouse embryo cells Skoog and 1 mM(1 hr) 0.18 0.13 1.2 2.1
Nordenskjold, 1971
10 mM(1 hr) 0.18 0 1.2 2.4
Activated Human Tyrsted, 1982 0.1 mM (28 hr) 0.2 0.7 0.8 0.7
Lymphocytes
1.0 mM (28 hr) 0.1 0.4 0.4 0.6
Mouse Fibroblasts Bianchi et al., 1986b 0.1 mM 0.36 0.23 0.61 1.1
3.0 mM 0.37 0.25 0.71 1.2
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medium and by dearnination of intracellular dCTP. No such cycling system exists for
the purine deoxynucleotides and, therefore, these pools are depleted (Reichard, 1988).
Many attempts have been made to circumvent the effects of HU on cellular
pools by the addition of one or more deoxynucleotide(s) or deoxynucleotide(s) (Adams
and Lindsay, 1967; Gale, 1967; Plageman and Erbe, 1974; Lagergren and Reichard,
1987; Eriksson et al., 1987; Walker et al., 1977; Yarbro, 1968; Young et al., 1967).
Unexpectedly, the results of these investigations were preponderantly negative.
11.1.5.3 Mechanisms of Resistance
Drug resistance can occur through many different mechanisms. The cytotoxic
effect of hydroxyurea makes it a very good selective agent for isolating drug-resistant
cell lines with specific alterations in ribonucleotide reductase (reviewed by Wrightet
al., 1990). Characterization of cultured cell lines grown in the presence of low to
moderate amounts of HU has revealed that amplification of the small subunit R2gene
encoding ribonucleotide reductase is a common mechanism responsible for resistance
(Wright et al., 1987; Choy et al., 1988; Tagger and Wright, 1988). At these
concentrations of HU, R2 gene amplification leads to elevated R2message and protein
levels, without any changes in RI gene expression. At higher concentrations of HU,
R2 amplification is accompanied by large subunit R1 gene amplification and expression
(McClarty et al., 1987; Choy et al., 1988; Hurta and Wright 1990). Molecular
mechanisms for HU resistance involving ribonucleotide reductase alterations have also
been studied for the yeast (Rittberg and Wright, 1989) and vaccinia virus (Slabaugh
and Mathews, 1986; Slabaugh et al., 1988) reductase genes. In bothcases, the ability
to overcome sensitivity to HU was dependent on small subunit gene amplification.40
11.1.6 Regulation of Gene Products
Like many other enzymes involved in deoxynucleotide metabolism, the activity
of ribonucleotide reductase increases when cells prepare for DNA synthesis (Reichard,
1988). This increase in activity does not depend on DNA synthesis but is regulated (in
cultured and eukaryotic cells) in connection with the cell's mitotic cycle. Figure II.10 is
a diagram depicting the four stages of the cell cycle. Experiments have been used to
correlate increases in enzyme activities during the cell cyle, with increases incontent of
enzyme proteins and mRNAs. This section describes experiments that determined the
modes of regulation for ribonucleotide reductase during E. coli growth and during the
mammalian cell cycle.
11.1.6.1E. coli Subunits
Synthesis of the two subunits of E. coli ribonucleotide reductase is coordinately
regulated and occurs in parallel with DNA synthesis (Filpula and Fuchs, 1977).
However, inhibition of DNA synthesis by chemical agents results inan increase in
ribonucleotide reductase activity (Hanke and Fuchs, 1983). Itwas determined that the
increased activity was due to an increased rate of reductasegene transcription (Hanke
and Fuchs, 1983). Molecular analyses of the genes and promotersequences around the
bacterial nrd genes have led to a model for transcriptional regulation of E. coli
ribonucleotide reductase (Tuggle and Fuchs, 1986, 1990). Thetwo genes that encode
the large and small subunits, are located on a single operon (Carlsonet al., 1984).
Deletion analysis identified two negative regulatory regions flanking the reductase
promoter (Tuggle and Fuchs, 1986). A positive regulatory site was also mapped
upstream from the large subunit gene (Tuggle and Fuchs, 1986). The presence of both
positive and negative regulatory elements allows the bacterial cell to communicatethe
need for DNA synthesis to the operon. A DNA/protein bindingassay has beenFigure II.10Eukaryotic Cell Cycle
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developed and is currently being used to identify the proteins responsible for regulation
of these genes (Tuggle and Fuchs, 1990).
11.1.6.2 Mammalian subunits
Like the E. coli reductase genes, the genes that encode the mammalianenzyme
are coordinately regulated. The genes encoding both the human (Yang-Feng et al.,
1987) and mouse (Brissenden et al., 1988) ribonucleotide reductase have been
characterized and located to separate chromosomes. Using antisense RNA probes, it
was established that the levels of both genes increased when cultured mouse cells
progressed from either Go or GI into the S-phase of the cell cycle (Bjorklundet al.,
1990). The decline in message levels of both subunit mRNA'swas also found to be
coordinate (Bjorklund et al., 1990). Dispite these findings, posttranslationalregulation
of the two proteins was found to be quite disparate. Expression of the smallsubunit
protein in proliferating cells correlates strictly with the S-phase of the cell cycle
(Eriksson et a/., 1984). The levels of RI protein,on the other hand, are constant
during the cell cycle (Engstrom et al., 1984). This regulatory paradox of coordinate
mRNA expression and uncoordinate protein level accumulationwas resolved when the
stability of the two proteins was measured. Breakdown of the R2 proteinoccurs
readily, with a protein half-life of 3 h (Eriksson et al., 1984). However,the RI protein
is very stable (half life of 20 h), and therefore remains intact throughout thecell cycle
(Mann et al., 1988). Indeed when RI protein was measured in quiescentor terminally
differentiated cells, the levels were almost undetectible (Engstromet al., 1984; Mann et
al., 1988). It has been demonstated that eukaryotic ribonucleotide reductaseactivity is
cell cycle-dependent and that activity correlates with cellular DNAcontent (Eriksson et
al., 1984). This finding first suggested that the R2 proteinwas limiting at times other43
than S-phase and that enzyme activity was regulated by the levels of small subunit
protein.
11.2 Vaccinia Virus
Vaccinia is a member of the Poxviridae family of viruses, which infect both
vertebrate and invertebrate hosts. Within the genus Orthopoxvirus is the notorious
variola virus, the causative agent of smallpox. Nonetheless, the prototype for this
genus is the well-characterized vaccinia virus. Vaccinia virus was originally identified
as an immunizing agent against cowpox in 1798 by Edward Jenner (Jenner, 1959).
Because of the serological relatedness of the vaccinia and variola viruses, vacciniawas
administered as a live vaccine in the campaign by the World Health Organization to
eradicate smallpox (World Health Organization, 1988). Vaccinia continues to be used
as a vector for developing recombinant viruses for use as live vaccines (reviewed by
Fenner, 1988; Moss, 1991). The virus is particularly well-suited for use as a vaccine
because it has a broad mammalian host range and the genome has a large capacity to
accept foreign DNA (up to 25 kilobases). Because of these advantages, vaccinia has
also become extensively used as a eukaryotic cloning and expression vector (Fuerst et
al., 1987).
The vaccinia virus particle is a large brick-shaped structure composed of an
outer lipoprotein envelope, a single duplex DNA genome, and two lateral protein
bodies with unknown function. With the advent of molecular biology, it was
discovered that the poxviruses exhibit the unusual ability to replicate within the
cytoplasm, rather than the nucleus, of the infected host cell (reviewed by Moyer and
Graves, 1981). Because of the cytoplasmic site of replication, viral nucleotide and
deoxynucleotide metabolism are controlled entirely by viral gene products. In fact,44
vaccinia encodes functions necessary for control of viral transcription, mRNA
processing, DNA replication, and DNA recombination.
11.2.1 Genome Organization and Replication
The vaccinia virus genome is a covalently-closed linear duplex DNAmolecule
that contains two 10-kilobase regions of AT-rich inverted terminalrepeats (reviewed by
Traktman 1990). A Copenhagen strain of the vacciniagenome has been completely
sequenced and it was determined that the 190 kilobases of viral DNAencode 198 open
reading frames (ORFs) of at least 60 amino acids (Goebelet al., 1990). The ORFs
are bidirectional, tightly spaced, and contain no intervening sequences. Each viralgene
contains its own transcriptional promoter. Computer analysis hasdemonstrated a high
degree of sequence homology within the central region of thegenome among different
members of the poxvirus family. Among the viralgenes of known function that have
been sequenced, there is also much sequence homology with mammalianprotein
counterparts (reviewed by Moss, 1990). Sequence variability is foundat the ends and
within the terminal repeats of thegenomes. Through the use of temperature sensitive
mutants and genetic analyses, many essential genes have been physically mapped
within the genome (Condit and Motyczka, 1981; Conditet al., 1983).
Although the host cell nucleus is required for maturation of virusparticles,
vaccinia virus is able to replicate its DNA within enucleated cells(Prescott et al., 1971).
Accordingly, the virus must encode all the functionsnecessary for viral DNA
replication. The locations of the genes encodingmany of the enzymes involved in
replication and deoxynucleotide metabolism have been determinedand are shown in
Figure II.11. It should be noted that thegenes that encode the viral ribonucleotide
reductase proteins are separated by 35 kilobases.CNMK F
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Viral DNA replication takes place in cytoplasmic inclusion bodies called
virosomes (Dahl and Kates, 1970). Virosomes are composed of viral nucleoprotein
and immunolocalization studies have revealed the presence of ribonucleotide reductase
(Davis, 1992) and other replication enzymes at these viral DNA factories. Early studies
demonstrated that the rate of viral DNA replication is several times that of dividing
eukaryotic cells and that a full 30% of all virally-replicated genomesare packaged into
virions by 24 h post infection (Joklik and Becker).
Experiments which measure [3H]- thymidine incorporation into acid-precipitable
material have been used to estimate the time course of viral DNA replication. These
studies concluded that DNA synthesis begins approximately 1.5 h after viralentry into
a cell, reaches a maximal rate at 2.5 to 3 hours post infection, and then declines rapidly
(Joklik and Becker, 1964). However, recent quantitative filter hybridization
experiments to measure accumulation of viral DNA have shown contradictory results.
The hybridization experiments demonstrate that increases in intracellular vaccinia DNA
are detected by 3 h post infection and then accumulate at a constant rate until
approximately 10-12 h post infection (Ensinger, 1987; Rempel et al., 1990). This
experimental discrepancy towards the viral DNA replication kinetics probably reflects
the inherent innaccuracies in measurements of deoxynucleotide pools (thymidine levels)
in an active metabolic system. A basic assumption of the [3H]- thymidine incorporation
experiments is that the intracellular concentration of thymine nucleotides isconstant.
However, this assumption has not been tested in virus-infected cells. Moreover,
deoxynucleotide pools in other eukaryote systems have been shownto fluctuate
extensively during replication (Reichard, 1988; Bianchi et al., 1986). The
hybridization experiments, therefore represent a more accuratemeasure of viral DNA
synthesis.47
The mechanism of viral replication has been well characterized (reviewed by
Moss et al., 1983; Moyer and Graves, 1981). Briefly, DNA nicks are introducednear
either end of the parental genome soon after viral infection and replication begins at
these sites. Viral DNA is apparently self primed and synthesis occurs in a semi-
discontinuous fashion. During replication, hairpen loop structures form at the inverted
terminal genome repeats. Replication eventually generates viral concatamers in which
genomes are joined head-to-head and tail-to-tail. Resolution of each concatameric
junction results in the formation of two full length genomes.
11.2.2 Viral Infectivity and Inhibition ofCellular Macromolecular Synthesis
Infection of a single eukaryotic cell with vaccinia virus can lead to the
production of several hundred to thousands of infectious virus particles, dependingon
the type of cell infected, and the multiplicity of virus used for the infection (Joklik and
Becker, 1964). This section discusses the viral mode of infection and the effect of the
virus on host macromolecular processes.
Poxvirus entry into the host cell occurs naturally through the cellularprocess of
membrane pinocytosis (Dales, 1963). Because entry of virus is not restricted, the host
range of the poxviruses is determined not by cell entry, but through the action of a
virally-encoded protein protein. In vaccinia virus, an hr (host range)gene has been
sequenced (Gillard et al., 1986) and a viral host range protein has been physically
characterized (Gilard et al., 1989). Mutant deletion studies suggest that the hostrange
protein acts as an antagonist towards host factors which inhibit viral protein synthesis
(Drillien et al., 1981)
In order to replicate and package so many virions in a relatively short period of
time (20-30 h), the poxviruses suppress the metabolic activities of their hosts. Vaccinia
virus inhibits host cell DNA synthesis (Jungwirth and Launer, 1969), cell protein48
synthesis (Moss, 1968), transfer of nuclear RNA into the cytoplasm, and eventually
RNA synthesis (Becker and Joklik, 1964). These degradative events allow the virusto
control, and in some cases, to utilize the metabolic potential of the cell. In thecase of
host cell DNA synthesis, it is believed that upon infection, a host specific
deoxynuclease is released directly from the virus core. Host cell DNA synthesis
inhibition begins immediately after infection and cellular DNA is degraded into large
DNA fragments of discrete sizes (Parkhurst etal., 1973). The degraded cellular DNA
is not made available to the virus for utilization under normal conditions (Kit and
Dubbs, 1962).
11.2.3 Viral Lifecycle and Regulation of Viral Gene Transcription
Within the viral life cycle, there are three distinct classes ofgenes and gene
transcription; early, intermediate, and late. These stages form a cascade of temporal
gene expression; each class of gene is expressed at a specific period in the viral lifecycle
and only for a discrete length of time. For a complete review of viral transcription
regulation, see Moss, (1990). Depending on the cell type and multiplicity of infection,
the entire viral life cycle is completed within approximately 8-12 h. All of theenzymes
necessary for early gene expression are packaged within the virion core of the
infectious particle (Nevins and Joklik, 1977). Upon infection, the virionenters the
host cell through direct penetration or membrane fusion (Dales, 1963). Two uncoating
processes then release the intact viral core from various membrane proteins and
glycoproteins. Transcription of early genes begins immediately after infection,
continues for about 3-4 h, and then ceases. Early genes include those encoding
replication functions, virion proteins, and intermediate transcription factors. Coincident
with the start of DNA replication (approximately 2 h post infection) is the activation of
intermediate genes by the intermediate transcription factors. The intermediategenes49
primarily encode late transcription factors. Late transcription factors activate synthesis
of structural coat proteins, other virion proteins, early transcription factors, and the
early transcription enzymes destined for encapsidation. Early, intermediate, and late
genes can be distinguished by differences in promoter consensus sequences. Also,
because early genes contain termination signal sequences, early messagesare of a
discrete size. Intermediate and late genes do not contain termination signals, however,
and synthesize run-on messages. In addition, there are differences in 5'-capping and
3'-polyadenylylation of the various temporal messages.
A complex series of morphogenetic events are responsible for virus particle
formation. Along with DNA replication, immature virion formation takes place within
and surrounding the virosomes. Crescent shaped structures derived from host cell
lipids form around a portion of the viroplasm, and then through a series of morphologic
steps (which are clearly identifiable with an electron microscope) the infectious particle
takes form. Many of the viral core and membrane polypeptides contain
posttranslational modifications, including proteolytic cleavage, phosphorylation,
glycosylation, and ADP-ribosylation (VanSlyke and Hruby, 1990). These
modifications help to regulate the events in viral morphogenesis.
11.3 Vaccinia Virus Ribonucleotide Reductase
Preliminary characterization of the viral ribonucleotide reductasewas
accomplished in large part by the work of both Slabaugh and Roseman. As mentioned
previously, the genes that encode the viral ribonucleotide reductase have been
sequenced and localized within the HindIII F (R2) and HindIII I (R1) genomic
restriction fragments (Slabaugh et al., 1988; Tengelson et a/., 1988; Schmitt and
Stunnenberg, 1988). (Figure 11.12). Primer extension and Si nuclease mappingC NMK FE POI6LJ H D A B
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experiments were subsequently used to define the reductase transcriptional units. In
addition, Northern blot analysis has demonstrated that both genesare transcribed early
in the viral life cycle (Tengelson et al., 1988; Roseman and Slabaugh, 1990).
Comparison of the amino acid sequences of ribonucleotide reductases from
several species reveals a high degree of homology between the mammalian reductase
and vaccinia virus polypeptides (Slabaugh et al., 1988; Tengelson et al., 1988). Figure
11.13 is an amino acid comparison of nine different R2 proteins. Themouse and
vaccinia small and large subunit amino acid sequences share 80% and 72% amino acid
identity, respectively. In contrast, there is only 20% homology between the vaccinia
virus and E. coli or T4 bacteriophage R2 amino acid sequences. The three herpes
simplex viral polypeptide sequences share only 30% homology with the vaccinia R2
sequence. Slabaugh proposes that the strong sequence homology between the mouse
and vaccinia enzymes suggests that the viral enzymes are of eukaryotic origin. Figure
11.14 is a phylogenetic tree that was generated by computer analysis of the R2 amino
acid sequences. The tree also suggests a large degree of evolutionary relatedness
between the vaccinia and mouse R2 proteins.
Initial characterization of the vaccinia virus ribonucleotide reductase also
demonstrated allosteric similarities of the enzyme to its mammaliancounterpart
(Slabaugh and Mathews, 1984a). Unlike the T4 bacteriophage and herpes simplex
virus enzymes, which are insensitive to many of the regulatory signals for the cellular
reductases (Averett et al., 1983; Berglund, 1972), vaccinia virus R2 is allosterically
inhibited by both dATP and dTrP and shows a strict requirement fora positive
activator. Further characterization of the vaccinia virus enzyme proved that therewere
also distinctions between the mammalian and viral enzymes (Slabaugh and Mathews,
1984b). The viral Km for CDP is three-fold lower than that for the mammalianTI
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enzyme. Additional differences in Mg2+ requirements and substrate affinities were also
uncovered. To more carefully compare the kinetic and allosteric properties of the viral
and mammalian enzymes, large quantities of purified active enzyme from both
organisms would be required. The importance of further characterizing the vaccinia
virus ribonucleotide reductase were motivating factors towards the subsequent work to
produce and overexpress recombinant viral enzyme.
Although viral insertion and deletion mutants had been isolated in regions
spanning the entire viral genome, it was indeed surprising when it was revealed that
viable viral mutants could be isolated with mutations harbored in both the R1 and R2
genes (Child et al., 1990; Perkus et al., 1986). In all cases, the viral mutants showed
reduced virulence, but were capable of sustaining viral growth after infection of either
resting or dividing cells. These data firmly establish that neither reductase subunit is
essential for viral replication. How then, is the supply of deoxynucleotide precursors
supplied for viral replication in these mutants? The answer to this question may rest
with the cellular host reductase. Immunolocalization of cellular R1 and R2 indicates
that the subunits are both cytoplasmic (Engstrom et al., 1984; Engstrom et al., 1988).
It is possible that the mammalian host enzyme substitutes for the viral enzyme in these
insertion and deletion mutants. An informative experiment would be to compare the
expression kinetics of the host ribonucleotide reductase during a viral infection using
wild-type vaccinia, with that from a viral infection using the ribonucleotide reductase
minus mutants. It would also be very interesting to determine if the host ribonucleotide
reductase remained cell-cycle dependant after infection with these mutant viruses.
Another untested explanation for the viability of the vaccinia reductase mutants is that
one of the host range subunits (large or small) may complement and activate the viral
reductase with the missing subunit component. In this case, the reductase activity55
would not come from the holoenzyme, but from a hybrid combination of viral subunits
and host subunits.56
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1II.1 Abstract
During its infectious cycle, vaccinia virus expresses a virus-
encoded ribonucleotide reductase which is distinct from the host cellularenzyme
(Slabaugh et al 1984a, 1984b). We have cloned the gene for the small subunit
of vaccinia virus ribonucleotide reductase (designated VVR2) into Escherichia
coli, and expressed the protein using a 17 RNA polymerase plasmid expression
system. Following isopropyl B-D-thiogalatopyranoside induction, accumulation
of a 37-kDa peptide was detected by SDS-polyacrylamide gel electrophoresis,
and this peptide reacted with polyclonal antiserum raised againsta TrpE-VVR2
fusion protein. The 37-kDa protein was purified to homogeneity, and gel
filtration of the purified protein revealed that the recombinant protein existedas
a dimer in solution. Purified recombinant VVR2 protein was shown to
complement the activity of purified recombinant ribonucleotide reductase large
subunit, with a specific activity that was similar to native VVR2 froma virus-
infected cell extraxt. A CD spectrum of the recombinant viral protein showed
that like the mouse protein, the vaccinia virus protein has 50% a-helical
structure. Like other iron-containing ribonucleotide reductase small subunits,
recombinant VVR2 protein contained a stable organic free radical thatwas
detectable by EPR spectroscopy. The EPR spectrum of purified recombinant
VVR2 was identical to that of vaccinia virus-infected mammalian cells. Both
the hyperfine splitting character and microwave saturation behavior of VVR2
were similar to those of mouse R2 and distinct from E. coli R2. By using
amino acid analysis to determine the concentration of VVR2,we determined that
0.6 radicals were present per R2 dimer. Our results indicate that vaccinia
virus R2 is similar to mammalian ribonucleotide reductases.58
111.2 Introduction
Ribonucleotide reductase is an essential enzyme in DNA replication, providing
the only source of de novo-synthesized deoxyribonucleotides. In both Escherichia coli
and eukaryotic organisms, the holoenzyme is composed of two homodimers:an
allosteric/catalytic subunit, designated R12,whose protomers have molecular weights
of 83,000 to 87,000, and a smaller iron-containing subunit, designated R2, with
protomer molecular weights of 37,000 45,000 (Sjoberg and Graslund, 1983).
Although several types of ribonucleotide reductase have been described, accumulating
evidence suggests that all forms of the enzyme utilize a free radical mechanismto
initiate reduction of the four ribonucleotide substrates (reviewed in Stubbe, 1990). In
the iron-containing reductases, the source of the radical isa tyrosine side chain
(Larsson and Sjoberg, 1986) that has recently been shown byx-ray crystallography to
reside within a hydrophobic pocket in each R2 protomer, adjacentto a diferric iron
center (Nordlund et al., 1990).
The mechanism by which the diferric tyrosyl radical center in R2 is formed and
maintained is currently the subject of intense research (Sahlin et al., 1989; Ochiaiet al.,
1990; Fontecave et al., 1990; Sahlin et al., 1990; Stubbe, 1990). Iron bindingto
mouse R2 apoprotein appears to be highly cooperative (Ochiai et al., 1990), and
evidence from the E. coli and mouse proteins indicates that generation of the radical is
concomitant with oxidation of the diferrous protein to the oxo-bridged diferricstate.
However, tyrosyl radical quantitation by EPR of R2 proteins from varioussources has
yielded variable results, usually around 0.5 radical/polypeptide chain, rather than the
2 The abbreviations usedare: E. coli, Escherichia coli; R2 and R1, small and large
subunit of ribonucleotide reductase, respectively; SDS, sodium dodecyl sulfate;
PMSF, phenylmethylsulfonylfluoride; HEPES, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; HPLC, high performance liquid chromatography; mW,
milliwatts.59
theoretical maximum of 1.0/R2 monomer (Lynch et al., 1989; Sahlin et al., 1989).
Additionally, the mechanistic role of the iron center and its associated radical remains
obscure since changes in the redox state of either entity havenever been detected under
substrate turnover conditions (reviewed in Stubbe, 1990).
We have previously shown that ribonucleotide reductase is encoded by the
eukaryotic orthopoxvirus, vaccinia, and is actively expressed during viral infection.
The genes for the large and small subunits, which are separated by 35 kilobaseson the
vaccinia genome, are transcribed early in the infective cycle (Roseman and Slabaugh,
1990; Tengelsen et al., 1988). Because of the difficulties involved in obtaining large
amounts of enzyme from vaccinia-infected cell extracts, we chose to overexpress the
genes for both subunits of ribonucleotide reductase in a bacterial expression system.
Comparison of the amino acid sequences of the vacciniagene products to other
ribonucleotide reductase subunits revealed that the vaccinia virusenzyme has far greater
similarity to the mammalian and yeast reductases than it doesto the corresponding
enzyme from E. coli, T4 bacteriophage, or the herpes viruses (Slabaugh et al., 1988).
In fact, the vaccinia proteins share 70-80% amino acid identity with the respective
mouse subunits. In contrast to the herpes virus ribonucleotide reductase, which is
unregulated (Averett et al., 1983), the vaccinia virus-inducedenzyme exhibits the same
pattern of allosteric regulation as the mammalian enzyme (Slabaugh et al., 1984). The
regulatory and structural similarity of the VVR2 protein to the mammalian R2 subunits
as well as the genetic advantages offered by the readily manipulated nature of the
vaccinia virus genome (Traktman, 1990) have ledus to pursue study of the vaccinia
virus ribonucleotide reductase.
In this report, we describe the cloning and overexpression of the vacciniasmall
subunit ribonucleotide reductase gene in E. coli. We describe purification of VVR2and
compare the specific activities and migration on an SDS- polyacrylamide gel, of the60
native and recombinant proteins. We show that the recombinant protein is susceptible
to hydroxyurea inactivation, as evidenced by a decrease in the light absorption spectrum
of the R2 free radical and iron center. The radical content of the small subunit is
quantitated, and the EPR and CD spectra of recombinant protein are compared to
spectra of small subunit proteins from other sources.
111.3 Materials and Methods
Buffers. Buffers used in this work were as follows. Buffer A: 50 mM
HEPES (pH 7.6), 2 mM dithiothreitol, 1 mM PMSF, 5% glycerol, 2 mM MgC12.
Buffer B: 100 mM potassium phosphate (pH 7.6), 2 mM dithiothreitol, 5% glycerol, 1
mM PMSF. Buffer C: 50 mM Tris-HC1 (pH 7.6), 2 mM dithiothreitol, 5% glycerol, 1
mM PMSF. Buffer D: 50 mM Tris-HC1 (pH 9.5), 150 mM NaC1, 2 mM EDTA, 0.1%
polyoxyethylene sorbitan monolaurate. Dithiothreitol and PMSFwere added
immediately before use of the buffer.
Bacterial Strains and Media. The E. coli strain BL21(DE3) isa lambda
lysogen that carries the gene for T7 RNA polymerase under the control of the inducible
pL promoter (Rosenberg et al., 1987). The plasmids pET11d (Studier et al., 1990) and
pETlld -R2 were transformed into BL21(DE3) by the method of Chunget al. (1990).
pET plasmids and suitable bacterial hosts were generously supplied by William Studier,
Department of Biology, Brookhaven National Laboratory. Bacteria containing
plasmids were routinely grown at 30°C in Luria broth medium (per liter, 10g of
tryptone, 5 g of yeast extract, 5 g of NaC1, 1 ml of 1 N NaOH) containing 100 p.g/ml
ampicillin.
The E. coli strain N6405/pSPS2, which overproduces the R2 subunit of E. coli
ribonucleotide reductase, was a gift of JoAnne Stubbe (Salowe and Stubbe, 1986).61
Cloning and Overexpression. The gene for the 37-kDa VVR2 proteinwas
previously localized to the left end of the HindIII F fragment of the vaccinia virus
genome (Slabaugh et al., 1988). A 2.3-kilobase Xbal fragment containing the gene
was cloned into the XbaI site in the polylinker of the phagemid vector pIBI30
(International Biotechnologies, Inc., New Haven, (:l"). An NcoI sitewas engineered
at the initiating ATG start codon of the VVR2 gene by site-directed mutagenesis
(Kunkel et al., 1987) using the oligonucleotide 5'-
GGATGGGITCCATO_QCFAAATTAACAATAA- 3'. This generateda two base pair
change (AA to GG; underlined in the oligonucleotide sequence) directlyupstream of the
start codon. The manipulation did not change the coding sequence of the VVR2gene.
The new construct, pXR2a-NcoI, was digested with Ncol and HindlII andthe
fragment containing the VVR2 gene was ligated into the expressionvector pET1 Id
(Rosenberg et al., 1987). Routinely, a 1-liter culture of BL21(DE3) cellsharboring the
plasmid pET11d-R2 was grown overnight at 30°C. The saturated culturewas diluted
1:1 with Luria broth and incubated at 30°C for 1 h before induction for 4 hwith 0.4
mM isopropyl B-D-thiogalactopuranoside.
Large-Scale Purification of Recombinant VVR2 Protein.The
purification scheme used to isolate the recombinant VVR2 protein involved
streptomycin sulfate and ammonium sulfate precipitations, gel filtration, andanion-
exchange chromatography. Precipitation steps were performedat 0-4°C, and column
chromatography was done at ambient temperature. Beyond the ammoniumsulfate step,
we found it advantageous to include glycerol (5%, v/v) in purification buffersto avoid
precipitation of vvR2 protein. Cells were harvested by centrifugationat 3,500 x g, and
the cell pellet was resuspended in 5 volumes of Buffer A and lysed ina French press.
Debris was pelleted by centrifugation at 10,000 xg for 20 min. To remove nucleic
acids, solid streptomycin sulfate was added to the clarifiedextract to 0.5% (w/v). After62
stirring on ice for 30 min, the solution was centrifuged at 8,500 x g for 20 min to
remove insoluble material. To concentrate the protein extract, solid ammonium sulfate
was added to 40% saturation with stirring for 30 min on ice, and the following
suspension was centrifuged at 8,500 x g for 20 min. The supernatant was discarded
and the precipitate was resuspended in Buffer A and applied directly to a Superose 6
HR16/50 fast protein liquid chromatography gel filtration column (16 x 50 mm,
Pharmacia LKB Biotechnology Inc.) that had been pre-equilibrated with Buffer B.
Following elution in Buffer B, fractions were analyzed for the presence of VVR2 by
SDS-polyacrylamide gel electrophoresis. The recombinant protein eluted as a single
peak. For the final step in purification, anion-exchange chromatography, pooled eluate
from the Superose 6 column was loaded onto a Mono Q HR5/5 fast protein liquid
chromatography column and eluted with a triphasic salt gradient of 0-0.3 M NaCl in
Buffer C.
SDS-Polyacrylamide Gel Electrophoresis and Western Blots.
Proteins were separated by electrophoresis on 10% SDS-polyacrylamide gelsas
described by Laemmli (1970). Peptide bands were visualized by staining with
Coomassie Brilliant Blue. For immunoblots, proteins were transferred to Immobilon-P
transfer membranes (Millipore, Bedford, MA) for 30 min at 200 mA by usinga
semidry electroblotter (Idea Scientific, Minneapolis, MN) as described by Towbinet al.
(1979). The membrane was blocked in Buffer D with 1% gelatin, incubated in Buffer
D containing polyclonal antiserum to the vaccinia R2 protein at a dilution of 1:2,000,
and then incubated in Buffer D containing goat anti-rabbit antibody conjugated to
alkaline phosphatase at a dilution of 1:5,000 (Boehringer Mannheim).
Polyclonal Antisera. An EcoRV-XbaI DNA fragment encodingsequences
for 30 kDa of the vaccinia virus R2 gene product was cloned intoa pATH bacterial
expression vector (Dieckmann and Tzagoloff, 1985). TrpE-VVR2 fusion proteinwas63
purified by SDS-polyacrylamide gel electrophoresis and injected into rabbits by using
established procedures. Antiserum to VVR2 was demonstrated to be specific for
vaccinia virus R2 by Western blot and irnmunoprecipitation3.
Enzyme Activity Measurements and Preparation of Native VVR2
Extracts. The assay for ribonucleotide reductase measured conversion of [3H1 -CDP
to[3H]-dCDP and was performed as described previously (Slabaugh et al., 1984).
Bovine serum albumin was added to reaction mixtures to normalize the protein
concentration. Assay reactions were run in triplicate, and the resultswere averaged.
A unit of enzyme activity is defined as the amount of VVR2 protein which
catalyzes the formation of 1 nmol of dCDP in 1 min in thepresence of an excess of
complementary vaccinia virus ribonucleotide reductase large subunit (VVR1) proteinat
30°C. Specific activity is defined as units of enzyme activityper mg of protein. The
most reliable measurements of enzyme activity were made when VVR2 proteinwas
present at 0.01-0.5 units/20 p1 reaction, and the complementary VVR1 proteinwas
present in a 5-fold molar excess. In preliminary experiments, we incubated
preparations of recombinant VVR1 and VVR2 together before initiation of the reaction
to determine whether preassociation of the two subunits affected enzyme activity. Pre-
incubation periods of 1, 10, or 40 min at 30 or 37°C did not affect the activity detected
in a 10-min period immediately after the preincubation.
Virus-infected and uninfected cell extracts were preparedas described
previously (Slabaugh and Mathews, 1984). VVR1 and host cell R1 proteinwere
specifically removed from virus-infected and uninfected extracts by usingan affinity
matrix, dATP-Sepharose. Crude extracts were incubated at 4°C for 30 minwith dATP-
Sepharose resin, and separated from the resin by brief centrifugation. This resultedin
extracts with no endogenous ribonucleotide reductase activity and no immunoreactive
3 Howell et al., manuscript in preparation.64
VVR1. For specific activity measurements, VVR2 protein was complemented with
purified recombinant vaccinia virus large subunit4.We choose to use recombinant
VVR1 in our complementary enzyme assay because although native VVR1can be
recovered from the dATP-Sepharose affinity resin, it is contaminated with host R 1.
For the activity assay measurements in Figure 111.4, 0.27ug of VVR1 was included in
each reaction.
To add equivalent amounts of recombinant and native VVR2 to the reactionswe
estimated the concentration of native VVR2 in the cellular extract by quantitative
Western blot analysis. Incremental amounts of purified recombinant VVR2 (0.07-0.70
14) were electrophoresed on an SDS-polyacrylamide gel alongside aliquots ofextract
from virus-infected cells. This procedure allowed us to estimate the VVR2
concentration in the extract to within 10%.
Protein Concentration Determination. Protein concentrationswere
determined by the Bradford method (Bradford, 1976), using bovineserum albumin as
the standard. The relative amount of VVR2 protein in extractswas determined by
scanning laser densitometry of Coomassie-stained extracts in SDS-polyacrylamidegels
using a Zeineh model SL-504-XL instrument (Biomed Instrument Inc., Fullerton,CA).
The extinction coefficient of purified VVR2 was determined by amino acidanalysis.
This procedure was performed as described by Malencik et al., (1990). Briefly,
vacuum-dried VVR2 protein (approximately 5 p.g) was subjectedto acid hydrolysis
with 6 M HC1 in the vapor phase for 24 h at 160°C. After dabsyl chloride
derivatization, approximately 100 total nmoles of amino acidwere chromatographed on
a reverse-phase Ultracarb 20 HPLC column. Absorbance was monitored at 460nm
and peak areas were determined by using Dynamic Solutions' Baseline data acquisition
4 Slabaugh et al., manuscript in preparation.65
system (version 3.0). Based on parallel analysis of a known amount of chicken
lysozyme, recovery of VVR2 was quantitative.
Amino acid analysis yielded a molar extinction coefficient for active VVR2 of
119,000 W1 cm-1 at 280 nm.
Circular Dichroism. The circular dichroism spectrum for VVR2 was
recorded on a Jasco J-41A spectropolarimeter that was calibrated by using (+)-10-
camphorsulfonic acid, AI = 2.42 at 290.5 nm. The measurement was made using a
200 µm pathlength cell and the protein solution was 5.7 p.M in 50 mM sodium
phosphate buffer (pH 7.8). The secondary structure prediction was made using the
variable selection method computer program outlined by Compton and Johnson (1986),
with a basis set of 26 proteins.
Electron Paramagnetic Resonance Measurements. EPR spectra were
obtained on a Varian E-109 spectrometer equipped with an E-102 microwave bridge
and an Air Products liquid helium cryostat and appropriate cavity for measurements at
30 K. For quantitation of the tyrosyl radical content, measurements were performed at
108 K (by use of a Varian variable temperature accessory that flows chilled nitrogen
gas over the sample) at a power of 1 mW and a modulation amplitude of 5 gauss. The
area of the double integral was compared with that obtained from a 1.0 mM Cu(C104)2
standard in 2 M NaC1O4, 10 mM HC1 (pH 2) under similar instrumental conditions.66
111.4 Results
111.4.1 Overexpression of the VVR2 Subunit in E. colt
As shown in Figure MA, induction of BL21(DE3) cells containing pET11d-R2
with isopropyl B-D-thiogalactopyranoside resulted in high-level expression ofa 37-kDa
peptide (lanes 2-5). This peptide was not detected in BL21(DE3) cells containing the
control plasmid, pET11d (lane I). After 4 h of induction, VVR2 accumulatedto
approximately 15% of the total soluble protein as determined by densitometric scanning
of Coomassie-stained electrophoretic bands. Approximately 40mg of recombinant
VVR2 was produced per liter of bacterial culture.
pET11d-R2 was induced at several different temperatures inan attempt to
increase the ratio of soluble to insoluble VVR2 protein in the cell extracts. When
cultures were induced at 37°C, only 50% of the total amount of expressed VVR2
protein was soluble. However, when the cultures were inducedat 30°C, more than
70% of the recombinant protein was expressed in soluble form. Inductionat
temperatures below 30°C under the same growth conditions decreased the level of total
protein expression.
111.4.2 Summary of VVR2 Purification
A typical purification of recombinant VVR2 is summarized in Table II1.1. Two
liters of bacterial culture yielded 18.8 mg of purified VVR2 protein witha specific
activity of 48 units/mg. The final step in purification, chromatographyon a strong
anion-exchange matrix, separated full-length VVR2 monomers from partially degraded
VVR2 polypeptides. As shown in Figure 111.2A, VVR2 eluted intwo peaks. The first
peak, eluting at 0.20 M NaCl, contained full-length 37 -kDa VVR2as well as several
peptides of discrete sizes (35.5, 34.5 and 33 kDa) whose electrophoretic mobilities67
Figure III.1Expression of Recombinant VVR2 protein in E.
coli at 30°C. Isopropyl P-D-thiogalactopyranoside was added to
cultures to 0.4 mM and 1-ml aliquots were removed from cultures of
pET11d-R2 at 0, 1, 2, and 4 h post induction (lanes 2-5) and from
pETIld at 4 h (lane 1). Aliquots were centrifuged, and each cell pellet
was resuspended in 200 ill of SDS-containing sample buffer. Extracts
were sonicated, heat denatured at 100°C for 2 min, and 20 Ill was
loaded onto an SDS-polyacrylamide gel.9 7
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Figure 111.2Anion-Exchange Chromatography of
Recombinant VVR2 Small Subunit. Partially-purified VVR2 (-100 jig)
was applied to a Mono Q HR5/5 column and eluted using a triphasic salt
gradient of 0-0.3 M NaC1 in Buffer B. Panel A, NaC1 gradient and
absorbance at 280 nm of the Mono Q eluate. Panel B, 50 .t1 of each
0.5-m1 fraction analyzed on an SDS-polyacrylamide gel. The fraction
numbers for the sample are indicated below the elution profile and
below the corresponding lanes of the gel.0.4
0.3
0.2
0.1
97-
70
5 10 15 20 25
66-6-4
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Figure 111.2Table MA Purification of Recombinant R2
Purification Total Total Enzyme Specific Yield Purification
Step Volume Protein Activity Activity
(mg) (units) (units/mg) -fold
crude extract a
amm. sulfate
gel filtration
anion-exchange
30 630 5090 8.1 100 1.0
5 151 1330 8.8 26 1.1
12 73 1190 16.3 23 2.0
6 18.8 900 48 17.6 6.0
aCrude extract denotes the supernatantfraction obtained after the removal
of cell debris72
were slightly greater than full-length VVR2 (Figure III.2B, Fractions 23-25). All
peptides in these fractions reacted positively to anti-VVR2 antiserum in Western blot
analysis, suggesting that the shorter fragments were derived from full-length VVR2.
The second peak, which eluted at 0.25 M NaC1, contained predominantly 37-kDa
monomer.
Sjoberg et al. (1987), described fractionation on a Mono Q HPLC anion-
exchange column as a method for separating E. coil R2 homodimers from heterodimers
consisting of one full-length and one R2 polypeptide of smaller molecular mass. The
truncated E. coil polypeptide was shown to be a carboxy-terminal proteolytic digestion
product that was present when PMSF was omitted from purification buffers. Mann et
al. (1991) reported that recombinant mouse R2 is also susceptible to partial degradation
during purification even in the presence of protease inhibitors, but that in this case,
degradation was from the amino-terminal end of the protein. Similarily, addition of the
protease inhibitors PMSF, pepstatin, leupeptin, and aprotinin to purification buffers did
not prevent formation of the degradation products that we observed. Analogous to the
formation of E. coil heterodimers, we hypothesize that the first fraction eluted from the
Mono Q column represents various VVR2 heterodimers of different molecularmasses.
The mobility of purified recombinant VVR2 was compared to that of native
VVR2 from a vaccinia infected-cell extract by migration of the two proteins in SDS-
PAGE (Figure III.3). Staining of a blot of the gel with antiserum against a TrpE-VVR2
fusion protein revealed a single 37 -kDa band in the lanes containing recombinant and
native VVR2, but no band in the lane containing extract from uninfected cells. Native
VVR2 degradation fragments were not detected in the lane containing VVR2.
Additional Western blot analysis of recombinant VVR2 during purification revealed that
the protein is not proteolytically degraded until after lysis of the bacterial cells.73
Figure 111.3Protein Gel and Western Blot Analysis of
Recombinant and Native VVR2. Lane 1, Purified recombinant VVR2
(0.35 p.g). Lane 2, 8 1.1.1 of a vaccinia virus-infected cellextract (1.2
mg/ml total protein). Lane 3, 8 p.1 of an uninfected cellextract (1.2
mg/ml total protein).200-
97-
66-
45-
31-
123 123
Figure 111.3
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To determine whether the recombinant vaccinia ribonucleotide reductase small
subunit was biologically active, VVR2 was combined with purified recombinant
VVR1. Neither VVR2 nor VVR1 preparations exhibited enzyme activity when assayed
alone. However, as shown in Figure 111.4, recombinant VVR2 did complement the
recombinant VVR1 preparation. To compare directly the specific activities of
recombinant and native VVR2 proteins, equivalent amounts of VVR2 were assayed for
enzyme activity in the same experiment (Native VVR2 concentration was estimated in
crude extracts from infected cells as described under "Materials and Methods"). The
saturation curve obtained by assaying increasing amounts of R2 with a constant amount
of R1 showed that the specific activity of the purified recombinant VVR2 was
equivalent to that of VVR2 produced in an infected eukaryotic cell.
111.4.3 Determination of the Apparent Molecular Mass for Native
VVR2 Protein
A Superose 12 HR10/30 fast protein liquid chromatography gel filtration
column (10 x 30 mm) was used to estimate the molecular mass of native R2 protein in
solution. The molecular mass of VVR2 monomer calculated from the deduced amino
acid sequence is 36,975 Da and the recombinant protein has an apparent size of 37 lc Da
as compared to standard proteins on an SDS-polyacrylamide gel. Purified VVR2 eluted
as a single peak on a Superose 12 gel filtration column at a retention time of 67.4 min
(Figure 111.5), corresponding to an estimated molecular weight of 64,000. We
conclude that the VVR2 protein exists in solution as a dimer. These results agree with
experiments on corresponding proteins from E. coli (Thelander, 1973) andmouse
(Thelander et al., 1985), which also describe the native R2 unit as a dimer.76
Figure 111.4Complementation of Recombinant and Native
VVR2 with Purified Recombinant VVR1. Vaccinia and host R1were
removed from the cell extracts by adsorption with dATP-Sepharose.
Assay parameters and the method for determining equivalent amounts of
recombinant and native VVR2 are described under "Materials and
Methods". Solid linelopen circle, Purified recombinant VVR2; Dashed
line /solid circle, Vaccinia virus- infected cell extract; Dashed line /open
triangle, uninfected cell extract.CELL EXTRACT, NI
0.10 0.20 0.30
RECOMBINANT VVR2, pg
Figure 111.4
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Figure 1115Gel Filtration Column Chromatography of
VVR2. Purified VVR2 protein was chromatographed on a Superose 6
molecular sieve column in 50 mM Tris-HC1 (pH 7.6), 5% glycerol and
2 mM dithiothreitol. The flow rate was 1.0 ml/min and 1-ml fractions
were collected. The inset panel depicts the correlation between the
migration of molecular weight standards and the retention time from the
column. Letters indicate elution of standards: d, aldolase at 148,000
Da; c, BSA at 68,000 Da; b, ovalbumin at 45,000 Da; a, cytochrome C
at 12,500 Da. e, Migration of recombinant VVR2 relative to standards.0.5
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111.4.4 Circular Dichroism
The circular dichroism spectrum recorded for VVR2 is shown in Figure 111.6.
Analysis of the spectrum revealed the secondary structure composition of VVR2 to be
47% a-helix, 6% B-sheet, 21% B-turn, and 29% other structures. Recent CD spectra
of mouse and E. coli R2 and three-dimensional structure analysis of E. coli R2, have
distinguished the two proteins on the basis of secondary structure (Mann et al., 1991;
Nordlund et al., 1990). It was demonstrated that E. coli R2 has a high a-helical
content (70%) corresponding to the helix-turn-helix structural motif. Mouse R2
exhibited a lower a-helical content (50%), and had a significant secondary structure
contribution from B-sheet (17%).
111.4.5 Effect of Hydroxyurea on the Absorption Spectrum of VVR2 Protein
The near UV absorption spectra of the iron-containing ribonucleotide reductases
exhibit characteristic bands that have been ascribed to the dinuclear iron center (325 and
370 nm) and the tyrosyl radical (390 and 410/416 nm) (Atkin et al., 1973; Thelander et
al., 1985). The mammalian radical peak at 416 nm (Mann et al., 1991) is slightly
shifted from the sharp E. coli radical peak at 410 nm (Petersson et al., 1980). The
absorption spectrum of purified VVR2 protein from 300 to 500 nm is shown in Figure
III.7A, curve a. In addition to absorption bands at 325, 370, and 390 nm, and similar
to the published spectrum for mouse R2, a VVR2 peak is also detected at 416 nm.
Vaccinia virus ribonucleotide reductase activity is inhibited by the radical
scavenger, hydroxyurea (Slabaugh and Mathews, 1986). Inactivation of mouse
ribonucleotide reductase by hydroxyurea results in a decrease in intensity of all the
near-UV absorbance bands (Thelander et al., 1985). In contrast, hydroxyurea
inhibition of E. coli R2 is characterized by the marked decrease in intensity of the
maxima at 390 and 410 nm but only slight changes in the ferric iron center81
Figure III.6Circular Dichroism Spectrum of Recombinant
VVR2. The spectrum of recombinant protein (0.42 mg/ml) in 50mM
sodium phosphate buffer, pH 7.6, was recorded witha 200 I=
pathlength at 25°C.19020021020230240250
Wavelength (nm)
Figure 111.6
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Figure 111.7Light Absorption Spectra Above 300 nm for the
vvR2 Subunit of Ribonucleotide Reductase. Panel A, The electronic
spectra of a, protein VVR2 (19 ii.M) in Buffer C and b, an identical
sample after incubation with 10 mM hydroxyurea for 20 min at 25°C.
The absorbance peaks exhibited by mouse R2 protein are indicated by
arrows. Spectral features are assigned to iron center (I) or radical (R).
Panel B, difference spectrum derived from data in A.A
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absorbances. (The 360-390 nm region contains overlapping contributions from both
the free radical and the iron center and this has made quantitative analysis of the
absorption signals somewhat ambiguous.)
To monitor the effects of hydroxyurea on the VVR2 protein, the electronic
signals of the free radical and the iron species were measured after treatment of purified
VVR2 with the inhibitor (Figure III.7A, Curve b). Hydroxyureawas added to the
purified VVR2 sample to 10 mM in the presence of 2 mM dithiothreitol, and the
preparation was incubated at 25°C for 30 min. A difference spectrum (Figure 111.7B),
derived by subtracting curve b from curve a,showed that absorbance maxima from the
tyrosyl radical (390 and 416 nm) were decreased by 45 and 40% respectively, and that
the iron center absorbance maxima (325 and 370 nm) were also significantly decreased
(20 and 35%, respectively).
111.4.6 Characterization of Tyrosyl Radical by EPR Spectroscopy
Purified vaccinia virus R2 protein exhibited a g = 2.0 EPR signal (Figure
III.8B) that is characteristic of a tyrosyl radical (Sjoberg and Graslund, 1983). The
EPR spectrum showed a hyperfine splitting pattern that was identicalto that of native
vaccinia protein expressed in virus-infected cells (Figure III.8C). No such signalwas
present in uninfected cells (Figure III.8D). Treatment of recombinant VVR2 with
hydroxyurea, which destroys the enzymatic activity and the 416-nm absorption band
associated with the tyrosyl radical (see above), also caused the disappearance of the
tyrosyl radical EPR signal. (The spectrum of VVR2 treated with 10 mM hydroxyurea
for 30 min, looked the same as the spectrum in Figure III.8D).
The hyperfine splitting of the tyrosyl radical signalappears to be extremely
sensitive to the orientation of the B-CH2 group with respect to the tyrosine ring
(Graslund et al., 1982). The close similarity of the EPR spectra in Figures III.8B and87
Figure 111.8EPR Spectra at 30 K of Tyrosyl Radicals in R2
Proteins. A, E. coli R2 protein from strain N6405/pSPS2 (0.1-mW
power, 1.6 gauss modulation amplitude). B, Purified recombinant
VVR2 protein, 10µM in R2 dimer (3 mW, 1.6 gauss). C, VVR2
protein from virus-infected BSC40 cells (3 mW, 4 gauss). D, Protein
from uninfected BSC40 cells (3 mW, 4 gauss). E, Hydroxyurea-
resistant, R2-overproducing mouse fibroblast 3T6 cells [data from
Lankinen et al. (1982)]. Samples in A, C, and D were partially purified
by ammonium sulfate fractionation. mT, millitesla.88
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8C indicates that expression of the vaccinia virus R2 gene in E. coli yieldsa protein
whose metal center is indistinguishable from that of the native virus. The hyperfine
splitting pattern of vaccinia virus R2 is readily distinguished from that of E. coli (Figure
LIL8A). In fact, the EPR spectrum of vaccinia virus R2 closely matches thespectra of
ribonucleotide reductases from eukaryotic sources such as mouse (Figure 111.8E,
Gras lund et al., 1982) and yeast (Harder and Follmann, 1990). Thespectra of the R2
radicals from the pseudorabies virus (Lankinen et al., 1982), herpes simplex virus
(Mann et al., 1991), and bacteriophage T4 (Sahlin et al., 1982)are all distinctively
different. These findings suggest that the vaccinia R2 gene is closely relatedto and
presumably derived from a mammalian gene, in agreement with amino acidsequence
comparisons (Slabaugh et al., 1988).
Another point of similarity between vaccinia and mouse R2 proteins is in the
power dependence for microwave saturation. As in the case of mouse R2 (Mann et al.,
1991), recombinant VVR2 begins to show saturation of its EPR signal (i.e., >10%
reduction in S/P
1/2)
when the microwave power exceeds 1 mW at 30 K. Incontrast,
the EPR signal of E. coli R2 begins to saturate already at 0.1 mWat 30 K, whereas that
of herpes simplex R2 saturates only above 10 mW at 30 K (Mannet al., 1991). The
differences in saturation behavior are believed to be related to the degree of magnetic
interaction between the tyrosyl radical and the dinuclear ironcenter (Sahlin et al.,
1987). Such an interaction enhances the spin-lattice relaxationrate, thereby making the
signal less susceptible to saturation. Thus, it wouldappear that the tyrosyl radical is
more closely associated with the dinuclear iron center in vaccinia and mouse R2 than it
is in E. coli R2.
The spin concentrations in two different preparations of purified recombinant
VVR2 were calculated by comparison to a copper standard. The protein concentration
was determined by amino acid analysis. These measurements indicated that at the90
completion of the purification procedure, 0.3 tyrosyl radicals were present per VVR2
polypeptide chain.
111.4.7 Attempted Reconstitution of Vaccinia Virus R2
In an attempt to increase the iron and tyrosyl radical content of recombinant
VVR2 protein, purified protein was subjected to aerobic (Thelander et al., 1985) and
anaerobic (Mann et al., 1991) reconstitution procedures. Briefly, this involved
exposing the protein to excess ferrous iron in the presence of dithiothreitol (aerobic
reactivation) or sodium ascorbate (anaerobic reactivation). To determine what effect
reactivation had on the VVR2 protein, we compared the enzymatic activities of
reconstituted and unreconstituted protein samples and measured the radical content of
the protein before and after reactivation procedures. Enzyme assay results reflected no
increase in activity resulting from either aerobic or anaerobic treatment of VVR2
compared to untreated protein. Additionally, inclusion of FeC13 or Fe(NH4)2(SO4)2 in
the enzyme assay had no effect on the activity detected in treated or untreated VVR2
protein. As measured by EPR, neither reactivation procedure significantly increased
the radical content of the vaccinia virus protein.
We also asked whether the activity (tyrosyl radical content) of recombinant
VVR2 could be increased by supplementing the bacterial growth medium with
exogenous iron or adding ferrous iron to lysis buffers. Neither of these approaches
increased activity above the value of approximately 50 units/mg reported in Table III.1.
111.5 Discussion
In these experiments, we have characterized the 37 -kDa vaccinia virus
ribonucleotide reductase small subunit protein that has been overexpressed in E. coll.91
By several criteria, we have shown that the recombinant VVR2 subunit is functionally
and physically equivalent to the R2 subunit expressed in vaccinia virus-infected
mammalian cells. Polyclonal antiserum made to a fusion protein containing a major
portion of the vaccinia virus R2 protein reacted with the recombinant protein expressed
in E. coll. When native and recombinant VVR2 were complemented with purified
recombinant VVR1, ribonucleotide reductase activity was readily detected, and the
specific activity of both proteins was the same. In addition, the EPR spectrum of
recombinant protein matched that of a partially purified preparation of VVR2 protein
produced by viral infection of BSC40 cells.
The circular dichroism spectrum of VVR2 revealed the viral protein to be similar
to mouse R2 in a-helical content (-50%). Thus, the eukaryotic R2 molecule appears to
diifer significantly in secondary structure from E. coli R2 which has been shown by
CD and crystallography (Mann et al., 1991; Nordlund et al., 1990) to be exceptionally
rich in ahelical content (70%). 8-sheet contributions to the CD spectrum in thecase
of VVR2 (6%), were intermediate between the reported values for E. coli (3%) and
mouse R2 (17%).
From our spectroscopic studies we conclude that the protein environment of the
tyrosyl radical in VVR2 is similar to that of the previously characterizedmouse and calf
thymus proteins and exhibits certain distinctions from the E. coli R2. The location of
the radical absorbance peak at 416 nm in the electronic spectrum of the recombinant
VVR2 protein differs from the 410 nm maximum for the E. coli protein but closely
matches the 416 nm absorption band of the mouse protein (Mann et al., 1991).
Hydroxyurea inhibition of VVR2 protein revealed that like analogously treatedmouse
R2, vaccinia virus R2 exhibits an absorption spectrum in which all fournear UV
electronic signals are attenuated in the presence of inhibitor. This contrasts with the
effect of hydroxyurea on E. coli R2, in which the ferric iron center electronic signals92
are only slightly decreased. One interpretation of these results is that the mammalian
ferric iron center is more susceptible to reduction by hydoxyurea than is the E. coli iron
center. Either reduction of ferric iron to the ferrous form or dissociation of iron from
the protein could cause the decreased intensity of the iron center electronic signal. We
are continuing inhibitor studies on the VVR2 protein to examine more closely the
mechanism of hydroxyurea inhibition.
The EPR spectrum of the recombinant VVR2 more closely resembles the EPR
spectrum for mouse protein than E. coli R2, both in the hyperfine splitting pattern and
in the susceptibility to microwave power saturation at low temperature. The former is
indicative of a conserved conformation for the tyrosyl radical side chain in the mouse
and vaccinia proteins. The latter suggests increased interaction between the tyrosyl
radical and the dinuclear iron center in mouse and vaccinia virus R2 relative to E. coli
protein.
Various preparations of recombinant VVR2 yielded protein with 25-30% of the
theoretical maximum of one tyrosyl radical per R2 protomer. For comparison, calf
thymus, mouse, and herpes virus R2 proteins purified from natural or recombinant
sources exhibit even lower levels of radical content (0-14%) and corresponding low
iron occupancies (0-6%) (Thelander et al., 1983; Mann et al., 1991). However,
whereas mouse and E. coli R2 can be reactivated to 70-100% iron occupancy (3.2-4.0
Fe/dimer), and up to 80% radical content (1.6 radical/dimer) (Bollinger et al., 1991;
Mann et al., 1991), identical reactivation procedures applied to the vaccinia virus
enzyme did not increase radical/R2 monomer ratios above 30%. Iron/radical centers in
herpes virus R2 were also reported to be resistant to full reactivation (Mann et al.,
1991). Additionally, inclusion of ferrous or ferric iron in the enzyme assay had no
effect on the activity measured in "unreactivated" or "reactivated" VVR2 preparations.93
This contrasts with the apparent lability of the iron center in calf thymus R2, which may
require continual regeneration during enzyme turnover (Thelander et al., 1983).
The lower specific activities of vaccinia and herpes virus R2 proteins
(approximately one-sixth that of mouse R2) may be caused by the lower steady-state
radical contents exhibited by these viral enzymes in vitro. Our results, taken together
with studies of R2 from other species, emphasize the variable nature of the stability of
the iron/radical center in this metalloprotein.
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IV.1 Abstract
Ribonucleotide reductase is considered a rate-limiting enzyme in DNA
synthesis. In the past, we have characterized the virus-encoded small subunit protein
of ribonucleotide reductase from the orthopoxvirus, vaccinia [Howell, M. L., Sanders-
Loehr, J., Loehr, T. M., Roseman, N. A., Mathews, C. K., and Slabaugh, M. B.
(1992) J. Biol. Chem. 267, 1705-1711] and in an accompanying manuscriptwe
describe characterization of the large ribonucleotide reductase subunit protein (Slabaugh
et al., this issue). In this report, we use quantitative analysis of ribonucleotide
reductase protein levels and DNA accumulation in vaccinia virus-infected cellextracts to
correlate the supply of deoxyribonucleotides with the demand for theseprecursors in
viral DNA synthesis. To facilitate our quantitation, polyclonal antiserawere generated
to TrpE fusion proteins constructed from the carboxyl termini of both subunits of viral
ribonucleotide reductase. Si nuclease and immunoprecipitation analysis were usedto
determine the transcriptional and translational kinetics of vaccinia virus ribonucleotide
reductase expression. Enzyme activity and ribonucleotide reductase protein stability
were also assayed during the viral time course of infection. Enzyme-linked
immunoassays were used to quantitate protein levels, and dot blot filter hybridizations
were used to measure the accumulation of viral DNA. Our results demonstrate that the
rate of catalysis of ribonucleotide reduction is sufficiently high in vaccinia virus-
infected cells to synthesize substrates at rates needed to sustain viral DNA synthesis.
IV.2 Introduction
Ribonucleotide reductase catalyzes the direct reduction of ribonucleotidesto
deoxyribonucleotides and occupies the first committed step in the denovo synthesis of99
DNA (Thelander and Reichard, 1979). As such the enzyme has been extensively
studied for its role in, or response to, cell divison and cell cycle control (Hurta and
Wright, 1992; Hurta et al., 1991; Elledge et al., 1992). Biochemical studies with the
mammalian enzyme have demonstrated that in vivo ribonucleotide reductase activity is
at a high level during S-phase, coincident with cellular DNA synthesis and metabolic
requirements for DNA precursors (Engstrom et al., 1985; Reichard, 1988). Further
work elucidated that expression of the mRNA's encoding the two subunits ofmouse
ribonucleotide reductase occurs coordinately during S-phase (Bjorldundet al., 1990;
Engstrom and Rozell, 1988; Mann et al., 1988), and that variation in the stability of the
two polypeptide subunits is the specific factor that regulates the level of enzyme activity
(Bjorklund et al., 1990; Mann et al., 1988).
Vaccinia virus, the prototypic poxvirus, contains a large duplex DNAgenome
(187 kb) and is a member of the only known family of DNA viruses that replicate in the
cytoplasm of infected cells (Moss, 1990; Goebel et al., 1990). Considering the
requirement for a ready supply of precursors for DNA synthesis by vaccinia virus, it is
not surprising that the virus encodes and expresses many of the enzymatic activities
required for DNA metabolism and synthesis, including ribonucleotide reductase
(Slabaugh et al., 1984). The genes that encode the viral ribonucleotide reductase
subunits have been sequenced and localized to positions on the vacciniagenome
separated by 35 kilobases (Slabaugh et al., 1988; Tengelson et al., 1988; Schmitt and
Stunnenberg, 1988). Like the mammalian enzyme, the vaccinia virus holoenzyme
consists of two dissimilar homodimers, both of which are essential for activity. The
viral large subunit (designated R1)1 is a homodimer comprisingtwo 86-kDa
polypeptides and contains binding sites for nucleotide substrates and allosteric effectors
1The abbreviationsused are: RI and R2, large and small subunit of ribonucleotide
reductase, respectively; SDS, sodium dodecyl sulfate; ELISA, enzyme-linked
immunosorbent assay.100
(Slabaugh et al., 1984; Slabaugh and Mathews, 1984). The small subunit (designated
R2) is a homodimer comprising two 37-kDa polypeptides and contains an iron-
stabilized free radical that is required for catalysis (Howell et al., 1992). Amino acid
sequence comparisons and physical characterization of the viral R2 ribonucleotide
reductase subunit have revealed several similarities with the mammalian counterpart
(Slabaugh et al., 1988; Howell et al., 1992).
The events of vaccinia virus replication have been well characterized. Early
studies, which measured viral DNA synthesis through incorporation of [3H]- thymidine
into acid precipitable material, demonstrated that during a vaccinia virus infection, DNA
replication begins at approximately 1-2 h post infection (Joklik and Becker, 1964;
Slabaugh and Mathews, 1986; Jungwirth and Launer, 1968). Synthesis of DNA was
shown through these measurements to remain high for 2-3 h and then sharply decline to
background levels by 8 h post infection. These studies also concluded that the maximal
rate of viral DNA replication is several times that of DNA replication in uninfected cells
(Joklik and Becker, 1964), and coincident with the burst of viral DNA synthesis is a
rapid inhibition of host-cell DNA synthesis (Jungwirth and Launer, 1968). After
inhibition, the host cell DNA is subsequently cleaved by a viral endonuclease to
discrete-sized fragments (Parkhurst et al., 1973) and these are not made available to the
virus for reutilization under normal conditions (Kits and Dubbs, 1962; Oki et al.,
1971). Viral DNA replication, therefore, relies on the synthesis of deoxyribonucleotide
precursors. Measurements of deoxyribonucleotide pools show that, as in other
organisms, free deoxyribonucleotides do not accumulate in the host cell, but are found
in very small amounts (4-20 pmol/106 cells at 4 h post infection; Slabaugh et al., 1991).
These results imply that following ribonucleotide reduction, deoxyribonucleotides are
immediately incorporated into DNA. If indeed the reduction of ribonucleotides is
limiting towards DNA replication, establishing the rate of synthesis and accumulation1 0 I
of ribonucleotide reductase is crucial to an understanding of the flux ofprecursors into
DNA.
In this study we determine the kinetics of expression of both vaccinia virus
ribonucleotide reductase subunits by an analysis of the products of transcription and
translation. The generation of polyclonal antisera to R1 and R2 of VV has enabledus
to monitor the synthesis and stability of ribonucleotide reductase proteins.
Additionally, by immunochemical quantitation of ribonucleotide reductasewe have
determined the stoichiometry of R1 and R2 polypeptide levels duringa viral infection.
To our knowledge, this is the first report to directly correlate the accumulation of
ribonucleotide reductase in any viral system with the rate of DNA replication andthe
amount of accumulated viral DNA.
IV.3 Materials and Methods
Cells and Virus. Vaccinia virus, strain WR, and BSC40 monkey kidney
cells were maintained as previously described (Earl et al., 1988). Mono layercultures
were grown in Eagle minimum essential medium supplemented with 5% (v/v) heat-
inactivated bovine calf serum (Hyclone Laboratories Inc. Logan, UT)
Transcription analysis. Viral mRNA was isolatedas described (Weinrich
et al., 1985). S1 nuclease mapping was performed as described (Roseman and Hruby,
1987).
Antibodies and antisera production. Overexpression ofsequences in or
portions of viral RI and R2 proteins was accomplished by fusion of viralsequences
downstream of the bacterial trpE gene in pATH expression vectors (Dieckmann and
Tzagoloff, 1985). Initially, the vaccinia virus HindIII F and I fragmentswere digested
with the restriction enzyme )(hal, and DNA fragments containing the entire coding1 0 2
sequences for R1 and R2 were isolated and cloned into pUC18 vectors. Plasmids
containing the full length reductase genes were then used in all further manipulations.
In both cases the HindlIl site described below is derived from the vector. The
construct for the 2316-nucleotide R1 gene consisted of a Bg/II-HindIII fragment which
contained 733 nucleotides of the carboxyl terminus of R1 coding sequence ligatedto
pATH 1 digested with BarnHI-Hind111. For the 956-nucleotide R2gene, an EcoRV-
HindIII fragment containing 818 nucleotides of the carboxyl terminus of R2 coding
sequence was ligated to the Smal-HindlIl site of pATH 2.
Synthesis of the fusion proteins was induced in JM83 strains containing these
plasmids by the addition of indoleacrylic acid. The insoluble fusion proteinwas then
purified as described (Miner and Hruby, 1989). The insoluble pelletwas applied to a
preparative SDS-polyacrylamide gel and electrophoresed. The insoluble fusion protein
band was excised and the protein eluted in an Elutrap device (Schleicher and Schuell
Inc., Keene, NH). Rabbits were initially injected intradermally with 100-200jig of
purified protein in Freund's complete adjuvant. Subsequent intramuscular injections
occurred at 1 week intervals with approximately 100 iig of protein in Freund's
incomplete adjuvant. Rabbits were bled two weeks following the third injection of
protein.
The mouse monoclonal antibody AD 203, which recognizes mammalian
ribonucleotide reductase R1, was purchased from InRo Biomedtek (lima Sweden).
The rat a-tubulin monoclonal antibody YL1/2, whichcross reacts with mammalian
ribonucleotide reductase R2, was purchased from Serotec (Station Field, IN).
Western Blots. For immunoblots, BSC40 cellswere virus-infected (10
plaque forming units/cell) or mock-infected and harvestedat 6 h post infection. Cells
were pelleted, resuspended in Laemmli buffer (Laemmli, 1970) and lysed by
sonication. Proteins were separated by electrophoresison 11% SDS-polyacrylamide1 0 3
gels and transferred to Immobilon-P transfer membranes (Millipore, Bedford, MA) for
60 min at 200 mA by using a semidry electroblotter (Idea Scientific, Minneapolis,
MN). The membranes were blocked in buffer (50 mM Tris [pH 9.5], 150 mM NaC1, 2
mM EDTA, 0.1% polyoxyethylene sorbitan monolaurate) with 1% gelatin, incubated in
buffer containing primary antiserum, and then incubated with secondary antiserum
conjugated to alkaline phosphatase. Anti-VVR1 and VVR2 sera were used at dilutions
of 1:500 and 1:2000, respectively, and AD 203 and YL-1/2 antisera were diluted 1:250.
Goat anti-rabbit alkaline phosphatase conjugate at a dilution of 1:5000 was used for
VVR1 and VVR2 antisera, and anti-rat and anti-mouse conjugate were used for anti-
YL-1/2 and anti-AD 203 sera, respectively, at dilutions of 1:2500.
Enzyme assays. Ribonucleotide reductase activity in the viral extracts was
determined by measuring conversion of [31-1] -CDP to [3H] -dCDP as previously
described (Slabaugh et al., 1984). For the time course experiment, the 20111 reaction
volume contained 10 ;A viral extract and 100 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (pH 8.2), 10 mM DTT, 2011M Fe(NH4)2SO4, 2 mM
MgC12, 2 mM 5'-adenylylimido diphosphate, 100 ].IM CDP and [3H] -CDP at 100
cpm/pmol. In the experiment to compare ribonucleotide reductase activity in the
presence of different reducing agents, dithiothreitol was substituted with either
glutathione (1 mM), purified virally-encoded glutaredoxin (0.1 mM), or both. The
purified glutaredoxin was a generous gift of Dr. Wayne Thresher. Enzyme activity was
expressed as pmol of dCDP produced/min/106 cell equivalents. Each extract was
assayed in triplicate and the error bars in Figure 5 represents the standard deviation of
the three determinations.
Immunoprecipitations. BSC40 monolayers at 95% confluence were
infected at a multiplicity of 10 plaque-forming units/cell and polypeptides were labeled
by the addition of[35S]-methionine (25 or 50 IlCi/m1). For pulse labeling experiments,104
cells were labeled for sequential 1 h periods up to 8 h post infection and then harvested.
For pulse-chase experiments, cells were labeled from 2.5 to 3 h post infection, washed
twice with phosphate buffered saline, and incubated in medium containinga one
hundredfold excess of unlabeled methionine. Radioactively labeled cells were
harvested with a rubber policeman, centrifuged, washed with phosphate buffered
saline, and resuspended in 1 ml of lysis buffer (50 mM Tris [pH 7.5], 150 mM NaC1,
1% [v/v] Nonidet P-40, 0.5% [w/v] sodium deoxycholate, 0.1% [w/v] sodium dodecyl
sulfate) and sonicated. Extracts derived from 1.5 x 106 cells were incubated with 5111
of antisera for 3 h on a rotating platform at 4°C. 100 p.1 of a 10% (v/v) suspension of
Protein A-Sepharose CL-4B (Pharmacia LKB Biotechnology Inc., Piscataway, NJ)
beads were added to each of two 500 p.1 aliquots and incubated at 4°C fora minimum of
4 hours. The beads were pelleted, the supernatant removed, and the beadswere
washed six times with lysis buffer. Immune complexes were released by boiling the
pellet in 50 p.1 Laemmli buffer (Laemmli, 1970). Following electrophoresison 11%
SDS-polyacrylamide gels, proteins were visualized by fluorography.
Polyclonal antibody-ELISA for RI and R2. The competitive inhibition
immunoassay was performed essentially as described by Arkoosh and Kaattari (1990).
Briefly, in all cases, purified R1 or R2 was used as coating antigento coat the
microtiter plate wells at concentrations of 0.8 and 0.2 µg/ml, respectively. Plateswere
then extensively washed in TBST buffer (50 mM Tris [pH 8.0], 100 p.M EDTA, 300
mM NaC1, 1% [v/v1 polyoxyethylenesorbitan monolaurate), and blockedto further
protein binding by incubation with a solution containing 1% (w/v) bovineserum
albumin, fraction V, in TBST buffer. Standard curves were preparedas follows.
First, purified R1 or R2 protein, in a solution of 1% (w/v) bovineserum albumin in
TBST, was added to the plate wells in serial dilutions. Next, primary (anti-VVR1or
anti-VVR2) serum was also added to the plate wells at dilutions of 1:500. The purifiedI 0 5
R1 and R2 proteins in solution act as antigen inhibitor to compete with the R1 and R2
coating antigen for the primary antisera. After incubation, immune complexes that are
not attached to the wells (antigen inhibitor complexed to primary antibody) are washed
away using TBST/bovine serum albumin buffer. The remaining immune complexes
(coating antigen complexed to primary antibody) are then further incubated with an
excess of secondary mouse anti-rabbit IgG conjugated to horseradish peroxidase
antiserum (Sigma, St Louis, MO). Immunoreactive antibody conjugate was then
quantitated by colorimetric detection on a Titertek multiscan plus plate reader (Flow
Laboratories Inc., Emeryville, CA). To quantitate RI and R2 in virus-infected extracts,
aliquots of serial dilutions of the extracts were added to the plate wells (after the
addition of coating antigen) in TBST/bovine serum albumin buffer to be used as antigen
inhibitor. The viral RI and R2 proteins in the extracts (antigen inhibitor) compete with
the purified R1 and R2 coating antigen for the primary antiserum. After incubation,
immunocomplexes in solution were washed away, and bound immunocomplexes were
incubated with an excess of secondary mouse anti-rabbit IgG conjugate and quantitated
as described above. The amount of the ribonucleotide reductase subunits in the extracts
was established through a kinetic-based analysis of the immunoassay (Arkoosh and
Kaattari, 1990). The concentrations of R1 and R2 in the extracts were determined by
comparison of the immunoassay data with the standard curve of purified viral
ribonucleotide reductase proteins. Each data point in Fig. IV6 represents the average
concentration of RI or R2 protein, determined in duplicate, from each of three separate
extracts.
In these ELISA experiments, the VVR2 antiserum described in this manuscript
was used for R2 quantitation. Polyclonal antiserum prepared against full length R1
protein (Davis, 1992) was used for RI quantitation because this was demonstrated to
be more specific (than antiserum against partial RI) for the vaccinia virus RI protein.1 0 6
The full length VVR1 antiserum was a generous gift from Dr. Ralph Davis of this
laboratory.
Quantitation of viral DNA by dot blot hybridization. Confluent 100
mm dishes of BSC40 cells were infected at a multiplicity of 10 plaque-forming
units/cell. After 1 h of adsorption, the inoculum was removed, and cultureswere
rinsed three times with phosphate buffered saline and then incubated, again, in
medium. At the indicated times, cells were harvested with a rubber policeman,
collected by centrifugation, and resuspended in 0.3 ml of buffer (50 mM Tris pH 8.0,
10() mM NaCI). To make extracts, the infected cells were frozen and thawed three
times and sonicated. Extracts were treated with 10 lag/m1deoxyribonuclease-free
ribonuclease A (Sigma) for 60 min at room temperature to remove RNA. 20-Ill
aliquots of each extract were then heat denatured and 3 ill was applied directlyto Zeta-
Probe blotting membrane (Bio-Rad Laboratories, Richmond, CA) and boundto the
membrane by UV crosslinking for 3 min with a UV Stratalinker 1800 transilluminator
(Stratagene, La Jolla, CA). Hybridization probe was synthesized froma 2.3-kb XbaI
fragment containing the VVR2 coding sequence by random hexamer priming and
digoxigenin-dUTP labeling using the Genius nonisotopic nucleic acid labeling and
detection kit from Boehringer Mannheim Co. (Indianapolis, IN). Extractswere
hybridized overnight according to the standard hybridization protocol included in the
kit. The hybridized filters were detected by reaction withan immunochemiluminescent
formulation (Martin et al., 1990) and examined by autoradiography. Hybridization
signal was quantitated by scanning laser densitometry of the autoradiography usinga
Zeineh model SL-504-XL instrument (Biomed Instrument Inc., Fullerton, CA). The
concentration of DNA in the viral extracts was determined by comparison witha
standard curve. The standard curve was derived from increasing amounts of purified
Hind III F fragment DNA hybridized to the labeled probe and detectedas described1 0 7
above. The HindlII F fragment DNA was quantitated by A260 and the purity of the
DNA was confirmed by agarose gel electrophoresis.
IV.4 Results
IV.4.1 Transcriptional Kinetics of Vaccinia Virus Ribonucleotide Reductase
The precise locations of the 5' ends of the vaccinia virus ribonucleotide
reductase transcriptional units have been previously determined (Slabaugh et al., 1988;
Tengelson et al., 1988). To determine when in the replication cycle viral mRNAs
encoding R1 and R2 are present, viral RNA was isolated at various times post-infection
and the presence of R1 and R2 transcripts were determined by S1 nuclease analysis
(Fig. IV.1). Appropriate 5' single-ended labeled probes (Fig. IV.1, Panel C) were
hybridized with viral mRNA isolated from infected cells in the presence of
cycloheximide or at the indicated times post infection. Following Si nuclease
digestion, protected hybrids were fractionated by SDS- polyacrylamide gel
electrophoresis. The protected hybrids for R1 and R2 migrate at the expected sizes of
540 and 490 nucleotides, respectively. Both genes are transcribed in the presence of
cycloheximide and both are maximally transcribed between 1 and 3 h post infection.
This analysis demonstrates that R1 and R2 are members of the immediate early gene
class. While it appears that mRNAs from both genes are present up to 9 h post
infection, we do not know whether this is due to continued transcription or mRNA
stability.
An 820-nucleotide protected band in Fig. IV.1, Panel A, present late in
infection is consistent with a transcriptional start just upstream of the start of the 15
open reading frame, thus defining ORF 15 as a late gene. The 860-nucleotide band in1 0 8
Figure IV.1.Si Nuclease Analysis of the Transcriptional
Kinetics of the VVR1 (A) and VVR2 (B) Genes. The 5' single
end-labeled probes (*) are diagrammed relative to restriction sites
and open reading frames (arrows) found in the region of the genome
(Panel C). Probes were hybridized to RNA isolated from cells
infected in the presence of cycloheximide (Lane C); or at 1, 3, 5,
and 9 h post infection in the absence of drug; or to tRNA (Lane -) as
a control. P, probe; A Accl; B, BamHI; Bg, BglII; E, Econ K,
KpnI; P, PstI; RV, EcoRV; X, XbaI. Markers sizes (expressed in
nucleotides) are shown on the left; sizes of protected fragments
(expressed in nucleotides) are shown on the right.C.
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Fig. IV.1, Panel B maps a 5' end approximately 330 nucleotidesinto the coding
sequence of ORF F5. Analysis of the sequence in this region does not resembleany
proposed late promoter signals (Davidson and Moss, 1989).The 1500-nucleotide
protected fragment in Fig. IV.1. Panel B (lane C),maps initiation at ORF F5 and is
consistent with previous work (Slabaugh et al., 1988; Roseman andSlabaugh, 1990).
ORF F5 appears to be expressed at a low level during infectionsince initiation from this
open reading frame in the absence of cycloheximide gives a weak signal.
IV.4.2 Characterization of Vaccinia Virus Ribonucleotide
Reductase Antisera
Upon induction with indoleacrylic acid, bacteria containing plasmidsbearing the
carboxyl termini of either the R1 or R2gene fused to the amino terminus of the trpE
gene both expressed a fusion protein of the predicted molecular weight. Thefusion
proteins were purified by elutriation after SDS-polyacrylamidegel electrophoresis and
injected into rabbits. Sera were collectedas described in "Materials and Methods". To
determine whether an immune responsewas elicited by the highly conserved
riboncleotide reductase proteins, VVR1 and VVR2 antiserawere used for Western blot
analysis of virus-infected and mock-infected cellextracts (Fig. IV.2). No cross
reactivity with host or viral proteinswas seen with pre-immune sera (data not shown).
Immunoblots of vaccinia virus-infected cells with anti-VVR1(lane 1) and anti-VVR2
(lane 3) sera demonstrated that each is specific fora protein of the expected molecular
weight of 86 and 37 kDa respectively.
IV.4.3 Translational Kinetics of Vaccinia VirusRibonucleotide Reductase
To determine whether the transcriptional kinetics of theviral reductase genes is
consistent with the time course of ribonucleotide reductaseprotein synthesis,
immunoprecipitations of pulse-labeled infected cellswere done. Mock-infected or1 1 1
Figure IV.2.Characterization of VVR1 and VVR2
Antisera by Western Blot Analysis. Extracts made from BSC40
cells which were virus-infected (Lanes I and 3)or mock-infected
(Lanes 2 and 4) were separated on an 11 % SDS-polyacrylamide gel
and incubated with antisera to either VVR1 (Lanes I and 2)or
VVR2 (Lanes 3 and 4). Molecular weight standardsare shown on
the left; the molecular weights of immunoreactive proteinsare
shown on the right.3
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virus-infected cells were pulse-labeled at the indicated times forone hour and then
harvested. Cell extracts were incubated with either VVR1 (Fig. IV.3, Panel A)or
VVR2 (Fig. IV.3, Panel B) antisera, followed by immunoprecipitation with protein-A
Sepharose. Both R1 and R2 proteins are present in virus-infected cells by 1 hpost
infection and the peak of protein synthesis for both subunitsoccurs between 3 and 4 h
post infection. Translation of these proteins continues up to 9 h post infection. These
results are consistent with the transcriptional data. Since the relative quantityof each
protein in the infected cell cannot be derived by this analysis, competitiveELISA was
used to quantitate the amounts of R1 and R2 proteins.
The VVR2 antiserum cross-reacted with a host protein of 42 kDa whilethe
V VR1 antiserum faintly cross-reacted witha host protein of 92 kDa. Infection by
vaccinia virus appears to result in the cessat ion of synthesis andturnover of both of the
immunoreactive host proteins. The following results demonstrate that thecross-
reacting 92-kDa band is the host large subunit of ribonucleotide reductase.Immunoblot
analysis of the infected and mock-infected extracts using AD 203 monoclonal
antiserum, which reacts to mammalian R1 (Engstrom, 1982; Engstromet al., 1984),
revealed cross reactivity with the 92-kDa host protein, butno immunoreactivity was
detected with the vaccinia 87-kDa R1 protein (data not shown). Immunoblotanalysis
using monoclonal antiserum to rat a-tubulin, which has been demonstratedto cross-
react with mouse and calf ribonucleotide reductase R2 protein (Kilmartinet al., 1982;
Thelander et al., 1985), revealed no cross reactivity with the 42-kDahost monkey
protein, and only faint reaction with the viral 37-kDa R2 protein afterincubation of the
antibody conjugate overnight with alkaline phosphatase substrate. Wewere therefore
unable to identify the 42-kDa band on the immunoblotas the corresponding host
ribonucleotide reductase protein.I1 4
Figure IV.3.Immunoprecipitation Analysis of the Time
Course of Vaccinia Virus Ribonucleotide Reductase Protein
Synthesis. Pulse-labeled cell extracts were immunoprecipitated with
antisera to either VVR 1 (Panel A) or VVR2 (Panel B). Mock-
infected (M) or virus-infected cells (10 plaque forming units/cell)
were pulse-labeled with 50 liCi/m1 135S1-methionine for 1 h at the
indicated times post-infection. Molecular weight standardsare
shown on the left; the molecular weights of immunoprecipitated
proteins are shown on the right.97
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IV.4.4 Protein Stability of Vaccinia Virus Ribonucleotide Reductase
To determine the stability of the RI and R2 proteins during the time course of
viral infection, immunoprecipitations of pulse-labeled cell extracts were performed.
Mock-infected or virus-infected cells were labeled from 2.5 to 3 h post infection with
[35S1- methionine and then chased withan excess of unlabeled methionine for the
indicated times and then harvested. Cell extracts were incubated with a combination of
VVR I and VVR2 antisera (Fig. IV.4), followed by immunoprecipitation with protein-A
Sepharose. The levels of both RI and R2 proteins were relatively constant over the 9 h
of incubation in unlabeled methionine, indicating that the turnover numbers of these
proteins are low.
IV.4.5 Ribonucleotide Reductase Activity in Vaccinia
Virus-Infected Extracts
Ribonucleotide reductase assays were performed with mock-infected and virus-
infected cell extracts to determine the time course of enzyme activity. Toprevent
degradation of substrate in the reaction mixture (presumedly due to catalysis by
nucleoside diphosphate kinase) ATP was substituted with the uncleavable analog 5'-
adenylylimido diphosphate. The kinetics of ribonucleotide reductase activity in the
infected cell extracts is shown in Figure IV.5. Activity increased from 1 to 6 hpost
infection and the maximal activity of virus-infected extracts (689 fmolimin/106cells)
was greater than ten times that of mock-infected extracts (61 fmol/min/106 cells). The
specific activity of ribonucleotide reductase (approximately 5 nmolimin/mg RI)was
established by using the quantitative ELISA results to determine the amount of R1
(limiting) protein in the crude extracts.
The recent expression and purification of a virally encoded glutaredoxin2
enabled us to examine the effect of the glutaredoxin reducing system on ribonucleotide
2 W. Thresher, manuscript in preparation.11 8
Figure IV.4.Immunoprecipitation Analysis of the Stability
of Vaccinia Virus Ribonucleotide Reductase Protein. Pulse-chased
cell extracts were immunoprecipitated with antisera to both VVR I
and VVR2. Virus-infected (VV) or mock-infected (M) cellswere
pulsed with 25 1.1Ci/m1 135S1-methionine between 2.5 and 3.0 h post
infection and harvested at the indicated times post infection. Panel
A, Stability of VVR I protein. Panel B, Stability of VVR2 protein.VV
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Figure IV.5.Time Course of Induction of Vaccinia Virus
Ribonucleotide Reductase Activity. BSC40 cells were infected with
10 plaque forming units/cell and harvested at the indicated timespost
infection. Extracts were assayed for enzyme activity using theassay
parameters described in the text. Each bar represents the average of
triplicate determinations.0.2
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reductase activity in the crude extracts. Substitution of dithiothreitol with either
glutathione, glutaredoxin, or both (at concentrations tenfold higher than the Km values
for mammalian glutathione and glutarexon), maintained but didnot increase the level of
enzyme activity (data not shown).
IV.4.6 ELISA of R1 and R2 Proteins in Vaccinia Virus-Infected Extracts
The kinetics of ribonucleotide reductase protein accumulationwas quantitated
by using a competitive inhibition enzyme-linked immunoassay. Extractsmade from
cells infected at the indicated times were used to inhibit the reaction of purifiedviral
ribonucleotide reductase with anti-VVR I or anti-VVR2sera. Antibody complexes were
measured by reaction of the antisera with a horseradish peroxidase anti-rabbitconjugate
and colorimetric detection of the enzyme reaction byan ELISA plate reader. The time
course of accumulation of both viral proteins is shown in Figure IV.6, Panels A and B.
Both vaccinia proteins accumulated through 6 h of infectionto maximal levels of 4.2 x
106 R1 molecules/cell and 23x106 R2 molecules/cell. The kineticsof protein
accumulation, shown in Figure IV.6, duplicated that of ribonucleotide reductase
activity. This direct correlation between protein accumulation andenzyme activity
suggests that enzyme activity is regulated solely by subunit protein levels.
The immunoassay results also define the molar stoichiometry of thetwo
reductase subunits during infection. The R2 subunit (20.3 pmol monomer/106cells)
accumulated in the extracts to a level that is six times higher than the concentrationof
the RI subunit (3.4 pmol monomer/106 cells). These results establish thatthe R1
subunit is limiting in vaccinia virus-infected cell extracts. These dataare supported by
recent kinetic analysis of the purified recombinant enzyme. In those experiments,
maximal enzyme activity was obtained only when the R2 subunitwas present in a
fourfold excess1 2 3
Figure IV.6.Quantitative ELISA Analysis of the
Accumulation of Vaccinia Virus Ribonucleotide Reductase Protein.
BSC40 cells were infected with 10 plaque forming units/cell and
harvested at the indicated times post infection. VVRI and VVR2
protein levels in the extracts were measured by competitive
inhibition assay and quantitated by comparison with purified
recombinant VVRI and VVR2 protein standards as described in the
text. Panel A, time course of VVRI accumulation. Panel B, time
course of VVR2 accumulation.13
Figure IV.6
25
C.)
20
15
10
5
U0 12345678
Time of Infection, (hours)
0
U0 1234567 8
Time of Infection,(hours)
1 2 41 2 5
IV.4.7 Viral DNA Accumulation in Vaccinia Virus-Infected Cells
Vaccinia virus DNA replication takes place in cytoplasmic foci, termed
virosomes (Cairns, 1960). The rate of DNA synthesis at the virosomes has been
estimated by incorporation of [3H1-thymidine into acid-precipitable material (Joklik and
Becker, 1962: Condit and Motyczka, 1981; Slabaugh and Mathews, 1986) These
measurements, however, assume that there is a constant flow of thymine nucleotides
into DNA and that the thymidine triphosphate pool size remainsconstant and, therefore,
so does the specific activity of 13141-thymidine. To the contrary, deoxynucleotide pool
measurements in eukaryotic cells demonstrate extensive pool fluctuations during DNA
synthesis (Bianchi et al., 1986a; Bianchi et al., 1986b). To circumventthese problems,
we used a dot blot filter technique to more directly measure the accumulation of viral
DNA. Cell extracts infected with virus at a multiplicity of 10 plaque formingunits/cell
were hybridized to an excess of random-primed vaccinia virus-specific probe.
Hybridization was quantitated by immunochemiluminescent detection (Martinet al.,
1990) and the DNA concentration in the extractswas determined by comparison with a
standard curve of hybridized purified vaccinia virus DNA. Control experimentswere
performed to establish that the hybridization probewas in excess and that hybridization
was due to DNA and not RNA in the extracts. The kinetics of accumulation of virus-
specific DNA sequences in infected cell extracts is shown in Figure IV.7. ViralDNA
accumulated throughout the measured time course and therate of accumulation was
constant from 3-8 h post infection. Quantitatively, more than 1200 viralgenomes
equivalents are replicated in each cell by 8 h post infection under the experimental
conditions. The kinetics established in this experimentare consistent with previous
work which also measured vaccinia DNA accumulation by the hybridizationtechnique
(Ensinger 1987; Hooda-Dhingra et al., 1989; Rempel et al., 1990). Thesegroups all
found that DNA accumulation is constant until 10-12 hpost infection. The quantitative126
Figure IV.7.Quantitative Dot Blot Hybridization Analysis
of the Accumulation of Vaccinia Virus DNA. BSC40 cellswere
infected with 10 plaque forming units/cell and harvested at the
indicated times post infection. Cells were disrupted and a portion of
each sample was bound to a filter and probed with a nonisotopically-
labeled HindlII F fragment of vaccinia virus DNA. Hybridization
was measured by an immunochemiluminescent formulation and
quantitated by comparison with purified Hind III F fragment DNA.z
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amounts of virally-synthesized DNA determined in this study for BSC40 cell infections
also agree with early studies that quantitated infectious particle formation of vaccinia
virus in other host cell types (Joklik and Becker, 1964; Jungwirth and Launer, 1968).
These early studies also demonstrated that 30% of viral DNA (by weight) is packaged
into virions during an infection within a 24 h period.
IV.4.8 Comparison of the Accumulation of Viral DNA
with Viral Ribonucleotide Reductase Levels During
Vaccinia Infection
Since the kinetics of viral DNA accumulation and ribonucleotide reductase
accumulation have both been measured quantitatively, a direct comparisoncan be made
between the supply of deoxynucleotide precursors and their utilization. This
comparison (Table IV.1) demonstrates that the levels of ribonucleotide reductase in
virus-infected cells are indeed sufficient to supply adequate levels of
deoxyribonucleotides for the accumulation of viral DNA. From the DNA hybridization
experiment, it was established that viral DNA replication results in the synthesis of
more than twelve hundred viral genomes/cell by 8 h of infection (Column 2). To
synthesize this amount of DNA by 8 h, the number of limiting ribonucleotide reductase
subunits (R1) in the infected cell must be at least 2.3 x 106 molecules (Column 3)or
94,000 molecules (Column 4), depending on which value forenzyme specific activity
is used for the calculations. ELISA analysis to determine ribonucleotide reductase
protein levels demonstrate that there is indeed enough enzyme at 8 h (3.1x 106
molecules RI and 1.9 x 107 molecules R2) to synthesize appropriate amounts of DNA
(Column 5). Only during the early hours of viral DNA synthesis (1-3 hpost infection,
where quantitation of the diminutive amounts of DNA and enzyme is difficult and
inaccurate) is the level of ribonucleotide reductase insufficient to account for the rate ofTable IV.1Comparison of Deoxyribonucleotide Supply and Demand
Flours of InfectionDNA accumulation aRequirement for Rlb Requirement for R1 cAccumulation of RI
(h) (genomes/cell) (molecules/cell) (molecules/cell) (molecules/cell)
0
1 72 1,000,000 43,000 320,000
2 162 1,200,000 48,000 320,000
3 397 1,900,000 79,000 560,000
4 545 1,900,000 82,000 1,400,000
5 708 2,000,000 84,000 2,200,000
6 885 2,100,000 88,000 3,300,000
7 1010 2,100,000 87,000 4,200,(>0
8 1260 2,300,000 94,000 3,100,000
a
Values determined from dot blot filter hybridization experimentas described in text
b
Values calculated as described in text using specific activity of 5 nmol/min/mg R1for virus-infected extracts
Values calculated as described in text using specific activity of 120 nmol/min/mgR 1 for purified holoenzyme
dValues determined from ELISA experiment as described intext1 3 0
accumulation of viral DNA. This inadequacy is also only found when the lower
specific activity value is considered.
The numbers in Column 2 were determined by first calculating the weight of
genome equivalents in the infected cells from the DNA hybridization data: for the 8 h
calculation, (1263 genomes/cell) x (187,(X)0 bp/genome) x (660g bp/mol) -4- (6.02 x
1023 molecules/mol)= 2.6 x10-13pg bp/cell; then by determining themolar
concentration of nucleotides needed as substrate for DNA synthesis in the infected
cells, 1 pg by = 1 pg nucleotide, (2.6 x 10-13 pg nucleotide/cell)4- (330 g/mol
nucleotide) = 7.9 x 1016 mol nucleotide/cell; then by establishing therate at which the
nucleotide substrates must be provided by dividing by the length of time in which the
DNA accumulation measurements were made, 7.9 x (1016 mol nucleotide/cell)+ (8 h)
x (1 h/60 min) = 1.6 x 10-18 mol nucleotide/min/cell; and finally by dividing this sum
by the specific activity of viral ribonucleotide reductase and the molecular weightof the
RI (limiting) subunit, (1.6 x 1018 mol nucleotide /min /cell)(5 x 10-9 mol
nucleotide/min/mg R1) x (6.02 x 1023 molecules R 1/mol RI)x (1 mol R1/87,000 g R1)
= 2.3 x106 molecules Rl/cell.
To ensure that the calculations in Table 1 are valid, the values used for the
specific activity of ribonucleotide reductase (5 nmol/min/mg R1)must be considered.
Slabaugh and coworkers have recently demonstrated that the specific activity of
ribonucleotide reductase can be dramatically increased by optimizing reaction conditions
for the purified enzyme3. The value obtained for the purifiedenzyme under the
optimized reaction conditions (50 mM dithiothreitol instead of 10 mM and ATP instead
of 5'-adenylylimido diphosphate) was 120 nrnol /min /mg of RI. However,we felt that
because the specific activity value used in the quantitation calculations should
approximate the physiological conditions of virus-infected cells, it might be inaccurate
3 M. Slabaugh, manuscript in preparation.1 3 1
to use the value for purified enzyme. Accurate specific activity determinations on virus-
infected cell extracts, however, have been elusive. Activity measurementson virus-
infected cell extracts in the presence of 10 mM dithiothreitol and 2 mM 5'-
adenylylinaido diphosphate have given specific activity values between 3-8
nmol/min/mg R1 (this study). Unfortunately, the optimal reaction conditions for the
purified enzyme are severely inhibitory90%) to the activity found in virus-infected
crude extracts. Much of this inhibition is almost certainly due to phosphorylation of
CDP to CTP by nucleoside diphosphate kinase and the effects of other ATP utilizing
enzymes, which render the adenosine nucleoside products unable to activate
ribonucleotide reductase. Moreover, enzyme assayson purified ribonucleotide
reductase have demonstrated that ATP is tenfold more effectiveas an activator than is
5'-adenylylimido diphosphate. Therefore, specific activity measurements in infected
cell extracts in the presence of 5'-adenylylimido diphosphate would be expectedto give
estimates that are much lower than the actual value. For thesereasons, we have used
the specific activity values determined for both purified ribonucleotide reductase(120
nmol/min/mg R1) and that determined in virus-infected cellextracts (5 nmol/min/mg of
R1) in our calculations.
IV.5 Discussion
The availability of deoxynucleotides is a crucial factor in determining therate at
which a cell or organism is able to replicate its DNA. The denovo synthesis of these
precursors was thought to be limited by the rate of catalysis of the enzyme
ribonucleotide reductase (Thelander and Reichard, 1979). In thisreport we have
measured both the accumulation of DNA and the accumulation and activity of
ribonucleotide reductase in BSC40 cells infected with vaccinia virus. Quantitationof1 3 2
these processes has allowed us to directly relate the synthesis (supply) of
deoxynucleotide precursors with their demand in viral DNA replication. Vaccinia
expresses the enzymes necessary for viral DNA synthesis and directs its own
replication in the cytoplasm of the host cell. Moreover, vacciniaexpresses all of the
functions necessary for its own cytoplasmic DNA replication and is not dependenton
host factors for this process. Because host DNA synthesis is inhibited by viral
infection and cellular DNA is not used by the virus in itsown DNA synthesis, we
reasoned that vaccinia virus provided an ideal system for this study. Since host DNA
synthesis is inhibited and not available for viral DNA synthesis, theseparameters did
not have to be considered in the quantitations.
This work is of key significance in that through quantitative experimentationwe
can answer the central question of whether the rate of de novo deoxynucleotide
synthesis is sufficiently high to account for the accumulation of DNA in this viral
system. This question of deoxyribonucleotide supply and demand has been
approached in the past by measuring the ribonucleotide reductase activities inextracts
from different cell types and comparing these values with estimates of the cellular
requirements for deoxyribonucleotides (Eriksson et al., 1977; Felleret al., 1980,
Larsson, 1969). These early investigations however, reportedenzyme activities that
were too low to account for the cellular demand for deoxynucleotides. As in our work,
the standard reaction conditions used to measureenzyme activity in these reports (5'-
adenylylimido diphosphate), gave much lower values thanmeasurements with purified
enzyme which use physiological enzyme activator (ATP) (Mann et al., 1991; and
Slabaugh4 ). Our approximation of specific activity from virus-infectedcells is most
certainly an underestimate, while the conditions used to determine the higher specific
activity value for purified vaccinia virus ribonucleotidewere not physiological. We feel
4 M. Slabaugh, manuscript in preparation.1 3 3
confident however, that the bona fide value for viral ribonucleotide reductase specific
activity falls between these two determinations.
S1 nuclease and immunoprecipitation analysis revealed that the transcriptional
and translational expression of the genes encoding ribonucleotide reductaseoccur
coordinately and early during viral infection. The timecourse of expression and the
stability of the ribonucleotide reductase proteins parallel other virus-inducedenzymes
involved in DNA metabolism. Similar studies with viral DNA polymerase(Traktman et
al., 1984), thymidylate kinase (Smith et al., 1989), and thymidine kinase (Hrubyand
Ball, 1981) all demonstrate similar expression kinetics. Thesegene products all belong
to the 'immediate early class' of viral gene expression (Moss, 1990). Like
ribonucleotide reductase, these replication proteins are also quite stable andare resistant
to post-translational degradation processes.
The finding that R1 was limiting with respect to R2 duringa viral infection was
somewhat suprising since it was previously demonstrated that in mammaliancells,
enzyme activity is limited during the cell cycle by R2 protein levels (Engstrom et al.,
1985; Mann et al., 1988; Eriksson et al., 1984) In other studied viralsystems (herpes
simplex virus and T4 bacteriophage), both subunits of ribonucleotidereductase form
tight a2f32 subunit complexes and are present in stoichiometricamounts in infected cell
extracts (Ingemarson and Lankinen, 1987; Berglund, 1975). It appears that this
enzyme has recruited quite a range of regulatory schemes. That vaccinia virus
expresses an excess of the R2 protein is seemingly advantageous in light of recent
experiments that demonstrated that vaccinia virus R2 preparations containa low tyrosyl
radical content (0.6 radicals/R2 dimer) (Howell et al., 1992). Theexcess R2 protein in
vaccinia-infected extracts may compensate for the low radicalcontent detected in
vaccinia virus R2 preparations.1 3 4
We used competitive inhibition ELISA to quantitate viral ribonucleotide
reductase levels and dot blot filter hybridization experiments to measure viral DNA
accumulation. To relate these values we determined the specific activity of
ribonucleotide reductase in virus-infected extracts. Our specific activity determinations
revealed values that were significantly lower than that for purifiedenzyme (Slabaugh et
al., this issue). Significant differences in specific activities of purifiedenzyme and
enzyme from crude extracts have also been demonstrated for ribonucleotide reductases
from herpes simplex (references), bacterial (references), and mammalian (references)
sources. This discrepancy is not understood but may in part be due to naturally
occurring enzyme inhibitors in the extracts (Schimpff et al., 1978; Lewiset al., 1977).
Because we did not want to overestimate ribonucleotide reductase activity in the viral
extracts we used the lower value for vaccinia virus specific activity. Even with this
lower estimate our calculations still reveal an adequate supply ofenzyme.1 3 5
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V. CONCLUSIONS
The work presented in this dissertation adds to the wealth of knowledge abouta
very complex and fascinating enzyme, ribonucleotide reductase. This work
characterizes the small subunit of the enzyme encoded by the orthopoxvirus, vaccinia,
and demonstrates that the enzyme shares many physical similarities with the well-
characterized mammalian ribonucleotide reductase. In addition, the accumulation of
viral ribonucleotide reductase and viral DNA have been quantitated anda direct
relationship has been made between these two processes. Finally, the effects of the
inhibitory drug, hydroxyurea, have been examined by deoxynucleotide pool
measurements of virus-infected cells, and a mechanism for circumvention of
hydroxyurea inhibition has been detailed. The relevance of each of these projects and
further experiments that would additionally enhance these studiesare presented below.
V.1 Small Subunit Characterization
The manuscript describing the physical characteristics of the small subunit
protein demonstrated that the circular dichroism spectrum, visiblespectrum and EPR
spectrum of the viral protein and recombinant viral protein were nearly identical (in
many respects) to those from the mammalian R2 protein (Howell et al., 1992).
Purification of VVR2 from a recombinant source has allowed usto prepare large
amounts of protein for further study. Taken together, the biochemical results in this
manuscript and amino acid sequence comparisons with other R2 proteins, provide
strong evidence that the genes encoding the vaccinia ribonucleotide reductase are
derived from a mammalian host. Because of these strong physical and genetic1 4 1
similarities between the two proteins, and because of theease of genetic manipulations
in the virus, vaccinia represents an ideal modelsystem within which to continue study
of the mammalian ribonucleotide reductase.
However, one important difference was uncovered between the viral and
mammalian R2 subunits in our experiments, and this deserves furtherstudy. Not only
did the vaccinia R2 protein containa much lower radical content (one-third that of the
mammalian enzyme), but the radical content of purified viral R2protein could not be
increased by anaerobic reconstitution procedures. [These reconstitutionprocedures
significantly increased the radical content of purifiedmouse R2 protein (Mann et al.,
1991).1 To begin to understand why the radicalcontent of the vaccinia virus R2 protein
is significantly low and well below the theoretical maximum,two central questions
must be answered.
First, it is important to determine whether the iron bindingcapability of the viral
R2 protein can account for the lower levels of radical formation.A hypothesis can be
put forth that radical formation is limited in the vaccinia R2 protein by theamount of
iron that the viral dimer is able to bind. Initial steps have been madeto examine this
question by performing iron assayson the vaccinia R2 protein and by examining
conditions which regenerate iron center/radical aftertreatment with hydroxyurea. The
preliminary experiment to measure R2 ironcontent (presented in Appendix B)
demonstrated that iron is present in purified recombinant R2preparations and that the
iron can be removed by treatment witha chelating agent (EDTA) or removed (to a lesser
degree) by treatment with hydroxyurea. The results alsorevealed that iron was present
in substoichiometric amounts; onlyone iron atom was bound /R2 monomer.
Unfortunately, this study did not examine the ironcontent of ribonucleotide reductase
from virus-infected cells, and therefore, conclusionsabout the iron center stoichiometry
of the native viral enzyme can not be made. Additionalpreliminary studies were1 4 2
performed to examine the requirements for iron center and radical regeneration after
hydroxyurea treatment.These data are present in Appendix C. The results of these
experiments show that radical formation (as detected by UV/visible spectroscopy) is
regenerated after hydroxyurea treatment only by the addition of both iron and
dithiothreitol. These experiments, although revealing, were not detailed studies. To
precisely determine the amount of iron bound to VVR2 protein and examine the
oxidation state of iron bound in the vaccinia virus R2 protein, atomic absorption and
further quantitative iron and radical analyses are necessary.
The second question of interest is whether important differences in the
stoichiometry of iron/radical center formation or activation of the vaccinia R2 protein
can account for the lower radical concentrations. Because the vaccinia radical EPR
spectrum was so similar to the mouse spectrum, it is improbable that there are large
differences in the radical environment or in the oxidation state of the stabilizing iron
center (reviewed in Chapter II.).It seems more likely that the source of the fourth
(extra) electron which is necessary for radical formation may be derived from an
alternate source in the vaccinia protein (Figure 11.6). Therefore, this second question
would best be approached by studies similar to those that determined the stoichiometry
of bacterial and mammalian R2 protein activation. Quantitative oxygen consumption
and Mossbauer studies could be used to reveal the source of electrons used in formation
of the viral iron/radical center. Perhaps a half-sites reactivity model (which predicts
less than full radical occupancy) would best fit the activation mechanism for the viral
protein.
We now know (from the quantitative ELISA experiments) that R2 protein is
synthesized in excessive amounts (sixfold higher) compared to the R1 protein
Northern blot analyses of the mRNA's encoding the R1 and R2 subunits reveal that the
strength of the R2 promoter is much greater than that of the R1 promoter (Roseman and1 4 3
Slabaugh, 1990; Tengelson et al., 1988). It can be postulated that R2 overexpression
is an evolutionary mechanism that the virus has developed to compensate for the
intrinsically low radical content of the protein.
V.2 Holoenzyme Interactions
The work to characterize the small subunit protein of vaccinia virus
ribonucleotide reductase has been augmented by complementary studies by Dr. Mary
Slabaugh (previously in this laboratory) with the large subunit of the enzymes. In
addition to purifying and physically characterizing recombinant viral large subunit
protein, Dr. Slabaugh has optimized reaction conditions for holoenzyme activity in
studies by using both viral recombinant reductase subunits in purified form. Still, there
are many more interesting aspects of holoenzyme kinetics and other interaction studies
that remain to be examined. Preliminary studies by Dr. Slabaugh suggest that viral
enzyme activity is maximal when the R2 protein is present in a fourfold excess over RI
protein levels. In addition, a preliminary KD value has been determined for R2 binding
to the R1 protein. Notwithstanding these experiments, none of the binding kinetics
studies with substrate and/or effectors have been performed with the purified viral
enzyme. It is currently not known, for instance, whether the viral enzyme reduces the
various substrates with the same efficiency in the presence of the appropriate effector.
The importance of this question and the need for performing these binding studies
becomes clear when the hydroxyurea studies (Appendix A of this dissertation) and the
work by Karlsson and co-workers
2are considered. These studies both suggest that
1M. Slabaugh, manuscript in preparation.
M. Karlsson, M. Sahlin, and B.-M. Sjoberg, submitted: Journal of Biological
Chemistry.I 4 4
hydroxyurea may display a differential effect on reduction of the various substrates. In
the case of the vaccinia virus system, the work in this dissertation has demonstated that
the phenotype of differential substrate reduction is not due to the phenomena of
substrate cycling. Additionally, whether the action of hydroxyurea indirectly affects the
specificity or substrate binding site is unknown. The premise of differential substrate
reduction should be examined in the viral system by substrate and effector binding
studies with the purified holoenzyme in the presence and absence of drug.
Another aspect of the ribonucleotide reductase that has not been examined is the
native structure of the holoenzyme. Chapter III. demonstrates that the VVR2 protein
exists in solution as a dimer. Analogous studies to determine the native structure of the
VVR1 protein have not yet been performed. An additionally compelling binding study
that would further characterize the viral holoenzyme is to examine the effect of dATP on
the physical structure of the holoenzyme. Dr. Ralph Davis (previously in this
laboratory) has performed preliminary glycerol gradient analyses and demonstrated that
the viral ribonucleotide reductase subunits do not co-migrate
3
.This experiment
suggests that the interaction of the two holoenzyme subunits is not sufficiently strong to
stabilize higher-order or multimeric species. Addition of dATP to holoenzyme
preparations of mammalian, bacterial, or T4 bacteriophage ribonucleotide reductase
caused the formation of tetrameric or higher-order reductase species consisting of both
subunits in one case. The effect of dATP (and perhaps other effectors or substrates) on
the native structure of vaccinia reductase should be examined by gel filtration
chromatography, glycerol gradient sedimentation, and/or by analytical
ultracentrifugation. Clearly, these studies would add to our understanding of the
enzyme structure.
3R.Davis, PhD Thesis, Oregon State University.1 4 5
Other important interaction studies with vaccinia virus ribonucleotide reductase
are currently beimg pursued in our laboratory. One unresolved aspect of viral
ribonucleotide reductase is the source of biological reducing equivalents thatare utilized
by the enzyme. To this end, the vaccinia virus gene encoding glutaredoxin has recently
been identified (Goebel et al., 1990) and overexpressed in bacteria by Dr. Wayne
Thresher in our laboratory. Dr. Thresher has purified the putative glutaredoxin protein
and has demonstrated biological glutaredoxin activity in purified preparations. In
addition to the work on the glutaredoxin protein, ribonucleotide reductaseassays were
recently performed on virus-infected cell extracts in studies designed to determine the
size of reducing factors needed in vivo for efficient reductase activity. This experiment
is presented in Appendix D. The results of this experiment demonstrate thatat least two
reducing components are required for maximal reductase activity:one of very small size
(may be replaced by dithiothreitol) and one of molecular mass between 5,000 to
30,000. Because no viral thioredoxin system has been detected, the
glutaredoxin/glutathione/glutathione reductase system is the obvious candidate toserve
as the biological reductant for ribonucleotide reductase in this viral system. We hope
that further characterization of the viral glutaredoxin system will demonstate its
catalytic role or interaction with the vaccinia virus ribonucleotide reductase.
Another important physical interaction that has recently been examined is that
between the virally-encoded single-stranded DNA binding protein and the R2 subunit
of vaccinia ribonucleotide reductase. Dr. Davis identified this interaction by preparing
anti-idiotypic antiserum to VVR2 subunit, and then analyzing immunoprecipitations
with virus-infected extracts
5.The addition of a purified preparation of single-stranded
binding protein was subsequently shown to stimulate the activity of ribonucleotide
4W. Thresher, manuscript inpreparation.
SR. Davis, PhDThesis, Oregon State University.1 4 6
reductase in preliminary studies. Affinity binding studiesare currently being performed
(by Dr. Thresher) to directly characterize this particular interaction. Thephysical
interaction studies with both the viral glutaredoxin and single-strandedbinding protein
demonstrate the importance of considering the physiological environmentsand
interactions of enzymes when studying enzyme structureor function.
V.3 Viral Ribonucleotide Reduction and Replication
In Chapter IV., we characterized the ribonucleotide reductase in virus-infected
crude extracts. We demonstrated that the transcriptional and translationalkinetics of
reductase expression are consistent with those of otherenzymes that are involved in
DNA replication. We also demonstrated that thereare adequate levels of ribonucleotide
reductase activity to synthesize the required amounts of deoxyribonucleotidesfor viral
replication (except at early hours in the viral life cycle and under certaincondiuons6
).
These results represent the first thorough quantitation of ribonucleotidereductase
protein levels in any system and also represents the first quantitativecomparison of
deoxyribonucleotide supply and demand during replication.
Unfortunately, the basis of our calculations requireda determination of the
enzyme specific activity, and measurement of this value was complicated by the
reaction conditions that are required to assay activity in crudeextracts. The complexity
of the in vivo system (enzymes that utilize ATP and CDP, the positiveactivator and
substrate of our enzyme assay) made our activitymeasurements impossible with the
activator, ATP. Additionally, the uncleavable analog 5'-adenylylimidodiphosphate,
that was used instead of ATP and remedied the interference fromother enzymes, was a
6
Special conditions represent specific activity measurement of 5nmol/min/mg R1 in
which enzyme assays were performed with the inefficientactivator, 2'-
adenylylimido 5' diphosphate.1 4 7
much worse activator than ATP in activity measurements with the purified
ribonucleotide reductase. We remedied this problem by using both the specific activity
value that we determined for crude viral extracts (in thepresence of 5'-adenylylimido
diphosphate) and the value that was recently determined for purified holoenzyme7(in
the presence of ATP). Since 5.-adenylylimido diphosphate lowersmeasurements of
enzyme activity, the correct specific activity value for ribonucleotide reductase is most
assuredly in the range of our determinations. To improve theaccuracy of our reductase
activity determinations in crude extracts (and, therefore, our estimation of
deoxyribonucleotide supply in the viral system), it would bevery beneficial to find a
fully active analog to substitute for ATP. Although several exist,one commercial
(inexpensive) analog to test for its ability to activate ribonucleotide reductase would be
y-adenylylthio 5'-diphosphate.
Our comparison of deoxynucleotide supply and demand demonstrates that the
activity of ribonucleotide reductase does not limit the rate of viral DNA replication
under the conditions tested. This finding is contradictory to early studies of the
bacterial enzyme that suggested, albeit indirectly, that ribonucleotide reductasewas the
limiting enzyme of DNA synthesis (reviewed by Thelander and Reichard, 1979).
These studies evoked the presence of temperature-sensitive ribonucleotide reductase
mutants (deficient in DNA synthesis) and insufficient enzyme activities in crude extracts
as indications of the importance of the enzyme to DNA synthesis. With purified
recombinant enzymes and immunological reagents, these researchersare now much
better equipped to directly determine the role of ribonucleotide reductase in DNA
synthesis. Whether the vaccinia virus replication system representsa suitable model for
mammalian or bacterial replication is unclear. However, studies suchas this one will
most assuredly provide insights into the regulation of these replication systems.
7
M. Slabaugh, manuscript in preparation.1 4 8
BIBLIOGRAPHY
Aberg, A., Hahne, S., Karlsson, M., Larsson, A., Ormo,M.,
Ahgren, A., and Sjoberg, B.-M. (1989) J. Biol. Chem.
264, 12249-12252.
Adams, R. L. P., Berryman, S., and Thomson, A. (1971)
Biochem. Biophys. Acta 240, 455-462
Adams, R. L. P., and Lindsay, J.G. (1967) J. Biol. Chem.
242, 1314-1317.
Akerblom, L., and Reichard, P. (1985) J. Biol. Chem. 260,
9197-9202.
Anonymous, in Physicians Desk Reference, 38th Edition,
(Medical Economics Co., Oradell, NJ, 1984) 1915-1916.
Arkoosh, M. R., and Kaattari, S. L. (1990) in Techniques in
Fish Immunology J. S. Stolen, T. C. Fletcher, D. P.
Anderson, B. S. Roberson, W. B. van Muiswinkel, Eds.
(SOS Publications, Fair Haven NJ) 15-24.
Ashley, G. W., Harris, G., and Stubbe J. (1986) J. Biol.
Chem. 261, 3958-3964.
Atkin, C. L., Thelander, L., Reichard, P., and Lang, G.
(1973) J. Biol. Chem. 248, 7464-7472.
Ator, M., and Stubbe, J. (1985) Biochemistry 24, 7214-7221.
Averett, D. R., Lubbers, C., Elion, G. B., and Spector, T.
(1983) J. Biol. Chem. 258, 9831-9838.
I3acchetti, S., and Whitmore, G. F. (1969) Cell Tissue Killer.
2, 193-211.
Backes, G., Sahlin, M., Sjoberg, B.-M., Loehr, T. M., and
Sanders-Loehr, J. (1989) Biochemistry 28, 1923-1929.
Becker, Y., and Joklik, W. K. (1964) Proc. Natl. Acad. Sci.
U. S. A. 51, 577-585.
Bender, C. J., Sahlin, M., Babcock, G. T., Barry, B. A.,
Chandrashekar, T., Salowe, S. P., Stubbe, J.,
Lindstrom, B. R., and Sjoberg, B.-M. (1989) J. Am.
Clzem. Soc. 111, 8076-8083.1 4 9
Beratan, D. N., Betts, J. N., and Onuchic, J. N. (1991)
Science 252, 1285-1288.
Berglund, O (1972) J. Biol. Chem. 247, 7276-7281.
Berglund, O (1975) J. Biol. Chem. 250, 7450-7455.
Berglund, O., and Sjoberg, B.-M. (1970) J. Biol. Chem. 245,
6030-6035.
Bianchi, V., Pontis, E., and Reichard, P. (1986a) Proc.
Natl. Acad. Sci. U. S. A. 83, 986-990.
Bianchi, V., Pontis, E., and Reichard, P. (1986) J. Biol.
Chem. 261, 16037-16042.
Bjorklund, S., Skog, S., Tribukait, B., and Thelander, L.
(1990) Biochemistry 29, 5452-5458.
Bollinger, J. M., Jr., Edmondson, D. E., I luynh, B. H.,
Filley, J. R., Norton, J. R., and Stubbe, J. (1991a)
Science 253, 292-298.
Bollinger, J. M., Stubbe, J., Edmondson, D., and Huynh, B.
H. (1991b) J. Am. Chem. Soc. 113, 6289-6291.
Bradford, M. M., (1976) Anal. Biochem. 72, 248-254.
Brissenden, J. E., Caras, I., Thelander, L., and Francke, U.
(1988) Exp. Cell. Res. 174, 302-308.
Brown, N. C., and Reichard, P. (1969a) J. Mol. Biol. 46,
25-38.
Brown, N. C., and Reichard, P. (1969b) J. Mol. Biol. 46,
39-55.
Bunker, G., Petersson, L., Sjoberg, B.-M., Sahlin, M.,
Chance, M., Chance, B., and Ehrenberg, A. (1987)
Biochemistry 26, 4708.
Cairns, J. (1960) Virology 11, 603-623.
Cameron, I. L., and Jeter, Jr., J. R., (1973) Cell Tissue
Kinet. 6, 289-301
Caras, I. W., and Martin, D. W. (1982) J. Biol. Chem. 257,
9508.
Carlson, J., Messing, J., and Fuchs, J. A., (1984) Proc.
Nail. Acad. Sci. U. S. A. 81, 4294-4297.1 5 0
Child, S. J., Palumbo, G. J., Buller, M. L., and Hruby,
D. E. (1990) Virology, 174, 625-629.
Choy, B. K., McClarty, G. A., Chan, G. A., Thelander, L.,
and Wright, J. A. (1988) Cancer Res. 48, 2029-2035.
Chung, C. T., Niemela, S. L., and Miller, R. H., (1989)
Proc. Natl. Acad. Sci. U. S. A. 86, 2172-2175.
Collins, A., and Oates, D. J., (1987) Eur. J. Biochem. 169,
299-305.
Compton, L. A., and Johnson, W. C., Jr. (1986) Anal.
Biochem. 155, 155-167.
Condit, R. C., and Motyczka, A. (1981) Virology 113,
224-241.
Condit, R. C., Motyczka, A., and Spizz, G. (1983) Virology
128, 429-443.
Dahl, R., and Kates, J. R. (1970) Virology 42, 453-462.
Dales, S. (1963) J. Cell Biol. 18, 51-72.
Darling, A. J. (1988) J. Gen. Virol. 69, 515-523.
Davis, R. (1992) PhD Thesis, Oregon State University.
Dieckmann, C. L., and Tzagoloff, A. (1985) J. Biol. Chem.
260, 1513-1520.
von Dike ln, U., and Reichard, P. (1976) J. Biol. Chem. 251,
3616-3622.
Drillien, R., Koehren, F., and Kim, A. (1981) Virology 111,
488-499.
Earl, P. L., Cooper, N., and Moss, B. (1988) in Current
Protocols in Molecular Biology F. M. Ausubel, R. Brent,
R. E. Kingston, D. D. Moore, J. G. Seidman, J. A.
Smith, K. Struhi, Eds. (John Wiley & Sons, New York,
NY) 16.16.1-6.
Ehrenberg, A., and Reichard, P. (1972) J. Biol. Chem. 247,
3485-3488.
Elgren, T. E., Lynch, J. B., Juarez-Garcia, C., Miinck, E.,
Sjoberg, B.-M., and Que, L., Jr. (1991) J. Biol. Chem.
266, 19265-19268.1 5 1
Eliasson, R., Jornvall, H., and Reichard, P. (1986) Proc.
Natl. Acad. Sci. U. S. A. 83, 2373-2377.
Eliasson, R., Fontecave, M., Jornvall, H., Krook, M.,
Pontis, E., and Reichard, P. (1990) Proc. Natl. Acad.
Sci. U. S. A. 87,3314-3318.
Elledge, S. J., Zhou, Z., and Allen, J. B. (1992) TIBS 17,
119-123.
Engstrom, Y. (1982) Org. Chem. Biochem. 5, 343-344.
Engstrom, Y., Rozell, B., Hansson, H.-A., Stemme, S., and
Thelander, L. (1984) EMBO 3, 863-867.
Engstrom, Y., Eriksson, S., Jildevik, I., Skog, S.,
Thelander, L., and Tribukait, B. (1985) J. Biol. Chem.
260. 9114-9116.
Engstrom, Y., and Rozell, B. (1988) EMBO, 7, 1615-1620.
Ensinger, M. J. (1987) J. Virol. 61, 1842-1850.
Eriksson, S., Sjoberg, B.-M., Hahne, S., and Karlstrom, 0.
(1977) J. Biol. Chem. 252, 6132-6138.
Eriksson, S., Thelander, L., and Akerman, M. (1979)
Biochemistry 18, 2948.
Eriksson, S., Caras, I. W., and Martin, D. W. (1982) Proc
Natl. Acad. Sci. U. S. A. 79, 81.
Eriksson, S., Graslund, A., Skog, S., Thelander, L., and
Tribukait, B. (1984) J. Biol. Chem. 259, 11695-117(X).
Eriksson, S., Skog, S., Tribukait, B., and Wallstrom, B.
(1987) Exp. Cell Res. 168, 79-88.
Esko, J. M., Wermuth, M. M., and Raetz, C. H., (1981) J.
Biol. Chem. 256, 7388-7393.
Fallon, R. J., and Cox, R. P. (1979) J. Cell. Physiol. 100,
251-262.
Feller, W., Schimpff-Weiland, G., and Follman, H. (1980)
Eur. J. Biochem. 110, 85-92.
Fenner, F., Henderson, D. A., Arita, I., Jezek, Z., and
Ladnyi, I. D., smallpox and its Eradication, (World
Heath Organization, Geneva, 1988).1 5 2
Fenner, F., Wittek, R., Dumbell, K. R., Orthopoxviruses
(Academic Press, San Diego, 1988).
Filpula, D. F., and Fuchs, J. A. (1977) J. Bacteriol. 130,
107-113.
Fontecave, M., Graslund, A., and Reichard, P. (1987) J.
Biol. Chem. 262, 12332-12336.
Fontecave, M., Eliasson, R., and Reichard. P. (1987) J.
Biol. Chem. 262, 12325-12331.
Fontecave, M., Eliasson, R., and Reichard, P. (1989) Proc.
Natl. Acad. Sci. U. S. A. 86, 2147-2151.
Fontecave, M., Gerez, C., Mansuy, D., and Reichard, P.
(1990) J. Biol. Chem. 265, 10919-10924.
Fox, B. G., Surerus, K. K., Miinck, E., and Lipscomb, J. P.
(1988) J. Biol. Chem. 263, 10553-10556.
Fox, R. M. (1985) P/tarmac. Titer. 30, 31-42.
Frenkel, E. P., Skinner, W. N., and Smiley, J. D. (1964)
Cancer Chemother. Rep. 40, 19-22.
Fuerst, T. R., Earl, P. L., and Moss, B. (1987) Mol. Cell.
Biol. 7, 2538-2544.
Gale, G. R., (1967) Experentia 24, 57-58.
Gerez, C., Atta, M., Fontecave, M., Gaillard, J., Scheer,
C., and Latour, J. M. (1991) J. lnorg. Biochem. 43, 536
Gillard, S., Spehner, D., Drillien, R., and Kim, A. (1986)
Proc. Natl. Acad. Sci. U. S. A. 83, 5573-5577.
Gillard, S., Spehner, D., Drillien, R., and Kim, A. (1989)
J. Viral. 63, 1814-1817.
Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W.,
Winslow, J. P., and Paoletti, E. (1990) Virology 179,
247-266.
Goldstein, D. J., and Weller, S. K. (1988) Virology 166,
41-51.
Griislund, A., Ehrenberg, A., and Thelander, L. (1982) J.
Biol. Chem. 257, 5711-5715.1 5 3
Hanke, P. D., and Fuchs, J. A. (1983) J. Bacteriol. 154,
1040-1045.
harder, J., and Follmann, H. (1990) Free Rad. Res. Commun.
10, 281-286.
Harris, G., Ator. M., and Stubbe, J. (1984) Biochemistry 23,
5214-5225.
Henderson, J. F., Brox. L., Zombor, G., Hunting, D., and
Lomas, C. A. (1977) Biochem. Pharmacol. 26, 1967-1972.
Hendrich, M. P., Elgren, T. E., and Que L., Jr. (1991)
Biochem. Biophs. Res Commun. 176, 705-710.
Hogenkamp, H. P. C., Follman, H., and Thauer, R. K. (1987)
FEBS Lett. 219, 197-201.
Holmgren, A. (1976) Proc. Natl. Acad. Sci. U. S. A. 73,
2275-2279.
Holmgren, A. (1979) J. Biol. Chem. 254, 3664-3671.
Holmgren, A. (1979) J. Biol. Chem. 254, 3672-3678.
Holmgren, A. (1985) Ann. Rev. Biochem. 54, 237.
Hooda-Dhingra, U., Thompson, C. L., and Condit, R. C. (1989)
J. Virol. 63, 714-729.
Howell. M. L., Sanders-Loehr, J., Loehr, T. M., Roseman, N.
A., Mathews, C. K., and Slabaugh, M. B. (1992) J. Biol.
Chem. 267, 1705-1711.
Hruby, D. E., and Ball, L. A., (1981) J. Virol. 40, 456-464.
Hurta, R. A. R., and Wright, J. A. (1990) Biochem. Biophys.
Res. Commun. 167, 258-264.
Hurta, R. A., Samuel, S. K., Greenberg, A. H., and Wright,
J. A. (1991) J. Biol. Chem. 266, 24097-24100.
Hurta, R. A., and Wright, J. A. (1992) J. Biol. Chem. 267,
Ingemarson, R., and Lankinen, H. (1987) Virology 156,
417-422.
Jackson, R. C. (1978) J. Biol. Chem. 253, 7440-7446.
Jacobs, S. J., and Rosenkranz, H. S. (1970) Cancer Res. 30,
1084-1094.1 5 4
Jenner, E., in Classics of Medicine and Surgery C. N. B.
Camac, Ed. (Dover, New York, 1959), 213-240.
Joklik, W., and Becker, Y. (1964) J. Mol. Biol. 10, 452-474.
Jungwirth, C., and Launer, J. (1968) J. Virol. 2, 401-408.
Karlsson, M., Sahlin, M., and Sjoberg, B.-M. J. Biol. Chem.,
submitted.
Kilmartin, J. V., Wright, B., and Milstein, C. (1982) J.
Cell. Biol. 93, 576-582.
Kit, S., and Dubbs, D. R. (1962) Virology 18, 286-293.
Kjo ller-Larsen, I., Sjoberg, B.-M., and Thelander L. (1982)
Eur J. Biochem. 125, 75-81.
Krakoff, I. H., Brown, N. C., and Reichard, P. (1968) Cancer
Res. 28, 1559-1565.
Kren, B., Parsell, D., and Fuchs, J. A. (1988) J. Bacteriol.
170, 308-315.
Kunkel, T. A., Roberts, J. D., and Zakour, R. A., (1987)
Methods Enzymol. 154, 27-91.
Kunz, B. A., and Kohalmi, S. E. (1991) Annu. Rev. Genet. 25,
339-359.
Laemmli, U. K. (1970) Nature 227, 680-685.
Lagergren, J., and Reichard, P. (1987) Biochem. Pharmac. 36,
2985-2991.
Lammers, M
27-91
Langelier, Y
21-31
Lankinen, H.
Virol
Larsson, A.,
2533.
.,and Foliman, H. (1983) Structure Bonding 54,
.,and Buttin, G. (1981) J. gen. Virol. 57,
,Graslund, A., and Thelander, L. (1982) J.
.41, 893-900.
and Reichard, P. (1966a) J. Biol. Chem. 241,
Larsson, A., and Reichard, P. (1966b) J. Biol. Chem. 241,
2540-2546.1 5 5
Larsson, A. (1969) Ear. J. Biochem. 11, 113-121.
Larsson, A., and Sjoberg, B.-M. (1986) EMBO 5, 2037-2040.
Larsson, A., Karlsson, M., Sahlin, M., and Sjoberg, B.-M.
(1988) J. Biol. Chem. 263, 17780-17784.
Lassmann, G., and Liermann, B. (1989) Free Rad. Biol. Med.
6, 241-244.
Laurent, T. C., Moore, E. C., and Reichard, P. (1964) J.
Biol. Chem. 239, 3436-3444.
Lewis, W. H., Mc Naughton, D. R., Goh, S. H., Le John, H. B.,
and Wright, J. A. (1977) J. Cell Physiol. 93, 345-352.
Lin, A. I., Ashley, G. W., and Stubbe J. (1987) Biochemistry
26, 6905.
Luthman, M., Eriksson, S., llolmgren, A., and Thelander, L.
(1979) Proc. Natl. Acad. Sci. U. S. A. 76, 2158-2162.
Luthman, M. and Holmgren, A. (1982) J. Biol. Clzem. 257,
6686-6690.
Lynch, J. B., Juarez-Garcia, C., Miinck, E., and Que, L., Jr.
(1989) J. Biol. Chem. 264, 8091-8096.
Malencik, D. A., Zhizhuang, Z., and Anderson, S. R. (1990)
Anal. Biochem. 184, 353-359.
Mann, G. J., Musgrove, E. A., Fox, R. M., and Thelander, L.
(1988) Cancer Res. 48, 5151-5156.
Mann, G. J., Graslund, A., Ochiai, E.-I., Ingemarsson, R.,
and Thelander, L. (1991) Biochemistry 30, 1939-1947.
Mao, S. S., Johnston, M. I., Bollinger, J. M., and Stubbe,
J. (1989) Proc Natl Acad. Sci. U. S. A. 86, 1485-1490.
Martin, R., Hoover, C., Grimme, S., Grogan, C., Holtke, J.,
and Kessler, C. (1990) BioTechniques 9, 762-768.
Mathews, C. K., in Progress in Nucleic Acid Research and
Molecular Biology, W. E. Cohn, and K. Moldave, Eds.
(Academic Press, San Diego), in press.
Mathews, C. K., and Slabaugh, M. B. (1986) Exptl. Cell Res.
162, 285-295.1 5 6
McClarty, G. A., Chan, A. K., Engstrom, Y., Wright, J. A.,
and Thelander, L. (1987) Biochemistry 26, 8004-8011.
McClarty, G. A., Chan, A. K., Choy, B. K., and Wright, J. A.
(1990) J. Biol. Chem. 265, 7539-7547.
Mckeag, M., and Brown, P. R. (1978) J. Chromatogr. 152,
253-254.
Meuth, M. (1989) Exp. Cell Res. 181, 305-316.
Miner, J. N., and Hruby, D. E. (1989) Virology 170, 227-237.
Moore, E. C., and Hurlbert, R. B. (1985) Pharmac. Ther. 27,
167-196.
Moss, B. (1968) J. Virol. 2, 1028-1037.
Moss, B. (1990) Annu. Rev. Biochem. 59, 661-668.
Moss, B. (1991) Science 252, 1662-1667.
Moss, B., Winters, E., and Jones, E. (1983) in Mechanisms of
DNA Replication and Recombination (Alan R. Liss Inc.,
New York, NY) 449-461.
Moyer, R. W., and Graves, R. L. (1981) Cell 27, 391-401.
Nevins, J. R., anf Joklik, W. R. (1977) J. Biol. Chem. 252,
6930-6938.
Nicander, B. and Reichard, P. (1985a) J. Biol. Chem. 260,
5376-5381.
Nicander, B., and Reichard, P. (1985b) J. Biol. Chem. 260,
9216-9222.
Nordlund, P., Sjoberg, B.-M., and Eklund, H. (1990) Nature
345, 593-598.
Nordlund, P., Uhlin, U., Hajdu, J., and Eklund, H. (1991) J.
Inorg. Biochem. 43, 542.
North, T. W., Bestwick, R. K., and Mathews, C. K. (1980) .
Biol. Chem. 255, 6640-6645.
Ochiai, E.-I., Mann, G. J., Graslund, A., and Thelander, L.
(1990) J. Biol. Chem. 265, 15758-15761.1 5 7
Oki, T., Fujiwara, Y., and Heidelberger, C. (1971) J. Gen.
Virol. 13, 401-413.
Parkhurst, J. R., Peterson, A. R., and Heidelberger, C.
(1973) Proc. Natl. Acad. Sci. U. S. A. 70, 3200-3204.
Perkus, M. E., Panicalli, D., Mercer, S., and Paoletti, E.
(1986) Virology, 152, 285-297.
Petersson, L., Graslund, A., Ehrenberg, A., Sjoberg, B.-M.,
and Reichard, P. (1980) J. Biol. Chem. 255, 6706-6712.
Plageman, P. G. W., and Erbe, J. (1974) J. Cell Physiol. 83,
321-336.
Prescott, D. M., Kates, J. R., and Kirckpatrick, J. B.
(1981) J. Mol. Biol. 59, 505-514.
Que L., Jr., and True, A. E. (1990) Prog. lnorg. Chem.
Bioinorg. Chem. 38, 97.
Reichard, P. (1988) Ann. Rev. Biochem. 57, 349-374.
Rempel, R. E., Anderson, M. K., Evans, E., and Traktman, P.
(1990) J. Virol. 64, 574-583.
Ribi, H. 0., Reichard, P., and Kornberg, R. D. (1987)
Biochemistry 26, 7974-7979.
Rittberg, D. A., and Wright, J. A. (1989) Biochem. Cell
Biol. 67, 352-357.
Rode, W., Scanlon, K. J., Moroson, B. A., and Bertino, J. R.
(1980) J. Biol. Chem. 255, 1305-1311.
Roseman, N. A., and Slabaugh, M. B. (1990) Virology 178,
410-418.
Rosenberg, A. H., Lade, B., Chui, D., Lin, S. W., Dunn, J.,
and Studier, F. W. (1987) Gene (Amst) 56, 125-135.
Russel, M., and Holmgren, A. (1988) Proc. Natl. Acad. Sci.
U. S. A. 85, 990-994.
Sahlin, M., Graslund, A., Ehrenberg, A., and Sjoberg, B.-M.
(1982) J. Biol. Chem. 257, 366-369.
Sahlin, M., Petersson, L., Graslund, A., Ehrenberg, A.,
Sjoberg, B.-M., and Thelander, L. (1987) Biochemistry
26, 5541-5548.1 5 8
Sahlin, M., Graslund, A., Petersson, L., Ehrenberg, A., and
Sjoberg, B.-M. (1989) Biochemistry 28, 2618-2625.
Sahlin, M., Sjoberg, B.-M., Backes, G., Loehr, T. M., and
Sanders-Loehr, J. (1990) Biochem. Biophys. Res. Commun.
167, 813-818.
Salowe, S. P., and Stubbe, J., (1986) J
363-366.
Salowe, S. P., Ator, M., and Stubbe, J.
26, 3408-3416.
.Bacteriol. 165,
(1987) Biochemistry
Sanders-Loehr, J., in Oxidases and Related Redox Systems,
H. S. Mason, T. E. King, M. Morrison, Eds. (Liss, New
York, 1990), 193-209.
Scarrow, R. C., Maroney, M. J., Palmer, S. M., Que, L., Jr.,
Salowe S. P., and Stubbe, J. (1986) Am. Chem. Soc. 108,
6832.
Schimpff, G., Muller, 11., and Follman, H. (1978) Biochim.
Biophys. Acta 520, 70-81.
Schmitt, J. F. C., and Stunnenberg, H. F., (1988) J. Virol.
62, 1889-1897.
Schrecker, A. W., Jacobsen, D. W., and Kirchner, J. (1968)
Anal. Biochem. 26, 474-477.
Scott, F. W., and Forsdyke, D. R. (1980) Biochem. J. 190,
721-730.
Sjoberg, B.-M., Loehr, T. M., and Sanders-Loehr, J. (1982)
Biochemistry 21, 96-102.
Sjoberg, B.-M. and Graslund, A. (1983) Adv. Inorg. Biochem.
5, 87-110.
Sjoberg, B.-M., Graslund, A., and Eckstein, F. (1983) J.
Biol. Chem. 258, 8060-8067.
Sjoberg, B.-M., Eklund, H., Fuchs, J. A., Carlson, J.,
Standart, N. M., Rudermen, J. V., Bray, S. J., and
Hunt, T. (1985) FEBS lett. 183, 99-102.
Sjoberg, B.-M., Karlsson, M., and Jornvall, H. (1987) J.
Biol. Chem. 262, 9736-9743.
Sjoberg, B.-M., Karlsson, M., and Jornvall, H. (1987) J.
Biol. Chem. 262, 9736-9743.1 5 9
Skoog, L. and Nordenskjold, B. (1971) Eur. J. Biochem. 19,
81-89.
Slabaugh, M. B., Johnson, T. L., and Mathews, C. K. (1984)
J. Virol. 52, 507-514.
Siabaugh, M. B., and Mathews, C. K. (1984) J.Virol.52,
501-506.
Slabaugh, M. B., and Mathews, C. K. (1986) J.Virol.60,
506-514.
Slabaugh, M. B., Roseman, N. A., Davis, R., and Mathews,
C. K. (1988) J.Virol.62, 519-527.
Slabaugh, M. B., Roseman, N. A., and Mathews, C. K. (1989)
Nucleic Acids Res. 17, 7073-7088.
Slabaugh, M. B., Howell, M. L., Wang, Y., and Mathews,
C. K. (1991) J.Virol.65, 2290-2298.
Snyder, R. D., (1984) Mutation Res. 131, 163-172.
Spector, T., Stonehuerner, J. G., Biron, K. K., and Averett,
D. R. (1987) Biochem. Pharmac. 36, 4341-4346.
Spyrou, G., and Reichard, P. (1987) J. Biol. Chem. 262,
16425-16432.
Spyrou, G., and Reichard, P. (1989) J. Biol. Chem. 264,
960-964.
Stoeckler, J. D., Agarwal, R. P., Agarwal, K. C., and Parks,
Jr., R. F., (1978) Methods Enzymol. 51, 530-538.
Stubbe, J. (1988) Biochemistry 27, 3893-3900.
Stubbe, J. (1990) Adv. Enzymol. 63, 349-419.
Stubbe, J. (1990) J. Biol. Chem. 265, 5329-5332.
Stubbe, J., Ator, M., and Krenitsky, T. (1983) J. Biol.
Chem. 258, 1625-1630.
Studier, F. W., Rosenberg, A. H., Dunn, J. J., and
Dubendorf, J. W. (1990) Methods Enzymol. 185, 60-89.
Tagger, A. Y., and Wright, J. A. (1988) Int. J. Cancer 42,
760-766.1 6 0
Tattersall, M. H. N., Lavoie, A., Ganeschaguru, K., Tripp,
E., and Hoffbrand, A. V. (1975) Eur J. clin. Invest. 5.
191-202.
Tengelson, L. A., Slabaugh, M. B., Bibler, J. K., and Hruby,
D. E. (1988) Virology 164, 7426-7432.
Thelander, L. (1973) J. Biol. Chem. 248, 4591-4601.
Thelander, L. (1974) J. Biol. Chem. 249, 4858-4862.
Thelander, L., and Reichard, P. (1979) Annu. Rev. Biochem.
48, 133-159.
Thelander, L., Eriksson, S., and Akerman, M. (1980) J. Biol.
Chem. 255, 7426-7432.
Thelander, L.. Grnslund, A., and Thelander, M. (1983)
Biochem. Biophys. Res. Commun. 110, 859-865.
Thelander, M., Graslund, A.. and Thelander, L. (1985) J.
Biol. Chem. 260, 2737-2741.
Timson, J. (1975) Mutat. Res. 32, 115-131.
Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl.
Acad. Sci. U. S. A. 76, 4350-4354.
Traktman, P., Sridhar, P., Condit, R. C., and Roberts, B. E.
(1984) J. Viral. 49, 125-131.
Traktman, P., Anderson, M. K., and Rempel, R. E. (1989) J.
Biol. Chem. 264, 21458-21461.
Traktman, P. (1990) Cell 62, 621-626.
Tuggle, C. K., and Fuchs, J. A. (1986) EMBO 5, 1077-1085.
Tuggle, C. K., and Fuchs, J. A. (1990) J. Bacteriol. 172,
1711-1718.
Tyrsted, G. (1982) Biochem. Pharmac. 31, 3107-3113.
VanSlyke, J. K., and Hruby, D. E., in Current Topics in
Microbiology and Immunology, R. W. Moyer, and P. C.
Turner, Eds. (Springer-Verlag, Heidelberg, 1990),
185-206.
Walker, I. G., Yatscoff, R. W., and Sridhar, R. (1977)
Biochem. Biophys. Res. Commun. 77, 403-408.1 6 1
Wallace, B. J., and Kushner, S. R., (1984) Gene 32, 399-408.
Walters, R. A., Tobey, R. A., and Hildebrand, C. H. (1976)
Biochem. Biophys. Res. Commun. 69, 212.
Walters, R. A., Tobey, R. A., and Ratliff, R. L. (1973)
Biochem. Biophys. Acta 319, 226-237.
Wawra, E., and Wintersberger, E. (1983) Cancer Res. 28,
1082-1087.
Weinberg, G., Ullman, B., and Martin, D. W. (1981) Proc
Natl. Acad. Sci. U. S. A. 78, 2447-2451.
Weinrich, S. L., Niles, E. G., and Hruby, D. E. (1985) J.
Virol. 55, 450-457.
Willing, A., Follman, 11., and Au lung, G. (1988a) Eur. J.
Biochem. 175, 167-173.
Willing, A., Follman, H., and Au lung, G. (1988b) Eur J.
Biochem. 170, 603-611.
Wright, J.A., Alam, T. G., McClarty, G. A., Tagger, A. Y.,
and Thelander, L. (1987) Somatic Cell Mol. Genet. 13,
155-165.
Wright, J. A., Chan, A. K., Choy, B. K., Hurta, A. R.,
McClarty, G. A., and Tagger, A. Y. (1990) Biochem.
Cell. Biol. 68, 1364-1371.
Yamazaki, I., and Piette, L. H., (1990) J. Biol. Chem. 265,
13589-13594.
Yang-Feng, T. L., Barton, D. E., Thelander, L., Lewis, W.
H., Srinivasan, P. R., and Francke, U. (1987) Genomics
1, 77-86.
Yarbro, J. W. (1968) Cancer Res. 28, 1082-1087.
Yeh, Y. C., and Tessman, I. (1978) J. Biol. Chem. 253,
1323-1324.
Young, C. W., and Hodas, S. (1964) Science 146, 1172-1174.
Young, C. W., Schochetman, G., and Karnofsky, D. A. (1967)
Cancer Res. 27, 526-534.APPENDICES162
Appendix A. Deoxyadenosine Reverses Hydroxyurea Inhibition of
Vaccinia Virus Growth
Mary B. Slabaugh, Meredith L. Howell, Yu Wang', and
Christopher K. Mathews
Dept. of Biochemistry and Biophysics, Oregon State University, Corvallis, OR 97331-
6503
Published in: Journal of Virology (1991) 65, 2290-2298.
1Present address:California Biotechnology, Mountain View,
CA 940401 6 3
A.1 Abstract
Hydroxyurea, an inhibitor of ribonucleotide reductase, blocks replication of
vaccinia virus. However, when medium containing hydroxyurea and dialyzrdserum
was supplemented with deoxyadenosine, the block to viral reproductionwas
circumvented, provided that an inhibitor of adenosine deaminasewas also present.
Deoxyguanosine, deoxycytidine and deoxythymidinewere ineffective alone and did not
augment the deoxyadenosine effect. In fact, increasing concentrations of
deoxyguanosine and deoxythymidine, but not deoxycytidine, eliminated the
deoxyadenosine rescue, an effect that was reversed by addition of lowconcentrations
of deoxycytidine. These results suggested that the inhibition of viralreplication by
hydroxyurea was primarily due to a deficiency of dATP. Deoxyribonucleoside
triphosphate pools in vaccinia virus-infected cellswere measured at the height of viral
DNA synthesis after a synchronous infection. With 0.5 mM hydroxyurea,the dATP
pool was >90% depleted, the dCTP and dGTP poolswere 40 to 50% reduced, and the
dTTP pool was increased. Assay of ribonucleotide reductase activityin intact virus-
infected cells suggested that HU may differentially affect reductionof the various
substrates of the enzyme.
A.2 Introduction
The ability of hydroxyurea (HU) and related hydroxamic acidsto preferentially
inhibit DNA metabolism was initially describedmore than 25 years ago (Young and
Hodas, 1964). HU- treated cells are reversibly arrested in the early Sphase, but
prolonged exposure results in cytotoxicity, leading to cell death (Bacchettiand
Whitmore, 1969; Fallon and Cox, 1979; Walterset al., 1976). Although neither the1 6 4
acute nor long-term effects are fully understood, HU continues to be used clinically as
an antitumor agent (Anonymous, 1984).
The rate-limiting enzyme in dNTP biosynthesis, ribonucleotide reductase (EC
1.17.4.1), is the immediate target of HU (Skoog and Nordenskjold, 1971), and the site
of HU action has been localized to the smaller of the two subunits of theenzyme
(Krakoff et al., 1968). Inhibition is thought to result from the ability of the drugto
destroy a stable organic free radical carried on a tyrosine residue that is invariant in
small subunits from sources as diverse as Escherichia coli, yeast species, mice, and
vaccinia virus (Sjoberg et al., 1985; Slabaugh et al., 1988). Although mechanistic
details of the reaction catalyzed by ribonucleotide reductase remain obscure, the tyrosyl
radical has been proposed to initiate reduction of the ribonucleotide substrates (Sjoberg
et al., 1983; Stubbe, 1988).
If HU acts by starving the replication apparatus forprecursors, then the block
should be reversed if dNTPs are supplied as exogenous deoxyribonucleosides, justas
thymidine can relieve inhibition of DNA synthesis by fluorodeoxyuridine,an inhibitor
of thymidylate synthase. Nevertheless, numerous attempts toreverse HU inhibition
have yielded preponderantly negative results (Adamset al., 1967; Cameron and Jeter,
1973; Eriksson et al., 1987; Gale, 1967; Lagergren and Reichard, 1987; Plagemanet
al., 1974; Walker et al., 1977; Yarbro, 1968: Young et al., 1967). and several ofthe
reported restorations of DNA sythesis can be ascribed to changesin131-11dTTP specific
activity (Scott and Forsdyke, 1980). These and other observations (Bachettiand
Whitmore, 1969; Wawra and Wintersberger, 1983) have ledto the suggestion that HU
may have additional sites of action (Adams et al., 1971; Skoog and Nordenskjold,
1971; Yarbro, 1968), or that certain precursor pools derived by salvagepathways are
excluded from replication forks (Mathews and Slabaugh, 1986; Scott and Forsdyke,
1980; Snyder, 1984).1 6 5
Although no additional primary targets for HU have been identified, and HU-
resistant cell and viral mutants all contain eitheran altered or amplified ribonucleotide
reductase small subunit (for a review, see Moore and Hurlbert, 1985), the cytotoxic
effects of the drug or its metabolites (e.g. chromosome breakage (Jacobsand
Rosenkranz, 19701 and membrane damage [Lassmann and Liermann, 19891)may
preclude effective rescue of cell growth from HU. To circumvent possible
complications due to secondary effects, we have re-examined the reversal ofHU-
inhibition using vaccinia virus, which encodes ribonucleotide reductasesubunits that
are highly homologous to their mammalian counterparts (Schmitt and Stunnenberg,
1988; Slabaugh et al., 1988; Tengelson et al., 1988). Vaccinia virusreproduction is
inhibited by HU with an 50% effective concentration of 0.5to 0.7 mM, and the virus-
encoded small subunit is presumed to be a target for the drug, sinceresistant mutants
with amplified genes for this protein have been isolated (Slabaughet al.. 1989).
We found that HU-mediated inhibition of vaccinia virus reproductionwas
reversible by exogenous deoxyribonucleosides, but only ifan inhibitor of adenosine
dearninase was present. Surprisingly, deoxyadenosine (dAdo) alonewas as effective
as a mixture of all four deoxyribonucleotides. The implications of these results for
understanding the interaction of HU with ribonucleotidereductase are discussed.
A.3 Materials and Methods
Materials. 12,8-
3
1-11Acienosine (1
3HIAdo, 39 Ci/mmol) and 15-
3
1-11cytidine
([31I1Cyd,25 Ci/mmol) were purchased from ICN Radiochemicals(Irvine, CA). [8-
3
H1Guanosine (13H1Guo, 11 Ci/mmol)was a gift from Dr. Buddy Ullman, Oregon
Health Sciences University. [2,8-3H1Adenosine 5'-diphosphate(25 Ci/mmol), 15-
3Hlcytidine 5-diphosphate (25.3 Ci/mmol), and [8-
3
Higuanosine 5'-diphosphate (51 6 6
Ci/mmol) were obtained from DuPont (NEN Research Products, Boston,Mass.).
Erythro-9-(2-hydroxyl -3-nonyl)adenine (EHNA) was donated by Burroughs Wellcome
Co. (Reseach Triangle Park, N.C.). HU and calf intestinal phosphatase (CIP)were
purchased from Boehringer Mannheim Biochemicals (Indianapolis, Ind.).
Deoxyribonucleoside triphosphates (dNTPs), poly(dA-dT), and poly(dI -dC) used in
the dNTP assays were purchased from Pharmacia (Piscataway, N.J.). Pol I(Klenow
fragment) was obtained from United States Biochemical (Cleveland, Ohio).All other
biochemicals were purchased from Sigma (St. Louis, Mo.).
Cells and virus. BSC40 monkey kidney cells and the WR strain of vaccinia
virus were maintained as described (Slabaugh et al., 1984a),except that virus stocks
were subjected to two freeze-thaw cycles rather than trypsinization before infections
were initiated. Periodic screening for mycoplasma with Hoechst 33258 dye revealed
no evidence of infection. Confluent cell monolayers received fresh medium containing
5% dialyzed fetal calf serum (Gibco) 16 h before the beginning ofan experiment and
again at the time of infection. For plaque reductionassays, cells were infected with
vaccinia virus at a dilution that yielded 100 to 300 plaquesper dish in the absence of
drugs or nucleoside. Plaques were visualized by staining monolayers with 0.5%
(wt/vol) methylene blue in 50% methanol. In most experiments, triplicatedishes were
used for each data point. Except where plaque numberswere low, the standard
deviation was <15% of the mean value.
Analysis of dNTP pools. Confluent monolayers of BSC40cells in 100 -
mm dishes were infected with vaccinia virus (multiplicity of infection, 10). Triplicate
dishes were prepared for each data point. Treatments (HU and/or
deoxyribonucleosides) were initiated at 3.5 h postinfection (hpi) and terminatedat 4.5
hpi by aspirating medium and rapidly washing the monolayers twicewith 2 ml of cold
Tris-buffered saline (10mM Tris-HCIIpH81, 150 mM NaCl). Nucleotideswere1 6 7
extracted into 2 ml of 60% methanol at -20°C for 1 h. After insoluble materialwas
pelleted, extracts were taken to dryness and suspended in 5% trichloroacetic acid (1(X)
p.I per 100-mm dish). After 30 min on ice, extractswere centrifuged to remove
insoluble material and supernatants were extracted withan equal volume of 0.5 M tri-n-
octylamine-78% Freon. dNTPs were quantitated by the enzymatic method,essentially
as described (North et al., 1980).
Analysis of ribonucleotide pools. Portions of theextracts prepared for
dNTP analysis were analyzed on a Partisil-10 SAX high-pressure liquid
chromatography ion-exchange column (Whatman, Clifton, N.J.) exactlyas described
(McKeag and Brown, 1978). Peaks were detected by A154 and identified bytheir
retention times as compared to standards.
Assay of ribonucleotide reductase activity. For in vitroassays,
vaccinia virus ribonucleotide reductase was partially purified from virus-infectedcells,
and CDP reduction measured as described (Slabaughet al., 1984a; Slabaugh and
Mathews, 1986). For measurement of ADP and GDP reduction, reactionmixtures (20
p.1) contained 100 InM 4-(-2-hydroxyethyl)-1-piperazine-N'-2-ethanesulfonicacid (pH
8), 10 mM dithiothreitol, 4 mM adenylylimido diphosphate, 2 mM magnesiumacetate,
20 p.M FeC13, 50 p.M tritiated substrate (specific activity 100 cpm/pmol)and effector
nucleotides at various concentrations. Reactionswere stopped by heating at 100°C.
Nucleotides were dephosphorylated by CIP (1 U per reaction, 37°C, 2 h),and reaction
products were chromatographed as described (Schreckeret al., 1968), and quantitated
by scintillation counting.
To measure in situ ribonucleotide reductase activity,we adapted a method
previously used in mammalian cells to estimate CDP reduction after HUtreatment
(Bianchi et al., 1986). Infected cell monolayers (35-mm dishes; multiplicityof
infection, 10 to 15) were treated with 0 to 5 mM HU at 3.5 hpi and thenexposed from1 6 8
4 to 5 hpi to a trace amount (0.3 p.M) of radioactive ribonucleosideprecursor
(I
3Ado, I3H1Guo, or [
3H]Cyd). Methanol-soluble molecules were extracted from
the cells, and radioactivity in deoxyribonucleosides and deoxyribonucleotideswas
quantitated using the same chromatography systems utilized for in vitroassays. The
methanol-insoluble fraction was digested with 0.3 N NaOH to hydrolyze RNA, and
radioactivity incorporated into DNA (base-resistant, acid-precipitable material)was
collected on GF/C filters. Radioactivity incorporated into DNA in thepresence of 0.1
M cytosine B-D-arabinoside was taken as background. This cytosine 13- D- arabinoside
concentration is 50-fold greater than the level required to eliminate vaccinia virus plaque
formation. To quantitate extracellular radioactivity in deoxyribonucleosides,a portion
of the medium was concentrated and analyzed.
In preliminary experiments to characterize this method in the vaccinia virus-
infected cell system, cultures were harvested 0, 30, 60, and 90 min after the additionof
labeled compounds. The rate of uptake of 13HIAdo and [3H1Cyd into the methanol-
soluble fraction was not affected by vaccinia virus infection. [3H]Cyd reached isotopic
equilibrium after 30 to 60 min, wheeras [3H]Ado did not achieve equilibriumeven after
90 min. This difference can be attributed to the ATP pool being much largerthan the
CIP pool. The acid-precipitable radioactivity present after base digestionwas 3 to 5%
of the total radioactivity present in the mehanol-insoluble fraction.
A.4 Results
A.4.1 Inhibition of Adenosine Deaminase Potentiates
dAdo Toxicity.
Before attempting to circumvent HU effects on vaccinia virus growth,we
addressed the problem of dAdo diversion resulting from the action of the salvage
enzyme adenosine deaminase (Plageman and Erbe, 1974). Using dAdo toxicity to1 6 9
virus growth as an assay (a phosphorylated metabolite of dAdo, dATP, inhibitsthe
activity of ribonucleotide reductase toward all four of its substrates, leadingto a
depression of DNA synthesis as dATP accumulates),we asked whether the adenosine
deaminase inhibitor, EHNA, was effective in countering diversion of dAdo(Henderson
et al.. 1977) in the vaccinia-infected cell. EHNA decreased the 50% effective
concentration of dAdo from 360 p.M (0 EHNA) to 60 p.M (5to 10 p.M EHNA). In
subsequent experiments we included EHNA at 5 p.M whenever dAdowas added to the
medium, unless otherwise noted.
A.4.2 HU-Mediated Inhibition of Plaque Formation Can be Reversed
by Deoxyribonucleosides and EHNA.
To see whether exogenous deoxyribonucleosides couldreverse 1 IU inhibition
of vaccinia virus growth, plaque assayswere conducted under the various conditions
indicated in Figure A.1. Only one combination of medium supplementstested10
p.M each dAdo, dGuo, dCyd, dThd, and 5 ttM EHNAsupported plaque formation in
the presence of 2 mM HU. Under these conditions, the number of plaquesper dish
was 75% of the control value (no HU or deoxynucleoside additions). Without EHNA,
neither a 10 p.M nor a 50 !AM deoxyribonucleoside supplementwas effective. The
higher concentration of precursors appeared to potentiate the inhibition by1-1U, whether
EHNA was present or not.It was also apparent that in the absence of HU, the
combination of EHNA plus 5011.M deoxyribonucleosideswas inhibitory.
A.4.3 Reversal of HU Inhibition is a Function of dAdo Concentration.
To determine the concentration of each of the four deoxyribonucleosideswhich
maximized reversal of HU inhibition, cellswere infected with virus in the presence of
I IU (2 mM), EHNA (5 pM), and three of the four deoxyribonucleosides(10 pM). The1 7 0
Figure A.1Effect of Deoxyribonucleosides and EHNA
on HU-Mediated Inhibition of Plaque Formation. Symbols;
0, control;f, 5 p.M EHNAA 10 p.M dAdo, dGuo, dCyd, and dThd;
A, 50 p.Ivl dAdo, dGuo, dCyd, and dThd; El, 5µM EHNA, 10 p.M
dAdo, dGuo, dCyd, and dThd;, 5µM EHNA, 50 pIvl dAdo, dGuo,
dCyd, and dThd. Results from three dishes were averaged for each
data point.p
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fourth precursor was added at concentrations ranging from 0 to 50 p.M. The
unexpected result was that restoration of plaque formation was solely a function of the
dAdo concentration (Figure A.2A). Furthermore, dAdo was effective only at
concentrations below 30 p.M. The finding that the efficiency of plaque restoration did
not change as dCyd, dThd, and dGuo were varied suggested that their presence was
not essential. This was confirmed by the experiment shown in Figure A.2B.
Conditions were identical to those in panel A, except that only one deoxyribonucleoside
precursor was added to each set of cultures. The results clearly demonstrared the
potency of dAdo at 3 to 10 .1.1\4, but only in combination with EHNA. The maximum
rescue efficiency achieved by dAdo plus EHNA was 73&.
A more sensitive measure of HU inhibition and its reversal is provided by a
two-step growth assay --a protocol in which the agents are present during several
cycles of viral reproduction in culture, followed by titration of total infectious virus by
plating in the absence of the inhibitor. The ability of dAdo alone to support virus
growth in the presence of HU was compared to the effect of all four precursors. As
shown in Figure A.3, HU alone depressed virus reproduction by three orders of
magnitude at 5 mM. Both treatments being tested supported a 13 -fold increase in viral
reproduction in the presence of 2 mM HU, and a 60- to 90-fold increase in thepresence
of 5 mM HU.
A.4.4 dAdo-Mediated Reversal of HU Inhibition Can be Eliminated
by dThd and dGuo.
One explanation for the effectiveness of dAdo in counteracting HU is that the
drug affects vaccinia replication primarily by inhibiting ADP reduction, leading toa
critical depletion of the dATP pool. To investigate the activity of ribonucleotide
reductase toward its pyrimidine-containing substrates under dAdo rescue conditions,1 7 3
Figure A.2 (A)Effect of Varying the Concentration
of Each Deoxyribonucleoside on HU-Mediated Inhibition
of Plaque Formation. HU was present in all dishes at 2 mM, EHNA
was present at 5 JIM, and three of the four deoxyribonucleosides were
present at 10 ii.M. The concentration of the fourth deoxyribonucleoside
is indicated on the x axis. Symbols:0, dAdo varied;adCyd varied;
A,dGuo varied;A, dThd varied. The control value (no HU) was 63
plaques per dish. Results from three dishes were averaged for each data
point.60
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Figure A.2 (B)Effect of Single Deoxyribonucleosides
on HU-Mediated Inhibition of Plaque Formation. HU was
present in all dishes at 2 mM. Symbols:0, dAdo plus EHNA (5 pM);
, dAdo;A, dCyd plus EHNA;11, dGuo plus EHNA; U. dThd plus
EHNA. Control value (no HU) was 141 plaquesper dish. Each data
point is the average of three determinations.120
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Figure A.3Effect of HU on Vaccinia Virus Growth.
Effect of HU on vaccinia virus growth in the absence (0)or presence (0)
of dAdo (10 laM) p1usEHNA (5 p.M) or in the presence of all four
deoxyribonucleosides (10 laM) plus EHNA (A). Mono layers of
BSC40 cells were infected at a multiplicity of infection of 0.1 and
harvested after 24 h; titers were determined by plaqueassay.109
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we took advantage of the allosteric regulatory properties of theenzyme. As isolated
from both E. coli and mammalian cells, theenzyme is inhibited toward reduction of
CDP or UDP by either clITP or dGTP, presumablybecause these effectors play
positive allosteric roles in GDP and ADP reduction, respectively(Brown and Reichard,
1969; Eriksson et al., 1979). We first determinedthat vaccinia-encoded ribonucleotide
reductase is regulated similar to the well-characterized E.coli and mammalian
enzymesin that dTTP and dGTP inhibited CDP reduction,but stimulated GDP and
ADP reduction, respectively (data not shown). Althoughthese experiments were done
using crude extracts, the activities measured almostcertainly represent the virus-
encoded enzyme, since the level of CDP reductaseactivity exceeded that in extracts
from uninfected cells by 10-fold. Additionally, ithas recently been shown that the
increase in ribonucleotide reductase activityseen following vaccinia infection is
dependent on an intact viral large subunitgene (Child et al., 1990). If the dAdo-
mediated reversal of HU inhibitionwas dependent on continued reduction of
pyrimidine substrates, therefore, the reversal should besensitive to dThd or dGuo
added to the culture medium. Thiswas tested in the experiment shown in Figure A.4A,
in which addition of either dThdor dGuo to the medium resulted in a dose-dependent
elimination of the reversal. The dAdo-mediated reversal,however, was insensitive to
exogenous dCyd; dCTP has no role in regulating ribonucleotide reductase(Eriksson et
al., 1979). To obtain evidence that the negativeeffects depicted in panel Awere, in
fact, due to depletion of the dCTP and/or d'ITPpools, we added a low concentration of
dCyd to culture containing HU, dAdo, EHNA,and various concentrations of dGuo.
Indeed, 10µM dCyd restored circumvention of theHU block (Figure A.48). The
difference in mean plaque number in cultures withand without dCyd in the absence of
any dGuo was not statistically significant (mean ± S.D.was 298 ± 39 vs. 250 ± 34,
respectively).1 8 0
Figure A.4(A)(A) Effects of dGuo (0), dThd ()
and dCyd (A) on Reversal of HU Inhibition by dAdo Plus
EHNA. HU (2 mM), dAdo (10 ilM), and EHNA (5 1.1.M)were
present in all dishes. The control value (no HU) was 54 plaques
per dish. Each data point is the average of three determinations.60
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Figure A.4 (B)Reinstatement by dCyd of Reversal
of HU Inhibition. HU, dAdo, and EHNA at the concentrations
indicated for panel A were present in all dishes. The effects of
increasing concentrations of dGuo with (0) or withoutdCyd
(10 p.M) are plotted.-0300
o
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A.4.5 Effects of HU on dNTP Pools in Virus-Infected Cells.
To determine the effects of HU on DNA precursor pools during the period of
active viral replication, we measured dNTP levels I h after addition of various
concentrations of HU. The dATP pool was most dramatically affected by HU; itwas
depleted to 10% of the untreated level by 0.5 mM 11U (Figure A.5). Changes inthe
(IGTP, dCTP and dTTP pools were more moderate andwere continuous over the range
of HU concentrations tested. The dGTP pool, (the smallest in the absence ofHU) and
the dCTP pool were both reduced to about half of control values by 0.5 mMHU, and
to about one-third of control values by 2 mM HU. The dTTP pool nearly doubled in
the liU range from 0 to 5 mM.
A.4.6 Replenishment of the dATP Pool by Addition of dAdo
and EHNA
To further explore the mechanism by which dAdo and EHNA rescued vaccinia
from HU inhibition, we measured the effects of these compoundson dNTP pool sizes
in the presence of various concentrations of HU. As anticipated, dAdo elevatedthe
dATP pool and this pool remained elevated at all HU concentrations tested(Figure
A.6). Aditionally, dAdo appeared to moderate the HU-induced increase inthe d'ITY
pool and augment the drug-mediated decrease in the dGTP pool. However,since the
conditions imposed in the Figure A.6 experimentare those that most effectively rescue
virus reproduction, the observed changes in the dTTP and dGTP poolsmay not be a
direct result of the dAdo supplementation but secondary to the demands ofongoing
DNA synthesis.1 8 5
Figure A.5Effect of HU on dNTP pools in
Vaccinia Virus-Infected Cells. Pool sizes were measured
1 h after the addition of HU to the concentrations indicated.
HU was added 3.5 hpi; the multiplicity of infection was 10.
Error bars indicate standard deviation for triplicate dishes.15
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Figure A.6Effect of HU on dNTP Pools in the
Presence of dAdo (10 1.1.M) and EHNA (5 1.1.M). Experimental
details were as described in the legend to Fig. A.5.50
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A.4.7 HU-Mediated Inhibition of the Flow of Tritiated
Ribonucleosides into DNA and Deoxyrinonucleoside
and Deoxyribonucleotide Pools
Since all four substrates of ribonucleotide reductase (ADP, GDP, CDP, and
UDP) are thought to be reduced in the same catalytic site, by a mechanism involving the
same HU-sensitive radical, differential inhibition of the four reactions catalyzed by this
enzyme was unexpected. To more directly examine the effects of HU on ribonucleotide
reductase in the vaccinia-infected cell, we measured the relative activity of theenzyme
with respect to three of its four substrates by using a protocol based on measurement of
the enzyme activity in uninfected cells (Bianchi et al., 1986). In the method, cellsare
exposed to a tracer amount of tritiated ribonucleoside (13 HIAdo,13 H1Guo,or
13HICyd); aftera period of time, intra- and extracellular fractions containing
deoxyribonucleoside and deoxyribonucleotide derivatives of theprecursors are
analyzed. Summation of the radioactivity that has passed through ribonucleotide
reductase during the labeling period yields an estimate of the relative activity of the
enzyme under various conditions.
Incorporation of all three precursors into DNA was profoundly inhibited by 0.5
mM HU and was almost undetectable after treatment with 2or 5 mM HU (Table A.1).
In contrast to the effects of HU on the incorporation of ribonucleosideprecursors into
DNA, however, the drug exhibited an apparent differential effecton precursor
incorporation into deoxyribonucleoside and deoxyribonucleotide pools. HUat 0.5 mM
decreased radioactivity flowing into [
3H] Ado-, [3H]Guo-, and[3H]Cyd- deriveddeoxy
pools by 96, 63, and 49%, respectively. Label derived from radioactive Cydwas
present in both dCyd- and dUrd-containing nucleotides at about a 1:1 ratio whether HU
was present or not (data not shown), suggesting that deamination of dCyd-containing
compounds was not affected by HU. Cytosine 13 -D- arabinoside (0.1 mM) hadno
effect on accumulation of radioactivity into any deoxyribonucleosideor1 9 0
Table VII.1Relative Effects of HU on In Situ Ribonucleotide
Reductase Activity. Cultures infected with vaccinia virus(multiplicity of infection,
15) were labeled from 3.5 to 4.5 h post infection with theindicated compounds
(0.3 .1.M). The radioactivity in DNA is methanol-insoluble,base-resistant,
acid-precipitable radioactivity. Background values (subtracted)were determined
in the presence of 0.1 mM cytosine B-D-arabinoside (113cpm for [3H]Cyd, 260 cpm
for [3H]Ado, 13 cpm for [3H]Guo). Values tabulatedare the mean of determinations
made on three independent 35-mm dishes of infected cells.ND,Table A
cpm per 35-mm dish ± SD
Precursor HU (mM) DNA Intracellular Extracellular
deoxy pools deoxy pools
Total (%)
[311]Cyd 0 2,418 ± 178
0.5 174 ± 45
1.0 129 ± 51
2.0 3 + 24
5.0 0
131-11Ado 0 5,261 ± 442
0.5 204 ± 41
1.0 10± 36
2.0 0
5.0 0
131-1IGuo 0 546± 82
0.5 76 ± 38
1.0 53 +
2.0 17 ± 5
5.0 56 ± 34
3,147 ± 303
1,997 ± 133
1,570 ± 153
1,547 ± 253
1,850 ± 273
1,033 ± 180
46 ± 29
51 ± 39
29 ± 108
27 ± 68
112± 26
41 ± 12
20± 28
23 ± 24
24 ± 23
7,897 ± 1,389 13,462 (100)
3,587 ± 756 5,758 (43)
2,743 ± 309 4,442 (33)
2,583 ± 476 4,133 (31)
2,243 ± 335 4,093 (30)
ND 6,294 (100)
250(4)
61(1)
29 (<1)
27 (<1)
ND 658 (100)
117 (18)
73 (11)
40 (6)
80 (12)1 9 1
deoxyribonucleotide pool (data not shown), indicating that the observed effectswere
not simply secondary to cessation of DNA synthesis. Although excretion of purine
deoxyribonucleosides was not detected, more than half the total radioactivity inthe
deoxy fractions derived from 13H1Cyd was presentas extracellular[3H]dCyd-
[
3
1-1]dUrd. The excretion and re-utilization of pyrimidine deoxyribonucleosidesin
mammalian cells have been well characterized (Nicander and Reichard,1985).
Summing the radioactivity in the various fractions yielded the datashown in the right-
hand column of Table A.1. The apparent relative sensitivityto HU at all concentrations
of the drug tested was ADP reduction > GDP reduction>> CDP reduction.
Although HU is reported to have littleor no effect on RNA metabolism
(Yarbro, 1968), and our preliminary labeling studies indicatedno significant effect of
the drug on incorporation of precursors into RNA (datanot shown), we wished to
determine directly whether HU altered ribonucleotide pool sizes,since such effects
could cause differential changes in the specific activities ofribonucleotide reductase
substrates. Methanol-soluble compounds extracted from vacciniavirus-infected cells
were resolved by chromatography on high pressue liquid chromatography anion-
exchange column (McKeag and Brown, 1978), and thepercentage of the total
absorbance present in each peak was calculated. Comparison of thevalues obtained
after a 1-h treatment with 0, 2 or 5 mM HU revealed that therewas no significant effect
of the drug on any NMP or NTP pool,as shown in the representative tracings from 0
mM and 5 mM HU treatments shown in Figure A.7. Additionally,the pyrimidine
nucleoside diphosphate pools were not detectably altered.However, treatment with
either 2 or 5 mM HU resulted ina twofold increase in the size of the peaks migrating at
the positions of GDP and ADP. From this analysis,we concluded that the specific
activity of [3HJCDP was unaltered but that the specificactivity of [3H]ADP and
[
3
HIGDP may have decreased approximately twofold aftertreatment with 2 to 5 mM1 9 2
Figure A.7Nucleotide Pools in Vaccinia-Infected
Cells at 4.5 h Post Infection Determined From High-Pressure Liquid
Chromatography. Upper tracing, control (90,148 total arbitrary
absorbance units); lower tracing, lh of treatment with 5 mM HU
(96,330 total arbitrary absorbance units).193
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HU. Changes of this magnitude, however, would not alter the conclusions we have
drawn from the data in Table A.1. The apparent increase in ADP and GDP pools
observed after 1 hr of HU treatment suggests that the drug block results in
accumulation of ribonucleotide reductase substrates. Additional characterization of
these peaks will be required before definite conclusions can be drawn.
A.5 Discussion
In the present study we report the novel and unexpected finding that 11U
inhibition of vaccinia virus growth was circumvented by addition of dAdo to the
growth medium. Although partial reversal of HU-inhibited Tetrahymena pyriformis
growth was achieved by adding the four deoxyribonucleoside precursors to the medium
(Cameron and Jeter, 1973), reversal of growth inhibition in mammalian cells has not
been reported. The conditional nature of the drug in the vaccinia virus system allowed
us to explore several parameters of HU action, and the results lead us to suggest that
HU inhibition of ribonucleotidereductase in vivo may be more complex than previously
assumed.
We considered various hypotheses that might account for our finding that dAdo
reversed HU inhibition of virus growth. Since resistance to HU can be mediated by
elevated levels of target enzyme (resulting most commonly fromgene amplification),
we asked whether dAdo might act by increasing the amount of either subunit of
ribonucleotide reductase produced during a vaccinia infection. As measured by
immunoblotting and enzyme assays, there was no such effect (data not shown). We
next considered the possibility that exogenously added dAdo provided a source of
deoxyribose that was then recycled by purine nucleoside phosphorylase to supplement
all four DNA precursor pools. Several results of our study, however, conflict with this1 9 5
hypothesis. EHNA, a potent inhibitor of adenosine deaminase, counteracts the
conversion of dAdo to deoxyinosine. Since deoxyinosine is a much better substrate
than dAdo for purine nucleoside phosphorylase (Stoeckler et al., 1978), the recycling
hypothesis predicts that EHNA would inhibit the dAdo rescue effect. Instead,we
found that EHNA was required to achieve the rescue effect, suggestinga specificity for
dAdo- containing compounds. Additionally, dGuo which is efficiently degraded and
recycled by purine nucleoside phosphorylase, was ineffective asa rescue agent. The
third hypothesis we considered is that HU inhibits preferentially the reduction of purine
substrates, especially the reduction of ADP, and that dAdo relieves inhibition by
replenishing directly the dATP pool and, perhaps indirectly, the dGTP pool. Three
lines of evidence, discussed in the following paragraphs, are consistent with this
hypothesis.
(i)Elimination of the dAdo rescue effect by dThd and dGuo.
These latter two deoxyribonuclosides are precursors of compounds thatserve as
allosteric regulators of ribonucleotide reductases extracted from E. coli and mammalian
cells (Brown and Reichard, 1969; Eriksson et al., 1979) and from vaccinia-infected
cells (this study). The simplest explanation of the results shown in Figure A.4 is that
the reduction of pyrimidine substrates is occuring at a rate sufficientto support viral
replication, albeit at a reduced level, in the presence of HU and dAdo, and that this
residual reduction can be eliminated by the allosteric effectors dTFP and dGTP. Of
course, these results do not eliminate the possibility that dThd anf dGuo. or their
metabolites, deplete the dCTP pool by some as-yet-undescribed mechanism.
(ii) dNTP pool studies. The differential pattern of dNTP pool changeswe
observed in HU-treated, vaccinia virus-infected cells was strikingly similarto that
reported by a number of other investigators using a variety of celltypes (Akerblom and
Reichard, 1985; Bianchi et al., 1986; Collins and Oates, 1987; Erikssonet al., 1987;I 9 6
Lagergren and Reichard, 1987; Nicander and Reichard, 1985; Skoog and
I"lordenskjold, 1971; Snyder, 1984; Walters et al., 1973). We found the dATP pool to
be depressed even more severly than what is usually reported, but this may be due to
the fact that in our experiments essentially all of the cells were engaged in (viral) DNA
synthesis, whereas most studies have been conducted on unsynchronized cell
populations. However, the concentration of I IU that caused a 90% depletion of the
dATP pool (0.5 mM) effects only a 50% inhibition of virus growth. This anomaly is
likely due to the different time scales of the two types of experiment. The biological
response of vaccinia virus to agents that inhibit DNA synthesis is abnormally prolonged
transcription and translation of early genes, a class that includes both ribonucleotide
reductase genes. The presence of HU during 24 to 28 h of virus growth thus leadsto
overproduction of ribonucleotide reductase, which eventually confers partial drug
resistance on viral replication (Slabaugh and Mathews, 1986).
(iii)Measurement of in situ ribonucleotide reductase activity. To
determine more directly whether HU differentially affects reduction of purineversus
pyrimidine substrates, we estimated relative ribonucleotide reductase activity in the
presence of increasing concentrations of HU by summing radioactivity present in
deoxyribose-containing molecules (DNA plus intra- and extracellular pools) labeled
from ribonucleoside precursors added to the cell growth medium. The accumulation of
radioactivity into total intracellular methanol-soluble and -insoluble poolswas not
significantly affected by HU; however, inhibition of the flow of label into dAdo-
containing acid-soluble pools paralleled the decrease in DNA labelingwe observed with
each of the three precursors; the radioactivity flowing into dGuo- and dCyd-containing
acid-soluble pools was less markedly affected. In these experiments,we attempted to
account for all significant metabolic fractions into which products of ribonucleotide
reductase might flow; however, we were unable tomeasure conversion of dUMP to1 9 7
dTMP by thymidylate synthase by measuring tritiatedwater in the cell culture medium
(Rode et al., 1980), because of a high background contributed bythe 13H1Cyd label.
Without knowing what fraction of the total dTTP pool is derived fromdCTP in vaccinia
virus-infected cells, we cannot estimate how much of the total CDPreduction output
was lost from our analysis by this omission. Nevertheless, since thymidylatesynthase
is insensitive to feedback inhibition by elevated dTTP levels(Jackson, 1978), this
likely resulted in an underestimate of CDP reduction in thepresence of HU. A
metabolic fate of the (1(.."11) pool unrelated to DNA synthesis,incorporation into
liponucleotides, utilizes 10 to 20% of this pool insome cell types (Esko et al., 1981;
Spyrou and Reichard, 1987; Spyrou and Reichard, 1989).Any 13H1dCIT so
incorporated in the present study would have been included inthe thin-layer
chromatographic quantitation of intracellularl3fIldCMP aftersample preparation by
acid hydrolysis (see Materials and Methods).
A differential effect of HU on purineversus pyrimidine substrate reduction has
not been demonstrated in vitro. Nevertheless, several authors have presentedindirect
evidence that reduction of purines, especially ADP, ismore sensitive to HU than
reduction of pyrimidines (reviewed by Moore and Hulbert,1985). A partial reversal of
HU-induced pool changes and DNA synthesis inhibitionwas recently reported in
hamster lung fibroblasts after combinedtreatment with dAdo (plus EHNA) and dGuo
(Lagergren and Reichard, 1987). Data obtained from isotope dilutionanalysis of rat
thymus cells led to the suggestion that the increased dTTP poolobserved after HU
treatment resulted from residual function of ribonucleotide reductase (Scott and
Forsdyke, 1980). Additionally, evidence ofa differential effect of HU on
ribonucleotide reduction was presented ina 1973 study of Chinese hamster cells
(Walters et al., 1973). Synchronized by mitotic shake-off andthen exposed to HU
during the G1 phase of the cell cycle, these cells accumulateddTTP, dCTP, and dGTP1 9 8
but not dATP as they approached the time they would normally have initiatedDNA
synthesis. Therefore, although we have studieda virus-infected cell system, it seems
likely that our results are relevant to an understanding of the effects of HUon cellular
replication.
That HU destroys the proteinaceous free radical of all known iron-containing
ribonucleotide reductases has been widely documented. However, theconcentrations
of HU requiredin vitroto yield a certain inhibition, and the conditions required for
regeneration of enzyme activity vary widely. Analyses that dependon assay of enzyme
activity may be complicated by spontaneous regeneration of the radicalunder the usual
reaction conditions employed (e.g. air, iron, dithiothreitol) (Thelanderet al., 1983),
and the recent demonstration of a strong pH dependence of theregeneration reactionin
vitromay provide a partial explanation for the differing results reported previously
(Fontecave et al., 1990).
Although we have interpreted the results of thepresent study as most consistent
with a differential susceptibility of ribonucleotide reductaseto HU, a mechanistic
explanation in light of the accepted model of HU action isnot readily apparent.
Substrate specificity is governed by allosteric effector siteson the large subunit of the
enzyme, whereas HU sensitivity is a property of the small subunit. Thestructure of the
E. coli small subunit was recently determined and revealed thatthe tyrosine residue on
which the HU-sensitive radical resides is buried within theprotein some 1.0 nm from
the nearest surface. The possibility of electron transfer betweenthe iron-tyrosyl center
and a surface residue at the interface between the large and smallsubunits was
suggested (Nordlund et al., 1990). In light of this, the allostericconformation of the
large subunit might influence exposure of the radical in theholoenzyme. A thoroughin
vitrostudy of this enigma awaits the availability of purifiedenzyme subunits from
cloned sources.1 9 9
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APPENDIX B. Iron Analysis of Vaccinia Virus R2 Protein
B.1 Materials and Methods
Iron assays were performed as previously described (Atkinset al., 1973).
Briefly, purified preparations of R2 proteinwere incubated with 5% trichloroacetic acid
for 10 min at room temperature (to remove iron from the protein),and then precipitated
protein was pelleted and removed. 40 µl of the iron-containingsupernatant was added
to 361111-120, 15 p.10.1% (w/v) sodium bathophenanthroline-sulfonate, and 5 p.160
mM acetic acid. After a 30 min incubation, 4 p.1 of saturatedammonium acetate was
added (to buffer the solution), and the color reaction (ironcontent) was monitored by
measuring the A535 A650. Iron was quantitated by comparison witha standard curve
(Figure BA) derived from iron assayson serial dilutions of a reagent Fe(NFI4)2(SO4)2
solution.
Iron was chelated from R2 preparations by two differenttreatment methods.
One preparation (500 p.g R2, treatment 2 in Fig. B.2)was incubated with 20 mM
hydroxyurea for 30 min. The other aliquot (500p.g R2, treatment 3 in Fig. B.2) was
dialyzed overnight against 100 mM EDTA. To determine howmuch iron remained in
the treated samples, chelated iron was removed from both samplesby gel exclusion
using G-50 Sephadex desalting spin columns. Proteinconcentration were normalized
before desalting. A control preparation containing unchelatedR2 protein(500 p.g R2,
treatment 1 in Fig. B.2) was also desalted using the spin columns.204
B.2 Results and Discussion
Iron assays were performed to determine the iron content of purified
recombinant R2 protein and to determine the iron content of recombinant R2 protein
treated with different chelating agents. The standard curve that was used to quantitate
the supernatants from R2 preparations in shown in Figure B.1 and results of the iron
assays are presented in Figure B.2. The quantitative values from these iron assays
demonstrate that the stoichiometry of iron (0.0065 limole) to recombinant R2monomer
(0.011 p.mole) is approximately 1:2 in the purified R2 preparations. This result
suggests that iron is bound to purified recombinant R2 preparations in
substoichiometric amounts. In addition, the low iron content is not the result of iron
deficiency in the bacterial growth media, as the addition of iron to bacterial media andto
protein purification buffers did not increase the radical content of R2 preparations (data
not shown). In a similar manner, the presence of iron in the enzyme reaction mixture
did not increase the activity of R2 preparations as measured byenzyme assays (data not
shown). One explanation for the low iron center content is that the conformationalstate
of the recombinant R2 protein may limit the extent of iron binding. Because of the
large amounts of protein required for this analysis, wewere unable to measure the iron
content of R2 protein from virus-infected cells. Therefore, it is not known whether the
low iron content is a unique characteristic of the recombinant R2 protein.
Treatment with the chelating agents, hydroxyurea or EDTA, caused reduction in
the iron content of the R2 preparation by 33 and 53%, respectively. This demonstrates
that iron binding is reversible in the recombinant viral protein. The finding that
hydroxyurea causes the dissociation of iron from the recombinant viral R2 protein is
significant and consistent with the proposed role of hydroxyurea in iron dissociation
within the mouse R2 protein (McClarty et al., 1990).2.0
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APPENDIX C. Regeneration of Vaccinia Virus R2 Radical
C.1 Materials and Methods
The radical/iron center of a purified R2 preparation (5 mg) was inactivated by
treatment with 50 mM hydroxyurea for 30 min at room temperature. Hydroxyurea was
subsequently removed by gel exclusion using a G-50 Sephadex desalting column.The
recovered preparation containing inactivated R2 was then incubated with the following
solutions for 30 min. Solution 2 contained only Buffer X (100 mM Tris [pH 7.81, 150
mM NaCI). Solution 3 contained Buffer X and 10 mM dithiothreitol. Solution 4
contained Buffer X and 100 p.M Fe(NR4)2(SO4)2. Solution 5 contained Buffer X, 10
mM dithiothreitol, 1001.tM Fe(NH4)2(SO4)2. R2 preparations containing the various
treatments were analyzed for iron center and radical content by UV/visible
spectroscopy. Enzyme activity of the various R2 preparations was measured by the
enzymatic assay described by Slabaugh et al., (1984). The R2 preparationswere
complemented with purified recombinant R1 for activity measurements. For treatment
2 in figures C.1 and C.2 (corresponding to solution 2), hydroxyureawas added to the
preparation before enzyme activity was measured. Treatment 1 in figures C.1 and C.2
represent R2 radical.iron center before inactivation by hydroxyurea. All protein
concentrations of R2 preparations were normalized before analyses.208
C.2 Results and Discussion
These experiments examine the requirements for regeneration of inactivated R2
preparations. Initially, R2 radical/iron center in the protein was inactivated by treatment
with hydroxyurea and then hydroxyurea was removed from the preparations. Addition
of iron and dithiothreitol to these preparations, partially restored the iron center/radical
content of inactivated R2 protein (Fig. C.1, panels B-D) as measured by UV/visible
spectroscopy. Solutions containing R2 and both iron and dithiothreitol restored the R2
radical content to the same level as untreated R2 (Fig. VII.10, panels A and E). These
results suggest that only iron and dithiothreitol are required to regenerate the iron
center/radical component of the viral R2 protein after hydroxyurea inactivation.
To examine the activity of the various R2 preparations, ribonucleotide reductase
assays were performed on the treated preparations. The results of the assays are
presented in Figure C.2 Although the iron/radical content of R2 protein was fully
regenerated by the addition of iron and dithiothreitol, enzyme activity was only partially
regenerated. Treatment of inactivated samples with dithiothreitol or dithiothreitol and
iron, restored activity levels to only 55-60% of the untreated R2 (Fig. C.2, column 1,
3, 4). The highest activity was achieved after treatment with iron alone (75% of
untreated R2). The lower activity measurement in the R2 sample with iron and
dithiothreitol may result from the lack of additional components (besides dithiothreitol
and iron) which may be necessary to restore full ribonucleotide reductase activity. The
high concentrations of dithiothreitol and iron that were used in the assays may also have
been inhibitory (in combinantion) to the activity measurement.209
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APPENDIX D. Size Determination of Biological Reductants Necessary
for In Vivo Ribonucleotide Reductase Activity
D.1 Materials and Methods
Virus-infected cell extracts were prepared as previously described (Chapter IV.,
this dissertation). To remove extract components, extracts werespun through either G-
25 or G-50 Sephadex spin columns. The G-25 spin columns retained onlyvery small
molecules (less than 5 kDa) while the G-50 column retained molecules of molecular
mass less than 30,000. A control experiment with purified R2 protein revealed that
there was full recovery of small subunit protein from the flow through of the G-50
Sephadex spin column. Extracts were assayed for enzyme activityas described
(Slabaugh et al., 1984), except that dithiothreitol was omitted in the indicated samples.
Background activity from host cell reductase was monitored by assaying mock-infected
extracts, and was subtracted from the viral extracts. The activity of the host reductase
was less than 10% of the ribonucleotide reductase activity from virus infected cells.
D.2 Results and Discussion
Enzyme activity measurements indicate that at least two differentcomponents
are required to serve as biological reducing agents for the viral ribonucleotide reductase.
The results of this experiment are shown in Figure D.1. Removal ofvery small
molecules (< 5 kDa) decreased the reductase activity of virus-infectedextracts by 60%
(column 2). Removal of molecules of molecular mass less than 30,000, completely
eliminated ribonucleotide reductase activity (column 3). However, the addition of2 1 2
dithiothreitol to the assay reaction mixture was able to restore or partially restore the
activity of both depleted extract preparations (columns 4, 5). The results with
dithiothreitol demonstrate that at least one component of the in vivo reducing system
may be replaced by this disulfide reductant.
Bacterial and mammalian systems encode genes for both thioredoxin and
glutaredoxin and both proteins are capable participating in the reduction of the
ribonucleotide reductase disulfide. Recently, a gene for glutaredoxin has been
identified in the vaccinia genome (Goebel et al., 1990). Because the glutaredoxin
systems in E. coli and mouse require components of the sizes indicated as necessary for
viral reductase activity, these experiments indirectly suggest that a viral glutaredoxin
system may provide the necessary reducing equivalents to ribonucleotide reductase.')1 3
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